In vivo gene therapy for hematopoietic stem cells, hematopoietic progenitor cells and / or differentiated hematopoietic cells
In vivo gene therapy using a vector for HSPCs in neonates addresses the limitations of ex vivo methods by ensuring safe and effective gene transfer to HSPCs, reducing toxicity and enabling systemic disease correction.
Patent Information
- Application Number
- PCT/EP2026/064116
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-13
- Filing Date
- 2026-05-13
- Publication Date
- 2026-11-19
AI Technical Summary
Existing ex vivo gene therapy for hematopoietic stem cells (HSPCs) faces challenges such as the need for cell harvesting, patient conditioning toxicity, and limited systemic correction of diseases, while in vivo gene therapy strategies have not been successfully reported in humans.
A vector comprising a nucleic acid for in vivo delivery to HSPCs, administered to neonates to overcome these challenges, leveraging the high proportion of HSPCs in the liver and spleen during this period for effective gene transfer.
Achieves safe and effective gene therapy by targeting HSPCs in vivo, providing durable correction and reducing the need for ex vivo manipulation and patient conditioning.
Smart Images

Figure IMGF000192_0001 
Figure IMGF000193_0001 
Figure IMGF000196_0001
Abstract
Description
[0001] In vivo gene therapy for hematopoietic stem cells, hematopoietic progenitor cells and / or differentiated hematopoietic cells
[0002] TECHNICAL FIELD
[0003] The present invention relates to vectors for use in treating diseases by in vivo gene therapy for hematopoietic stem cells and / or hematopoietic progenitor cells and / or differentiated hematopoietic cells.
[0004] BACKGROUND OF THE INVENTION
[0005] Gene therapy for hematopoietic cells, more specifically HSPCs (i.e., hematopoietic stem cells and / or hematopoietic progenitor cells) and / or differentiated hematopoietic cells, involves gene transfer to HSPCs (i.e., to hematopoietic stem cells and / or to hematopoietic progenitor cells) and / or to differentiated hematopoietic cells, and has the potential to cure diseases and disorders that are caused by deficiencies in genes. These diseases and disorders include, for example, immunodeficiencies, hemoglobinopathies, osteochondrodysplasias, inherited bone marrow failure syndromes, inherited metabolic disorders, hematological cancers, and solid tumors.
[0006] A known approach for achieving gene transfer to hematopoietic cells, e.g., to HSPCs, is ex vivo gene therapy for HSPCs. In this approach, HSPCs are first harvested from the patient. The harvested HSPCs are then cultured and modified ex vivo. Modifying the HSPCs ex vivo may involve using viral vectors to transfer a gene of interest into the HSPCs. Once a sufficiently large population of ex vivo modified HSPCs has been obtained, the recipient patient is subjected to conditioning, which involves depleting endogenous HSPCs from the bone marrow of the recipient patient, typically by subjecting the patient to chemotherapy. The HSPCs that were modified ex vivo are then transplanted into these recipient patients, typically by infusion.
[0007] One specific approach for ex vivo gene therapy for hematopoietic cells such as HSPCs is lentiviral vector ( LV)-mediated ex vivo gene therapy for HSPCs. In some aspects, LV-mediated ex vivo gene therapy for HSPCs is seen as having delivered on the promise of a "one-and-done" treatment for several diseases caused by deficiencies in genes. For example, integrating LVs pseudotyped with the vesicular stomatitis virus G protein in HSPCs have demonstrated both safety and efficacy in treating primary immunodeficiencies, hemoglobinopathies, and inherited metabolic disorders. Several ex vivo gene therapy products are now in advanced clinical development or have already been approved for clinical use (summarised, e.g., in Ferrari, G. et al., Gene therapy using haematopoietic stem and progenitor cells. Nat Rev Genet, 22, 216-234 (2021)).
[0008] Certain challenges, however, hinder the broader application of ex vivo gene therapy for hematopoietic cells such as HSPCs to all eligible patients. In particular, the need to harvest and preserve enough functional
[0009] hematopoietic cells from the patients to ensure rapid and durable hematopoietic reconstitution following ex vivo manipulation, as well as the toxicity associated with patient conditioning before transplantation of the ex vivo manipulated HSPCs, are major hurdles that restrict the safe and effective implementation of this approach. Moreover, ex vivo gene therapy enables correction only within HSPCs, whereas many diseases caused by deficiencies in genes have systemic manifestations that would benefit from broader correction.
[0010] Thus, there is a continuous quest to search for improvements in gene therapy for hematopoietic cells such as HSPCs.
[0011] Some studies suggest that the drawbacks of ex vivo gene therapy for HSPCs could be overcome by an in vivo approach. However, successful in vivo vector administration for in vivo gene therapy of hematopoietic cells such as HSPCs has not yet been reported in humans. For example, one of the few prior reports of in vivo gene therapy for HSPCs relied on targeted lipid nanoparticles delivering limiting amounts of RNA cargo (Breda, L. et al., In vivo hematopoietic stem cell modification by mRNA delivery, Science, 381, 436-443 (2023)). Other reported strategies in the art rely on the delivery of adenoviral vectors, engineered to be integrating, encoding for a gene conferring chemo-resistance to transduced HSPCs. Subsequently, transgene-positive cells are selected by chemotherapy, a regimen that cannot be applied to all patient groups and that should be avoided due to its high toxicity (Richter M. et al., In vivo transduction of primitive mobilised hematopoietic stem cells after intravenous injection of integrating adenovirus vectors, Blood, 128(18), 2206-2217 (2016)).
[0012] The present invention aims to provide a safe and effective strategy for in vivo gene therapy of hematopoietic cells, more specifically HSPCs (i.e., hematopoietic stem cells and / or hematopoietic progenitor cells) and / or differentiated hematopoietic cells, that overcomes challenges associated with ex vivo gene therapy of hematopoietic cells such as HSPCs, and also overcomes limitations of the few previously described approaches for in vivo gene therapy of HSPCs.
[0013] SUMMARY OF THE INVENTION
[0014] The present invention relates to a vector comprising a nucleic acid of interest for use in a method of treating a disease in a subject by in vivo delivering the nucleic acid of interest to HSPCs (i.e., hematopoietic stem cells and / or hematopoietic progenitor cells) and / or differentiated hematopoietic cells, wherein the method comprises in vivo administration of the vector.
[0015] FIGURES
[0016] Figure 1 | Characterization of the HSPC compartment in C57BI / 6 mice of different ages and in vivo HSPC gene transfer by LV.
[0017] (a) Experimental scheme: hematopoietic cells were collected from the bone marrow (BM), spleen, liver, or peripheral blood (PB) of newborn, 1-week-old, 2-week-old, or 8-week-old (adult) C57BI / 6 mice and analyzed by Fluorescence-Activated Cell Sorting (FACS) to evaluate the composition of total CD45-positive cells.
[0018] (b)-(e) Mean with standard error of the mean (SEM) for the percentage of different populations among lineage-negative (Lin-) / cKit-positive (cKit+) hematopoietic stem cells and / or hematopoietic progenitor cells in the BM (b), PB (c), spleen (d), or liver (e) of newborn, 1-week-old, 2-week-old, or 8-week-old C57BI / 6 mice. HSC: hematopoietic stem cells; MPP: multipotent progenitor cells; GMLP: granulocyte-monocyte-lymphoid progenitor cells; KSL: cKit+ Scal+ Lin- cells; LK CD150: Lin- cKit+ CD150+ cells; EP: erythroid progenitor cells; MEP: megakaryocyte-erythroid progenitor cells; GMP: granulocyte-monocyte progenitor cells. n=5 mice per group. Newborn PB samples represent 10 pools from 50 mice. Spleen samples: n=10.
[0019] (f)-(i) Single values and mean with SEM of the absolute count of HSCs in the BM (f), PB (g), spleen (h), or liver
[0020] (i) of newborn, 1-week-old, 2-week-old, or 8-week-old C57BI / 6 mice, as indicated. Kruskal-Wallis test with Dunn's multiple comparisons test (comparison to the newborn group).
[0021] (j) Experimental scheme: LV was administered intravenously (i.v.) to newborn C57BI / 6 mice (5e10 transducing units, TU / kg). GFP expression was monitored monthly in the blood of treated mice, and after 17 weeks, GFP-positive cells were FACS-sorted from the BM and transplanted into busulfan-conditioned adult C57BI / 6 mice.
[0022] (k)-(l) Mean with SEM of GFP-positive cells measured over time in peripheral blood mononuclear cells (PBMC) of treated mice (n = 19, k), or in the indicated spleen and BM populations, 17 weeks after LV administration
[0023] (l).
[0024] (m)-(q) Single values of GFP-positive cells measured over time in PBMCs of individual surviving transplanted mice (m-p) and in cells in the indicated populations and organs 20 weeks post-transplant (q).
[0025] (r) Heatmap showing shared integration sites (IS) (columns) among LV-treated newborn mice (pooled, n = 19) analyzed 17 weeks post-administration, and transplanted mice (pooled, n = 4), analyzed 20 weeks posttransplant (shown in k, I). Spleen- / Thymus- / BM-TPX refer to the whole organs of the transplanted mice shown in (m-q). " Sample count" indicates the number of samples (rows) that share a given IS. Each column represents a unique IS.
[0026] Figure 2 | In vivo HSPC gene transfer in mice post-mobilization or treated by CD47hi LV.
[0027] (a)-(b) Single values and mean with SEM of the absolute count of HSCs measured in the BM (a) or PB (b) of 2-week-old mobilized (n=6) or untreated (control; n=7) C57BI / 6 mice, as indicated. Mann-Whitney test.
[0028] (c)-(d) Mean with SEM of GFP-positive cells (c) or vector copies per diploid genome (vector copy number, VCN, d) measured in the circulation of 2-week-old mobilized or control C57BI / 6 mice at the indicated time after LV administration (1.1e11 TU / kg). Mann-Whitney test on the last time point. In (c), the comparison is among CD45-positive cells.
[0029] (e)-(f) Single values and mean with SEM of GFP-positive cells (e) or the VCN (f) measured in the BM (e) or total tissue from the indicated organs (f) of 2-week-old mobilized or control C57BI / 6 mice, 20 weeks after LV administration. Mann-Whitney test.
[0030] (g)-(i) Mean with SEM of GFP-positive cells (g,h) or VCN (i) measured in the circulation of mice transplanted with total BM cells harvested from either control (g, n=5) or mobilized (h, n=6) donor mice shown in (a-f), at the indicated time after transplant (15x106CD45-positive cells per recipient). Mann-Whitney test on the last time point analyzed.
[0031] (j) Single values and mean with SEM of GFP-positive cells measured in the BM of transplanted mice shown in (g-i) 16 weeks after transplant. Mann-Whitney test.
[0032] (k)-(l) Mean with SEM of GFP-positive cells (k) or VCN (I) measured in the circulation of mobilized (n=7) or control (n=6) newborn C57BI / 6 mice, at the indicated time after LV administration (9el0 TU / kg). Mann-Whitney test on the last time point analyzed. In (k), the comparison is among CD45-positive cells.
[0033] (m) Mean with SEM of GFP-positive cells measured in PBMCs over time after CD47hi-LV or CD47-free LV administration (5el0 TU / kg) to newborn or adult NSG mice (CD47hi-LV newborns, n=12; CD47-free-LV newborns, n=7; CD47hi-LV adults, n=6). Kruskal-Wallis test with Dunn's multiple comparisons test on the 20-wk time points.
[0034] (n) Single values and mean with SEM of GFP-positive cells in the indicated BM populations of mice shown in (m) 20 weeks post-LV administration. Kruskal-Wallis test with Dunn's multiple comparisons test.
[0035] (o) Mean with SEM of GFP-positive cells measured in the circulation of mobilized (n=8) and control (n=7) 2-week-old and adult NSG mice mobilized (n=4) or not (n=8) at the indicated time after CD47hi-LV administration (4.5el0 TU / kg). Kruskal-Wallis test with Dunn's multiple comparisons test on the last time point analyzed (compared to the 2-week-old control group).
[0036] (p) Single values and mean with SEM of GFP-positive CD45-positive cells measured 16 weeks after LV administration in the indicated mice. Note: These are the same data reported in (k,m), shown here for direct comparison. Kruskal-Wallis test with Dunn's multiple comparisons test.
[0037] (q)-(r) Single values of GFP-positive CD45-positive cells measured in the PB of C57BI / 6 or NSG mice treated at the indicated LV doses (X-axis) and ages. Newborns are shown in (q), while 2-week-old or adult mice are shown in (r). Note: NSG mice were treated with CD47hi-LV. n values are shown near each dot.
[0038] Figure 3 | In vivo HSPC gene transfer in adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) newborn mice by ADA-LV.
[0039] (a) Experimental scheme: newborn ADA-SCID mice or wild-type (WT) littermates were treated with 2.5el0 TU / kg of the indicated LV. At 20 weeks after LV administration, 10-13 x 106total BM cells were transplanted into irradiated NSG mice.
[0040] (b) Survival of ADA-SCID mice treated as newborns with PG K. ADA-LV (n=7), PGK. ADA.122mirT-LV (n=14), or ET. ADA.142mirT-LV (n=5), untreated (knockout, KO, n=17), and LV-treated WT (WT, n=30) littermates. WT littermates were treated in parallel with ADA-SCID mice; a pooled dataset of all LV-treated WT mice is
[0041] reported, regardless of the administered LV construct. Log-rank Mantel-Cox test with Bonferroni's correction (comparison to the PG K. ADA group).
[0042] (c)-(e) Mean with SEM of the VCN (c), T lymphocytes measured by FACS (d), or lymphocyte counts measured by hemocytometer (e) in the PB of ADA-SCID mice treated with the indicated LV as newborns. Sample sizes (n) at each time point are reported below the graphs. Linear mixed-effects (LME) model (comparisons vs. WT; complete analyses provided in Tables 3-5 in Examples).
[0043] (f)-(g) Mean with SEM of the percentage of different populations among CD45-positive cells in the spleen (f) or thymus (g) of ADA-SCID mice treated as newborns with the indicated LV or left untreated, 20 weeks after LV administration. Sample sizes (n) are reported above the bars.
[0044] (h) Survival of NSG mice transplanted with total BM cells isolated from ADA-SCID mice shown in (b-g). Logrank Mantel-Cox test with Bonferroni's correction (comparison to WT).
[0045] (i)-(j) Mean with SEM of lymphocyte counts in PB 8 weeks (i) or 12 weeks (j) after transplant. Kruskal-Wallis test followed by post hoc analysis.
[0046] (k)-(l) Mean with SEM of the percentage of the indicated populations among CD45-positive cells in the spleen (k) or thymus (I) of NSG-transplanted mice 12 weeks post-transplant. Sample sizes (n) are reported above the bars.
[0047] (m) Single values and mean with SEM of VCN measured in the indicated organs of NSG mice transplanted with cells isolated from ADA-SCID mice treated with the indicated LV, 12 weeks after transplant.
[0048] Figure 4 | In vivo HSPC gene transfer in osteopetrotic newborn mice by PGK. TCIRG1-LV.
[0049] (a) Survival of LV-treated osteopetrotic (OC-LV, n=ll) or WT mice (WT-LV, n=27) treated as newborns with PGK. TCIRG1-LV (l-2el0 TU / kg) compared to untreated OC mice (OC-unt, n=8) mice.
[0050] (b) Single values of the weight of OC-LV or WT-LV mice over time post LV treatment.
[0051] (c)-(d) Mean with SEM of white blood cell (WBC, c) or lymphocyte (d) counts measured by hemocytometer in the PB of OC-LV (n=10) or, WT-LV (n=16) mice, or untreated WT (WT-unt) mice (n=3) over time. Sample sizes
[0052] (n) at each time point are reported below the graphs.
[0053] (e) Mean with SEM of the VCN measured in the PB of OC-LV (n=9), WT-LV mice (n=15), or WT-unt mice (n=3) over time. Sample sizes (n) at each time point are reported below the graphs. Sfdak’s multiple comparisons test.
[0054] (f) Single values and mean with SEM of the VCN measured in the indicated organs at necropsy in OC-LV (n=9), WT-LV mice (n=14), or WT-unt mice (n=4). Mann-Whitney test.
[0055] (g) Single values and mean with SEM of C-terminal telopeptide (CTX) measured in the medium of osteoclast cultures from OC-LV (n=5) or WT-LV (n=4) mice following dentine resorption.
[0056] (h)-(i) Representative micro-tomography scans (h) or single values and mean with SEM of the quantification of bone mineral density (i) of WT-LV (n=7), OC-LV-treated (n=8), or WT-unt (n=l) mice. Asterisks indicate the longest-surviving OC-LV mice, one of which is also shown in the bottom-left panel in (h). Scale bar: 500 pm.
[0057] (j) Single values and mean of parathyroid hormone (PTH) concentration in the serum of OC-LV (n=10) or WT-LV (n=7) mice at the indicated time points. Sample sizes (n) at each time point are reported below the graphs.
[0058] Figure 5 | In vivo HSPC gene transfer in Ponca' ' newborn mice treated by PGK. FANCA-LV.
[0059] (a) Single VCN values measured at the indicated time points in the PB of Fanca' / ' mice treated as newborns (1.5elOTU / kg, FANCA-LV, n=5) or left untreated (FANCA-unt, n=5). LME model (5 vs. 45 weeks, p=0.0001; full analysis in Table 6 in Examples).
[0060] (b) Single values of the VCN fold expansion over time, compared to the first measurement (5 weeks post-LV). Dashed line = 1.
[0061] (c)-(d) Mean with SEM of WBC (c) or lymphocyte (d) counts measured by hemocytometer in the PB of FANCA-LV (n=5), FANCA-unt (n=5), or WT-unt (n=5) mice. Kruskal-Wallis test with Dunnett's multiple comparisons test (compared to WT-unt).
[0062] (e) Single values and mean with SEM of the VCN measured in the indicated organs 1 year after LV treatment in the mice shown in (a-d).
[0063] (f) Single values of the VCN measured at the indicated time points in the PB of Fanca' / ' mice transplanted at
[0064] 8 weeks of age with BM cells from the FANCA-LV (n=7) or FANCA-unt (n=7) mice shown in (a-e). LME model (5 vs. 28 weeks, p=0.0145; full analysis in Table 7 in Examples).
[0065] (g) Single values of the fold expansion of VCN over time in the transplanted mice shown in (f), compared to the first measurement (5 weeks post-transplant). Dashed line = 1.
[0066] (h) Single values and mean with SEM of the VCN measured in the indicated organs 1 year after transplant in the mice shown in (f,g).
[0067] (i) Single values of the VCN measured at the indicated time points in the PB of FANCA-LV treated as newborns (1.5el0 TU / kg, n=29) or FANCA-unt (n=14). A subset of FANCA-LV (n=15) or FANCA-unt (n=7) mice received two doses of Mitomycin C (FANCA-LV - MMC and FANCA-unt - MMC, respectively; arrows). LME model (5 vs.
[0068] 52 weeks: FANCA-LV, p<0.0001; FANCA-LV - MMC, p<0.0001; full analysis shown in Table 8 in Examples). Data from two independent experiments are shown.
[0069] (j) Single values of the VCN fold expansion over time compared to the first time point analyzed (5 weeks post-LV) in the mice shown in (I). Dashed line = 1.
[0070] (k)-(n) Mean with SEM of neutrophil (k), red blood cell (RBC, I) counts, hemoglobin concentration (HGB, m), or platelet counts (n) measured by hemocytometer in the PB of the mice shown in (j,k). Kruskal-Wallis test followed by post-hoc analysis (comparison to FANCA-LV group at 10 weeks).
[0071] (o) Single values and mean with SEM of the VCN measured in the indicated organs 1 year after LV treatment in the mice shown in (j,k). Mann-Whitney test.
[0072] (p) Mean with SEM of the VCN measured in the PB of FANCA-LV mice treated at 8-weeks-old (as adults) or at 2 weeks of age, either mobilized or not before LV administration (1.5el0 TU / kg). 2 weeks - Controls n=5; 2 weeks - Mobilized n=6; Adults - Controls n=6; Adults - Mobilized n=5. LME model (5 vs. 15 weeks 2 weeks -Mobilized: p=0.0447; Adults -Controls: p=0.6053; Adults - Mobilized: p=0.8903; full analysis shown in Table
[0073] 9 in Examples)
[0074] (q) Mean with SEM of the VCN fold expansion over time compared to the first measurement (5 weeks post-LV) in the mice shown in (p).
[0075] Figure 6 | Characterization of circulating HSPC in human samples.
[0076] (a) Mean with SEM of the percentage of different populations among circulating HSPCs in the PB of healthy donors of the indicated ages. HSC: hematopoietic stem cells; MPP: multipotent progenitors; MLP: multilymphoid progenitors; ETP: early T-cell precursors; pre-BNK: B and NK progenitor cells; CMP: common myeloid progenitors; GMP: granulocyte-monocyte progenitors; MEP: megakaryocyte-erythroid progenitors; EP: erythroid progenitors; and MKP: megakaryocyte progenitors.
[0077] (b)-(c) Single values and mean with SEM of the absolute count of circulating HSCs (b) or MPPs (c) in the PB of healthy donors of the indicated ages. Neonates (P0), n=63; 0-2 months, n=4; 3-8 months, n=6; >18 years, n=21. Kruskal-Wallis test with Dunn's multiple comparisons test (comparison to the neonate group). HSC / MPP counts from some donors in this figure are also reported in a separate study (Quaranta, P. et al., Circulating Hematopoietic Stem / Progenitor Cells subsets contribute to human hematopoietic homeostasis. Blood, 143(19), 1937-1952 (2024)) providing a detailed biological characterization of circulating HSPCs.
[0078] Figure 7 | Characterization of the hematopoietic system in mice of different ages and in vivo HSPC gene transfer by LV.
[0079] (a)-(d) Mean with SEM of the percentage of different populations among CD45-positive cells in the BM (a), PB (b), spleen (c), or liver (d) of newborn, 1-week-old, 2-week-old, or 8-week-old (adult) C57BI / 6 mice, as indicated. n=5 mice per group. Newborn PB samples represent 10 pools derived from 50 mice.
[0080] (e) Representative immunohistochemistry image of a liver section from a 1-week-old C57BI / 6 mouse stained with an anti-Ki67 (brown) antibody. Black arrowheads indicate proliferating hematopoietic cells; the red arrowhead indicates a representative megakaryocyte.
[0081] (f) Single VCN values measured in the indicated spleen populations or whole BM from the pooled donor mice shown in Fig. Ik and 11. BM cells from 19 LV-treated newborn mice were pooled into five groups (each containing 4-5 mice) for transplantation into five recipient mice after sorting.
[0082] (g) Body weights of individual busulfan-conditioned adult mice that were transplanted (TPX n=5) or not transplanted (not-TPX, n=1). The grey area indicates the period of busulfan treatment. Black crosses mark deceased mice.
[0083] (h) Single values of CD45-positive GFP-positive cells in the indicated organs of recipient mice 20 weeks posttransplant. VCN values are indicated above the bars.
[0084] (i)-(l) LV integration site (IS) analysis of GFP-positive cells from LV-treated donor mice and transplanted recipient mice at the study endpoint. Shared IS are color-coded. Clones with an abundance of <1% are shown in grey. The total number of IS detected is indicated above each bar.
[0085] (m) Common integration site analysis of LV-treated and transplanted mice, showing the distribution of integration events relative to known oncogenes.
[0086] (n) Mean with SEM of GFP-positive cells in PBMCs of LV-treated mice as newborns (n=4) and monitored for 1 year after LV administration (5el0 TU / kg).
[0087] (o) Mean with SEM of GFP-positive cells in PBMCs of LV-treated mice as adults (n=5, 8-week-old) via i.v. LV administration (8el0 TU / kg).
[0088] (р) Representative immunofluorescence image of the liver from a mouse shown in (o), revealing few-to-no GFP-positive cells. Scale bar: 500 pm. Blue: Hoechst; Green: GFP.
[0089] Figure 8 | Gene transfer efficiency to HSPC in 2-week-old C57BI / 6 mice after in vivo LV administration.
[0090] (a)-(b) Mean with SEM of GFP-positive cells (a) or VCN (b) measured in the PB of C57BI / 6 mice administered LV (LV, n=15; 3el0 TU / kg) at 2 weeks-of-age or untreated (Unt, n=1).
[0091] (с) Single values and mean with SEM of the VCN measured in the indicated organs in Unt and LV mice, 16 weeks after LV administration.
[0092] (d) Single values and mean with SEM of the absolute count of HSCs in the spleen of 2-week-old mobilized (n=6) or untreated control (n=7) mice, as indicated. Mann-Whitney test.
[0093] (e)-(f) Single values and mean with SEM of GFP-positive cells in the thymus (e) or spleen (f) of mobilized (n=6) or control (n=7) mice, 20 weeks after LV administration. Mann-Whitney test.
[0094] (g)-(h) Mean with SEM of the engraftment of CD45.2 cells in the PB of CD45.1 recipient mice over time. Controls: n=5 recipient; Mobilized: n=6 recipient. Mice were transplanted with 15x106total BM cells harvested from donor mice, 20 weeks after LV administration.
[0095] (i)-(j) Single values and mean with SEM of the VCN (i) or engraftment of CD45.2 cells (j) measured in CD45.1 recipient mice, 16 weeks after transplant in the indicated organs. Mann-Whitney test in (i).
[0096] (k)-(l) Single values and mean with SEM of GFP-positive cells in the thymus (k), or spleen (I) of CD45.1 recipient mice, 16 weeks after transplant. Mann-Whitney test.
[0097] Figure 9 | Administration of anti-interferon-a receptor blocking antibody (MAR-1) increase in vivo gene transfer to HSPCs.
[0098] (a)-(b) Mean with SEM of GFP-positive cells (a) or the VCN (b) measured over time in the PB of C57BI / 6 mice treated as newborns with MAR-1 (i.v., 50mg / kg, n=13) or an IgG control (i.v., 50mg / kg, n=13) 3 hours before LV administration (8el0 TU / kg). Mann-Whitney test on the last time point analysed. In (a), comparisons were made among
[0099] CD45-positive cells. Data from a pool of two independent experiments are shown.
[0100] (c)-(e) Single values and mean with SEM of GFP-positive cells in the spleen (c), thymus (d), and BM (e) of the mice shown in (a, b) 16 weeks after LV administration. Mann-Whitney test.
[0101] (f) Single values and mean with SEM of the VCN measured in the indicated organs, 16 weeks after LV administration in the mice shown in (a-e). Mann-Whitney test.
[0102] Figure 10 | Characterization of the HSPC compartment in NSG mice of different
[0103] ages and in vivo HSPC gene transfer by LV.
[0104] (a) Experimental scheme: hematopoietic cells were collected from the bone marrow (BM), spleen, liver, or peripheral blood (PB) of newborn, 1-week-old, 2-week-old, or adult NSG mice and analyzed by FACS to evaluate the composition of total CD45-positive cells. n=5 mice per group. Newborn PB samples from 40 mice were pooled into eight groups.
[0105] (b)-(e) Mean with SEM of the percentage of different populations among lineage-negative (Lin-) and cKit-positive (c Kit+) cells in the BM (b), PB (c), spleen (d), or liver (e) of the indicated NSG mice. HSC: hematopoieticstem cells; MPP: multipotent progenitor cells; GMLP: granulocyte-monocyte-lymphoid progenitor cells; KSL: cKit+ Scal+ Lin- cells; LK CD150: Lin- cKit+ CD150+ cells; EP: erythroid progenitor cells; MEP: megakaryocyte-erythroid progenitor cells; GMP: granulocyte-monocyte progenitor cells.
[0106] (f)-(i) Single values and mean with SEM of the absolute count of HSCs in the BM (f), PB (g), spleen (h), or liver
[0107] (i) of the indicated NSG mice. n=5 mice per group. Newborn PB samples from 40 mice were pooled into eight groups. Kruskal-Wallis test with Dunn's multiple comparisons test (comparison to the newborn group).
[0108] (j) Mean with SEM of the count of HSPC red or white colonies grown from GFP-positive (GFPpos) or GFP-negative (GFPneg) Lin- cells isolated from the BM of the mice in Fig. 2k-m, 20 weeks after LV administration.
[0109] (k) Single VCN values measured in FACS-sorted GFPpos or GFPneg Lin- cells isolated from mice shown in Fig.
[0110] 2m and 2n and cultured for 72 hours.
[0111] (l) Single VCN values measured from single-picked red (RFC) or white (WFC) colonies grown in MethoCult from GFPpos or GFPneg FACS-sorted Lin- cells isolated from the mice shown in Fig. 2m and 2n.
[0112] (m) Single values and mean with SEM of the GFP-positive area measured by immunohistochemistry in the indicated tissues, 20 weeks after LV administration in NSG mice treated as newborns (n=6) or adults (n=4) with CD47hi-LV (shown in Fig. 2m and 2n), or untreated (Unt, n=3).
[0113] (n) Representative immunohistochemistry images of the indicated tissues taken from the mice shown in (m). GFP-positive cells are shown in brown (black arrowheads). Scale bar: 300 pm.
[0114] Figure 11 | Gene transfer efficiency to HSPC in 2-week-old mice after in vivo LV administration.
[0115] (a)-(c) Single values and mean with SEM of the absolute HSC counts in the BM (a), PB (b), or spleen (c) of 2-week-old or adult mobilized (n=5 per group) or untreated (n=2 per group) NSG mice, as indicated. Mann-Whitney test.
[0116] (d)-(e) Single values and mean with SEM of GFP-positive cells measured in the indicated populations in the spleen (d) or BM (e) of the mice shown in Fig. 2o, 16 weeks after LV administration. Kruskal-Wallis test with Dunn's multiple comparisons (comparison to the 2-week-old control group).
[0117] (f) Single values and mean with SEM of the VCN measured in the indicated organs of the mice shown in Fig.
[0118] 2o, 16 weeks after LV administration. Kruskal-Wallis test with Dunn's multiple comparisons (comparison to the respective 2-week-old control groups).
[0119] Figure 12 | In vivo HSPC gene transfer in ADA-SCID mice by ADA-LV.
[0120] (a) Single values of the weight over time of mice shown in Fig. 3b.
[0121] (b)-(c) Mean with SEM of neutrophil (b) or monocyte (c) counts measured by hemocytometer in the PB of ADA-SCID mice treated with the indicated LV as newborns. The number of mice at each time point is reported below the graphs. LME model (only comparisons vs. WT and p-values<0.05 are reported; full analyses shown in Tables 10 and 11 in Examples).
[0122] (d)-(e) Single values and mean with SEM of ADA activity measured over time in the PB cellular fraction (d) or plasma (e) from ADA-SCID or wild-type (WT) mice treated with the indicated LV or left untreated. LME model (only comparisons vs. WT and p-values<0.05 are reported).
[0123] (f) Single values and mean with SEM of LV-RNA expression in the indicated organs or liver subpopulations 8 weeks after administration of the indicated LV to newborn ADA-SCID mice (n=5 per group, 2el0 TU / kg). Wpre: Woodchuck hepatitis virus post-transcriptional regulatory element, used to measure LV genome expression. Kruskal-Wallis test with Dunn's multiple comparisons test (comparison to the PG K. ADA group).
[0124] (g) Mean with SEM of the weights of the mice shown in Fig. 3h.
[0125] (h) Single values and mean with SEM of the engraftment of cells isolated from ADA-SCID or WT mice treated with the indicated LV as newborns and used as donors for irradiated NSG mice. LV-treated WT mice have been pooled, irrespective of the administered LV.
[0126] (i)-(j) Mean with SEM of the percentage of the indicated populations among CD45-positive cells in the PB of transplanted NSG mice, 8 (i) or 12 weeks (j) after transplant.
[0127] (k) Mean with SEM of the VCN measured in the PB of NSG-transplanted or untreated (Unt) mice over time. LME model (only comparisons vs. WT and p-values<0.05 are reported).
[0128] (l) Representative LV integration site analysis of cells from one LV-treated newborn ADA-SCID mouse, 20 weeks after PGK. ADA-LV administration (Fig. 3b, shown in left panel) and the corresponding NSG recipient mouse, 12 weeks after transplant (Fig. 3h, shown in right panel). Shared integrations are color-coded. Clones with abundance <1% are shown in grey. The total number of integrations is reported on top of the bars.
[0129] (m)-(n) Survival (m) and individual body weights (n) of ADA-SCID mice treated at 2 weeks-of-age with PGK. ADA-LV (n=5, 2.5el0 TU / kg) compared to WT (WT, n=2) littermates.
[0130] Figure 13 | In vivo HSPC gene transfer in osteopetrotic newborn mice by
[0131] PGK. TCIRG1-LV.
[0132] (a) Single values and mean with SEM of the total cell count isolated at necropsy from the BM or spleen of LV-treated osteopetrotic (OC-LV, n=7) or wild-type (WT-LV, n=15) mice. Mann-Whitney test.
[0133] (b)-(c) Single values and mean with SEM of the indicated populations among CD45-positive cells analyzed at necropsy in the spleen (b) or BM (c) of OC-LV (n=7) or WT-LV (n=15) mice.
[0134] (d) Representative images of osteoclasts (black arrowheads) differentiated from OC-LV or WT-LV mice, stained for tartrate-resistant acid phosphatase.
[0135] (e) Representative images of toluidine blue staining of dentine discs after a resorption assay of osteoclasts differentiated from the BM of LV-treated WT or OC mice, as indicated. The purple area represents resorbed dentine. Scale bar: 200 pm.
[0136] (f)-(g) Single values and mean with SEM of the bone volume fraction (f) and trabecular separation (g) of WT-LV (n=7), OC-LV-treated (n=8), or WT untreated (WT-unt, n=l) mice, measured by micro-tomography scan image quantification. Asterisks indicate the longest surviving OC-LV mice, one of which is also shown in the bottom-left panel of Fig. 4h.
[0137] Figure 14 | In vivo HSPC gene transfer in Fanca- / - mice by PGK. FANCA-LV.
[0138] (a) Mean with SEM of the percentage of different populations among lineage-negative (Lin") and cKit-positive (cKit+) cells (HSPCs) in the PB of newborn, 2-week-old, or 8-week-old (adult) Fanca- / -mice, as indicated. HSC: hematopoietic stem cells; MPP: multipotent progenitor cells; GMLP: granulocyte-monocyte-lymphoid
[0139] progenitor cells; KSL: cKit+ Scal+ Lin- cells; LK CD150: Lin- cKit+ CD150+ cells; EP: erythroid progenitor cells; MEP: megakaryocyte-erythroid progenitor cells; GMP: granulocyte-monocyte progenitor cells.
[0140] (b) Single values and mean with SEM of the absolute count of HSCs in the PB of newborn, 2-week-old, or 8-week-old Fanca- / -mice, as indicated. n=5 mice per group. Newborn PB samples represent six pools from 30 mice. Kruskal-Wallis test with Dunn's multiple comparisons test (comparison to the newborn group).
[0141] (c)-(e) Mean with SEM of neutrophil (c), monocyte (d), or platelet (e) counts measured by hemocytometer in the PB of LV-treated (FANCA-LV) or untreated (FANCA-unt) Fanca- / -mice (n=5) or untreated wild-type (WT-unt) mice (n=5). Kruskal-Wallis test with Dunnett's multiple comparisons test (comparison to WT).
[0142] (f) Single values and mean with SEM of the VCN measured after FACS-sorting cell populations from PB or BM of the mice shown in Fig. 5a-e, 1 year after LV administration.
[0143] (g) Representative LV integration site (IS) analysis of cells from one LV-treated newborn Fanca- / -mouse, 20 weeks after PGK. FANCA-LV administration (shown in Fig. 5a-e). Shared integrations among the indicated organs or FACS-sorted populations from PB or BM are color-coded. Clones with an abundance <1% are shown in grey. The total number of integrations is reported on top of the bars.
[0144] (h) Representative heatmap showing shared integrations (columns) in the indicated organs or FACS-sorted populations isolated from a PGK. FANCA-LV-treated mouse (shown in Fig. 5a-e). " Sample count" refers to the number of samples (rows) that share a given IS.
[0145] Figure 15 | Anti-interferon-a receptor (IFNaR) antibody administration prior to lentiviral vector in vivo gene therapy increases gene transfer efficiency in mobilized mice.
[0146] DP: CD8-CD4 double positive cells; DN: CD8-CD4 double negative cells; Lin-: lineage negative cells; Prog: progenitor cells; KSL: cKit-positive, Sca-l-positive, Lin- cells.
[0147] (a) Experimental scheme: newborn mice were treated with a hematopoietic stem and progenitor cell (HSPC) mobilization protocol mimicking the clinical use. In particular, newborn mice received 3 doses of G-CSF (250 ng / g mouse) administered intraperitoneally (i.p.) 12 hours (h) apart, followed by Plerixafor (2 pg / g mouse) i.p. administration 8h after the last G-CSF dose. Lentiviral vector (LV) was administered intravenously (i.v.) at 5el0 transducing units (TU) / Kg 2h after Plerixafor, at the peak of mobilization. Anti-IFNaR blocking antibody (MAR-1) or IgG control antibody were administered i.v. 3h prior LV (50mg / kg).
[0148] (b)-(c) Mean with standard error of the mean (SEM) of the percentage of GFP-positive cells (b), or of the measured vector copies per diploid genome (vector copy number, VCN; (c) in the indicated populations at the indicated weeks after LV administration in mobilized newborn mice treated with MAR-1 (n=6) or IgG control (n=5). Mann-Whitney test on CD45-positive cells at week 20.
[0149] (d)-(f) Mean with SEM of the percentage of GFP-positive cells in the indicated populations in the spleen (d), thymus (e), or the bone marrow (f) of the mice 20 weeks after LV administration. Mann-Whitney test.
[0150] DETAILED DESCRIPTION OF THE INVENTION
[0151] The present invention is based on the following contributions to the art:
[0152] • The present inventors discovered that there is a substantial proportion of HSPCs, including the most primitive and repopulating subsets, that persist in the liver and spleen for several weeks after birth. High numbers of circulating HSPCs observed in mammalian neonates, including humans, decline with advancing age (e.g., Examples 1 and 7; e.g., Figures 1, 6 and 10).
[0153] • Nucleic acid transfer to HSPCs can be achieved in vivo in neonates. Efficiency of nucleic acid transfer declines with advancing age, in parallel with the numbers of circulating HSPCs. This suggests that there is a period of time after the birth of mammals that provides a unique opportunity to access HSPCs in vivo for vector-based transfer of nucleic acids to these target cells (e.g., Example 2; e.g., Figures 1, 2, 7 and 10). This in vivo gene therapy approach overcomes disadvantages associated with ex vivo HSPC gene therapy.
[0154] • Nucleic acid transfer to hematopoietic cells such as HSPCs can also be achieved in vivo at later stages in life, for example, by combining the in vivo nucleic acid transfer to hematopoietic cells such as HSPCs with a mobilisation regimen for HSPCs and differentiated hematopoietic cells. Mobilisation of hematopoietic cells such as HSPCs increases the numbers of circulating hematopoietic cells such as HSPCs and / or differentiated hematopoietic cells, and enhances nucleic acid transfer efficiency to HSPCs and / or differentiated hematopoietic cells, at both early stages and also at later stages in life (e.g., Example 3; e.g., Figures 2, 5, 8, 11).
[0155] • Increased efficiency of in vivo nucleic acid transfer to hematopoietic cells such as HSPCs and / or differentiated hematopoietic cells can also be achieved through co-administration of clinically compatible transduction enhancers, such as co-administration of IFNa receptor blockade (e.g., Example 3; e.g., Figure 9) and / or by administering multiple doses of the vector comprising the nucleic acid of interest.
[0156] • Viral vectors having CD47 polypeptides or fragments thereof present on the surface of the viral vectors may be used to shield certain viral vectors from phagocytosis, thereby further increasing efficiency of in vivo nucleic acid transfer to the target cells, i.e., to HSPCs and / or differentiated hematopoietic cells, as shown herein for lentiviral vector mediated in vivo gene transfer to HSPCs (e.g., Example 3; e.g., Figure 2)
[0157] • In vivo nucleic acid transfer to HSPCs and / or differentiated hematopoietic cells as described herein can be used to treat or cure different diseases caused by genetic deficiencies in HSPCs and / or in differentiated hematopoietic cells, herein exemplified by adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID), autosomal recessive osteopetrosis (ARO) and Fanconi anemia (FA) (e.g., Examples 4-6; e.g., Figures 3-5 and 12-14).
[0158] • In vivo nucleic acid transfer to HSPCs and / or differentiated hematopoietic cells may also be useful in the treatment of cancers, not limited to hematopoietic cancers. More particularly, successful in vivo gene therapy of HSPCs and / or differentiated hematopoietic cells can, for example, produce differentiated hematopoietic cells such as macrophages that can reprogram the tumor microenvironment to, for example, release cytokines that result in an anti-angiogenic effect, in directtoxicity to the tumor cells, and / or in the activation of T cells. Thus, the strategy for in vivo gene therapy of hematopoietic cells, in particular HSPCs and / or differentiated hematopoietic cells, as described herein may also be useful in the treatment of solid tumors.
[0159] The present invention provides a vector comprising a nucleic acid of interest for use in a method of treating a disease in a subject by in vivo delivering the nucleic acid of interest to HSPCs (i.e., hematopoietic stem cells and / or hematopoietic progenitor cells) and / or to differentiated hematopoietic cells, wherein the method comprises in vivo administration of the vector.
[0160] As further detailed in the examples, the present inventors successfully demonstrated the strategy for in vivo gene therapy for HSPCs according to the present invention in mouse models of adenosine-deaminase deficiency, ARO and FA. Most strikingly, delivery of relevant nucleic acids of interest for each disease to HSPCs in vivo provided a selective advantage to corrected HSPCs in FA, leading to near-complete hematopoietic reconstitution and prevention of BM failure. Given that circulating HSPCs in humans are also most abundant shortly after birth, in vivo HSPC gene transfer holds strong translational potential across multiple diseases caused by deficient genes in hematopoietic cells, such as HSPCs. By bypassing the major barriers associated with ex vivo HSPC gene therapy, the present invention stands to offer broader accessibility to life-changing treatments.
[0161] Further embodiments of the invention are discussed in more detail below.
[0162] The present invention is not limited in its application to the details of construction and arrangement of components set forth in the present description or illustrated in the drawings. The invention also relates to other embodiments and can be practiced or carried out in various ways. The phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting.
[0163] Unless otherwise defined herein, scientific, and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well-known in the art. Generally, nomenclatures used in connection with, and techniques of biochemistry, enzymology, molecular and cellular biology, microbiology, virology, cell or tissue culture, genetics, and protein and nucleic acid chemistry, and the like that are described herein are those well-known and commonly used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification, unless otherwise indicated.
[0164] The use of wording such as "including", "comprising", "having", "containing", "involving" and variations thereof herein encompasses the items and / or steps listed thereafter and equivalents thereof, as well as additional items.
[0165] Vectors
[0166] The term "vector" as used herein refers to any nucleic acid molecule suitable for use as a vehicle to deliver a particular nucleic acid of interest to a target cell. The vector of the present invention comprises a nucleic acid of interest. In a preferred embodiment, the nucleic acid of interest comprises a gene of interest.
[0167] In one embodiment, the vector is a non-viral vector. In a preferred embodiment, the vector is a viral vector.
[0168] The term "non-viral vector" as used herein refers to any nucleic acid molecule suitable for use as a vehicle to deliver a particular nucleic acid of interest to a target cell, wherein the vector is not derived from a virus. Examples of non-viral vectors include Examples include liposomes, lipid nanoparticles (LNPs), cationic polymers, inorganic nanoparticles, and polymers. In a preferred embodiment of the non-viral vector, the non-viral vector is an LNP. LNPs are nanoparticles that consist of solid and liquid lipids and are stabilized by emulsifiers. LNPs as used herein are non-viral vectors comprising such lipids and emulsifiers to encapsulate the nucleic acid of interest. The skilled person knows, from their common general knowledge, how to identify suitable lipids for encapsulating a given nucleic acid of interest to form an LNP suitable for gene therapy.
[0169] The term "viral vector" as used herein refers to any nucleic acid molecule suitable for use as a vehicle to deliver a particular nucleic acid of interest to a target cell, wherein the vector is derived from (i.e., includes components from) a virus. The viral vector may be a non-replicating viral vector or replicating viral vector. The viral vector of the present invention is preferably a non-replicating viral vector.
[0170] In one embodiment, a viral vector may be in the form of a viral particle. In other embodiments, a viral vector may comprise a viral genome, optionally wherein the viral genome is enveloped. As used herein, a "viral genome" refers to a genome that comprises at least one element derived or derivable from a virus genome. The terms "viral vector" and "transfer vector" are used interchangeably herein.
[0171] The term "element derived or derivable from a virus genome" as used herein refers to an element of a component of a reference virus genome that may differ, e.g., in sequence, from the corresponding element of the component in the reference virus genome, but that fulfils the same function, to the same or a similar extent, as the corresponding element of the component in the reference virus genome. Typically, there are three components of a virus genome: (1) the regulatory cassette comprising regulatory elements, in particular enhancer, promoter and / or auxiliary elements that control expression of genes as an episome or as a
[0172] chromosomal integrant; (2) the nucleic acid of interest, such as a gene of interest; and (3) the protein envelope and / or capsid.
[0173] The viral vector of the present invention may be a transfer vector. For example, the viral vector may be a plasmid and / or the viral genome may be operably linked to a promoter, as further defined herein. As used herein, "operably linked" means that the components described are in a functional relationship that allows them to function together in the intended manner. For, example, in the context of polynucleotide elements, a nucleic acid sequence is "operably linked" to another nucleic acid sequence when it is placed in a functional relationship with the other nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if the promoter or enhancer affects the transcription of the coding sequence.
[0174] In one embodiment, the viral vector of the present invention is a non-integrating viral vector. In a preferred embodiment, the viral vector of the present invention is an integrating viral vector.
[0175] In one embodiment, the viral vector of the present invention is a viral vector selected from the group consisting of lentiviral vector, such as an integrase-defective lentiviral vector, adeno-associated viral vector, adenoviral vector, herpes viral vector, retroviral vector, baculoviral vector and / or virus-like particle vector.
[0176] In one embodiment, the viral vector of the present invention is a non-enveloped viral vector. In one embodiment, the viral vector of the present invention is a non-enveloped viral vector selected from the group consisting of adenoviral vector, adeno-associated viral vector and non-enveloped virus-like particle vector.
[0177] In one embodiment, the viral vector of the present invention is an enveloped viral vector. In another embodiment, the viral vector of the present invention is an enveloped viral vector selected from the group consisting of lentiviral vector, such as integrase-defective lentiviral vector, herpes viral vector, retroviral vector, baculoviral vector and / or enveloped virus-like particle vector.
[0178] In a preferred embodiment, the viral vector of the present invention is a viral vector selected from the group consisting of lentiviral vector, retroviral vector and / or enveloped virus-like particle vector.
[0179] In an even more preferred embodiment, the viral vector of the present invention is a lentiviral vector (LV).
[0180] Regulatory elements of the viral vector
[0181] The viral vector of the present invention may comprise one or more regulatory elements which can act pre-or post-transcriptionally. Suitably, the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, is operably linked to one or more regulatory elements which may act pre- or post-
[0182] transcriptionally. In one embodiment, the one or more regulatory elements may facilitate expression of the nucleic acid of interest in all cells. In another embodiment, the one or more regulatory elements may facilitate expression of the nucleic acid of interest in hematopoietic cells, in particular in HSPCs and / or in differentiated hematopoietic cells.
[0183] As used herein, "regulatory element" refers to any nucleotide sequence that facilitates expression of a polypeptide. For example, such a regulatory element acts to increase expression of a transcript or to enhance mRNA stability. Suitable regulatory elements include, for example, promoters, enhancer elements, post-transcriptional regulatory elements, polyadenylation sequences and Kozak sequences, as further defined herein.
[0184] Promoters
[0185] The viral vector of the present invention comprises a promoter.
[0186] As used herein, the term "promoter" refers to a region of DNA that leads to initiation of transcription of a gene. Promoters are located near the transcription start sites of genes.
[0187] As used herein, the term "ubiquitous promoter" refers to a promoter that is strongly active in a wide range of cells, tissues and at different stages in the cell cycle. A ubiquitous promoter provides high-level, long-term expression in most cell types. As used herein, the term "tissue-specific promoter" refers to a promoter that preferentially facilitates expression of a transgene in a specific type of cell or tissue. Suitably, a tissue specific promoter may facilitate higher expression of a transgene in one cell type as compared to other cell types.
[0188] The level of expression may be measured, for example, by measuring the expression of a transgene that is operably linked to the promoter. For example, when green fluorescent protein (GFP) is the transgene, the level of expression can be measured by measuring fluorescence intensity at a suitable wavelength close to the emission peak of GFP. The expression of the transgene correlates with the ability of the promoter to facilitate expression of the transgene. For example, a tissue-specific promoter may be a promoter that facilitates transgene expression levels that are at least 10% higher, at least 20% higher, at least 30% higher, at least 40% higher, at least 50% higher, at least 100% higher, at least 200% higher, at least 300% higher, at least 400% higher, at least 500% higher or at least 1000% higher in one cell type as compared to transgene expression levels in other cell types.
[0189] In some embodiments, the promoter is a ubiquitous promoter. In other embodiments, the promoter is a tissue-specific promoter.
[0190] In some embodiments, the promoter is a ubiquitous promoter selected from the group consisting of: phosphoglycerate kinase (PGK) promoter, cytomegalovirus (CMV) promoter, CAG promoter (i.e., the CMV enhancer fused to the chicken beta-actin promoter (CAG) promoter), elongation factor 1-α1 (EF1α) promoter, simian virus 40 (SV40) promoter, and / or murine stem cell virus / MSCV promoter). A promoter variant derived from any of these promoters may be used, provided that the promoter variant retains the capacity to drive expression of a gene of interest that is operably linked to the promoter variant at least in HSPCs and / or in differentiated hematopoietic stem cells. A skilled person will be able to arrive at such promoter variants using methods known in the art. The promoter variant may, for example, have at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any of the promoters referred to herein. A fragment of any of the promoters referred to herein (or variants thereof) may be used, provided that the promoter fragment retains the capacity to drive expression of a gene of interest that is operably linked to the promoter at least in HSPCs and / or differentiate hematopoietic cells. A skilled person will be able to arrive at such promoter fragments using methods known in the art. The promoter fragment may, for example, be at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides or at least 1000 nucleotides in length.
[0191] In a preferred embodiment, the promoter is a phosphoglycerate kinase (PGK) promoter or a variant and / or fragment thereof. The PGK promoter may have the following sequence: tgcgcagggacgcggctgctctgggcgtggttccgggaaacgcagcggcgccgaccctgggtctcgcacattcttcacgtccgttcgcagcgtcacccggat cttcgccgctacccttgtgggccccccggcgacgcttcctgctccgcccctaagtcgggaaggttccttgcggttcgcggcgtgccggacgtgacaaacgga agccgcacgtctcactagtaccctcgcagacggacagcgccagggagcaatggcagcgcgccgaccgcgatgggctgtggccaatagcggctgctcagc ggggcgcgccgagagcagcggccgggaaggggcggtgcgggaggcggggtgtggggcggtagtgtgggccctgttcctgcccgcgcggtgttccgcattc tgcaagcctccggagcgcacgtcggcagtcggctccctcgttgaccgaatcaccgacctctctccccagg
[0192] SEQ ID NO: 1
[0193] In some embodiments, the human PGK promoter comprises or consists of a nucleotide sequence that has at least 70% sequence identity to the sequence set forth in SEQ ID NO: 1 or a fragment thereof. Suitably, the human PGK promoter comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 1 or a fragment thereof.
[0194] The promoter may be a constitutive promoter. As used herein, a "constitutive promoter" is a promoter that is always active.
[0195] Alternatively, the promoter may be an inducible promoter. As used herein, an "inducible promoter" is a promoter that is only active under specific conditions. For example, expression of the transgene may be induced by a small molecule or drug (e.g., which binds to a promoter, regulatory sequence or to a
[0196] transcriptional repressor or activator molecule) or by using an environmental trigger. Types of inducible promoter include chemically inducible promoters (e.g., a Tet-on system); temperature inducible promoters (e.g., Hsp70or Hsp90-derived promoters); and light-inducible promoters. Suitably, the promoter is chemically inducible. Any suitable method for engineering an inducible promoter may be used.
[0197] Enhancer elements
[0198] In one embodiment, the viral vector of the present invention may comprise an enhancer.
[0199] As used herein, "enhancer" or "enhancer element" refers to a region of DNA that can be bound by proteins (activators) to increase the likelihood that transcription of a particular gene will occur. Enhancers are a cisacting element. As used herein "cis-acting element" refers to a sequence element that is not part of the coding sequence of the gene they regulate. Cis-acting elements may be near the promoter or the 5' region of the gene, or in some cases they may be many kilobases away from the gene, upstream or downstream from the start site.
[0200] As used herein, the term "ubiquitous enhancer" refers to an enhancer that is strongly active in a wide range of cells, tissues and at different stages in the cell cycle. A ubiquitous enhancer facilitates high-level, long-term expression in most cell types.
[0201] As used herein, the term "tissue-specific enhancer" refers to an enhancer that preferentially facilitates expression of a gene in specific cells or tissues. Suitably, a tissue-specific enhancer may facilitate higher expression of a transgene in one cell type as compared to other cell types. The level of expression may be measured, for example, by measuring the expression of a transgene that is operably linked to the enhancer. For example, when green fluorescent protein (GFP) is the transgene, the level of expression can be measured by measuring fluorescence intensity at a suitable wavelength close to the emission peak of GFP. The expression of the transgene correlates with the ability of the enhancer to facilitate expression of the transgene. For example, a tissue-specific enhancer may be an enhancer that facilitates transgene expression levels that are at least 10% higher, at least 20% higher, at least 30% higher, at least 40% higher, at least 50% higher, at least 100% higher, at least 200% higher, at least 300% higher, at least 400% higher, at least 500% higher or at least 1000% higher in one cell type as compared to transgene expression levels in other cell types.
[0202] In some embodiments, the enhancer is a ubiquitous enhancer. In other embodiments, the enhancer is a tissue-specific enhancer. In both of these embodiments, the enhancer is operably linked to the nucleic acid of interest, such as the gene of interest.
[0203] When the enhancer is a tissue-specific enhancer, the enhancer is preferably or is preferably derived from an enhancer associated with a gene with selective expression in HSPCs and / or in differentiated hematopoietic cells. Suitably, the enhancer may be (or may be derived from) an enhancer associated with a gene with selective expression in HSPCs and / or in differentiated hematopoietic cells.
[0204] Methods to identify the enhancer regions associated with genes will be well known to the skilled person.
[0205] An enhancer variant derived from any of these enhancers may be used, provided that the enhancer variant retains the capacity to drive expression of a nucleic acid of interest, such as a gene of interest, that is operably linked to the enhancer variant at least in HSPCs and / or in differentiated hematopoietic cells. A skilled person will arrive at such enhancer variants using methods known in the art. The enhancer variant may, for example, have at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any of the enhancers referred to herein or known in the art.
[0206] A fragment of any of the enhancers referred to herein (or variants thereof) or known in the art (or variants thereof) may be used, provided that the enhancer fragment retains the capacity to facilitate expression of a nucleic acid of interest, such as a gene of interest, that is operably linked to the enhancer fragment. A skilled person will be able to arrive at such fragments using methods known in the art. The enhancer fragment may be at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides or at least 1000 nucleotides in length.
[0207] Promoters and / or enhancer elements
[0208] In one embodiment, the viral vector of the present invention may comprise a ubiquitous promoter and / or a ubiquitous enhancer, i.e., a ubiquitous promoter and / or enhancer. Suitably, the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, is operably linked to a ubiquitous promoter and / or enhancer. The promoter and enhancer may be a combination of any of the above.
[0209] In another embodiment, the vector of the present invention may comprise a tissue-specific promoter and / or a tissue-specific enhancer, i.e., a tissue-specific promoter and / or enhancer. Suitably, the tissue-specific promoter and / or enhancer are specific for expression in HSPCs and / or in differentiated hematopoietic cells. Suitably, the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, is operably linked to a promoter and / or enhancer specific to HSPCs and / or to differentiated hematopoietic cells. Suitably, the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, is operably linked to a promoter and / or enhancer specific to HSPCs and / or to differentiated hematopoietic cells. The promoter and enhancer may be a combination of any of the above.
[0210] In a preferred embodiment, the viral vector of the present invention is operably linked to a ubiquitous promoter and / or a ubiquitous enhancer.
[0211] Post-transcriptional regulatory elements
[0212] The viral vector of the present invention may comprise one or more further post-transcriptional regulatory elements. Suitably, the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, is operably linked to one or more further post-transcriptional regulatory elements. The further post-transcriptional regulatory element or elements may improve gene expression.
[0213] The viral vector of the present invention may comprise a Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element (WPRE). Suitably, the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, is operably linked to a WPRE.
[0214] Suitable WPRE sequences will be well known to those of skill in the art (see, for example, Zufferey et al., Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances Expression of Transgenes Delivered by Retroviral Vectors, J of Virol, 73, 2886-2892 (1999)); Zanta-Boussif etal., Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: Application to the gene therapy of WAS, Gene Therapy, 16, 605-619 (2009)). Suitably, the WPRE is a wild-type WPRE or is a mutant WPRE. For example, the WPRE may be mutated to abrogate translation of the woodchuck hepatitis virus X protein (WHX), for example by mutating the WHX ORF translation start codon.
[0215] In some embodiments, the WPRE comprises or consists of a nucleotide sequence that has at least 70% sequence identity to the sequence set forth in SEQ ID NO: 2 or a fragment thereof. Suitably, the WPRE comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 2 or a fragment thereof.
[0216] In some embodiments, the WPRE comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 2 or a fragment thereof.
[0217] AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCC TTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGG CTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCC GTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGG CATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGG
[0218] CGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGAC
[0219] AATTCCGTGGTGTTGTCGGGGAAATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCAC
[0220] CTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTC
[0221] CTTCCCGC
[0222] (SEQ ID NO: 2)
[0223] Polyadenylation sequence
[0224] The viral vector or non-viral vector of the present invention may comprise a polyadenylation sequence (also referred to herein as poly(A) sequence or poly(A) signal sequence). Suitably, the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, is operably linked to a polyadenylation sequence. A polyadenylation sequence may be inserted after the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, to improve expression of the nucleic acid of interest.
[0225] A polyadenylation sequence typically comprises a polyadenylation signal, a polyadenylation site and a downstream element: the polyadenylation signal comprises the sequence motif recognised by the RNA cleavage complex; the polyadenylation site is the site of cleavage at which a poly-A tail is added to the mRNA; the downstream element is a GT-rich region which usually lies just downstream of the polyadenylation site, which is important for efficient processing.
[0226] Suitable polyadenylation sequences will be well known to those of skill in the art (see, for example, Schambach etal., Improving Transcriptional Termination of Self-inactivating Gamma-retroviral and Lentiviral Vectors, Molecular Therapy, 15, 1167-1173 (2007); Choi etal., Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons, Molecular Brain, 7, 1-10 (2014)). Exemplary polyadenylation sequences include the bGH poly(A) signal sequence and SV40pA signal sequence.
[0227] Kozak sequence
[0228] The viral vector of the present invention may comprise a Kozak sequence. Suitably, the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, is operably linked to a Kozak sequence. A Kozak sequence may be inserted before the start codon to improve the initiation of translation.
[0229] Suitable Kozak sequences will be well known to the skilled person (see, for example, Kozak, Nucleic Acids Research 15: 8125-8148 (1987)).
[0230] In some embodiments, the Kozak sequence comprises or consists of a nucleotide sequence that has at least 80% sequence identity to the sequence set forth in SEQ ID NO: 3 or a fragment thereof.
[0231] In some embodiments, the Kozak sequence comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 3 or a fragment thereof.
[0232] GCCACC
[0233] (SEQ ID NO: 3)
[0234] Other cis-acting elements
[0235] The viral vector of the present invention may comprise any other suitable cis-acting elements.
[0236] As used herein "cis-acting element" refers to a sequence element that is not part of the coding sequence of the gene they regulate. Cis-acting elements may be near the promoter or the 5' region of the gene, or in some cases they may be many kilobases away from the gene, upstream or downstream from the start site.
[0237] Depending on the type of viral vector, these cis-acting elements may be selected from the group consisting of one or more of a rev response element (RRE), a retroviral psi packaging element, a primer binding site (PBS), a TAT activation region (TAR), splice donor and acceptor sites, long terminal repeats (LTRs), and central and terminal polypurine tracts.
[0238] The viral vector of the present invention may further comprise one or more viral packaging elements. A viral packaging element is a cis-acting element that is involved in regulating the process of packaging the viral genome into the viral capsid during replication.
[0239] Different types of viruses comprise different viral packaging elements that may be included in corresponding viral vectors used in the present invention.
[0240] Suitable viral packaging elements for specific viral vectors will be well known to the skilled person. More specific definitions of packaging elements of some exemplary viral vectors are defined herein below.
[0241] Lentiviral vectors
[0242] In a preferred embodiment, the viral vector of the present invention is a lentiviral vector (also abbreviated as " LV" herein).
[0243] In one embodiment, the lentiviral vector may be in the form of a lentiviral particle. In other embodiments, the lentiviral vector may comprise a lentiviral genome, optionally wherein the lentiviral genome is enveloped.
[0244] As used herein, the term "lentiviral genome" refers to a genome that comprises at least one element derived or derivable from a lentivirus genome.
[0245] The term "element derived or derivable from a lentivirus genome" as used herein refers to an element of a component of a reference lentivirus genome that may differ, e.g., in sequence, from the corresponding element of the component in the reference lentivirus genome, but that fulfils the same function, to the same or a similar extent, as the corresponding element of the component in the reference lentivirus genome. Typically, there are three components of a lentivirus genome: (1) the regulatory cassette comprising regulatory elements, in particular enhancer, promoter and / or auxiliary elements that control expression of genes as an episome or as a chromosomal integrant; (2) the nucleic acid of interest, such as the gene of interest; and (3) the protein envelope and / or capsid.
[0246] Lentivirus is a genus of retroviruses, which contain an RNA genome that is converted to DNA in the transduced cell by a reverse transcriptase. Lentiviral vectors can transduce a wide range of cell types and integrate into the host genome in both dividing and post-mitotic cells, resulting in long-term expression of the proteincoding sequence both in vitro and in vivo.
[0247] The basic genes required for lentivirus survival and function are the gag, pol, and env genes: gag encodes structural proteins; pol encodes enzymes required for reverse transcription and integration into the host cell genome; and env encodes the viral envelope glycoprotein.
[0248] Lentiviruses may also have additional cis-acting elements, such as a rev response element (RRE), which enables the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell; a retroviral psi packaging element, which is involved in regulating the essential process of packaging the retroviral RNA genome into the viral capsid during replication; a primer binding site (PBS), where reverse transcription is initiated; the TAT activation region (TAR); splice donor and acceptor sites; and central and terminal polypurine tracts, which allow initiation of plus-strand synthesis.
[0249] In a lentivirus genome, the elements are typically flanked at both ends by regions called long terminal repeats (LTRs). The LTRs are responsible for integration and transcription. LTRs may also serve as enhancer-promoter sequences and can control the expression of the lentiviral genes. The LTRs themselves are identical or nearidentical sequences that can typically be divided into three regions: U3, R and U5. LTRs may be naturally occurring or may be modified. For example, U3 and U5 modifications are described in Iwakuma et al., SelfInactivating Lentiviral Vectors with U3 and U5 Modifications, Virology, 261, 120-132 (1999).
[0250] The lentiviral vector of the present invention may comprise a minimal lentiviral genome. As used herein, a "minimal lentiviral genome" means that the lentiviral genome has been manipulated so as to remove thenon-essential elements and to retain the essential elements in order to provide the required functionality to infect, transduce and deliver a nucleotide sequence of interest to a target host cell (see, for example, Kim et al., Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1, J of Virol, 72, 811-816 (1998)); Sertkaya et al., HIV-1 sequences in lentiviral vector genomes can be substantially reduced without compromising transduction efficiency, Scientific Reports, 11, 1-15, (2021)).
[0251] A lentiviral genome may comprise from 5' to 3': a 5' LTR, one or more lentiviral-derived cis-acting elements, and a 3' LTR. Suitably, a lentiviral genome may comprise from 5' to 3': a 5' LTR, a RRE, and a 3' LTR. Suitably, a lentiviral genome may comprise from 5' to 3': a 5' LTR, a retroviral psi packaging element, a RRE, and a 3' LTR. Suitably, a lentiviral genome may comprise from 5' to 3': a 5' LTR, a retroviral psi packaging element, a RRE, a cPPT, and a 3' LTR. Preferably, a lentiviral genome may comprise from 5' to 3': a 5' LTR, a PBS, a retroviral psi packaging element, a RRE, a cPPT, and a 3' LTR.
[0252] A lentiviral genome may further comprise a protein-coding sequence and, optionally, one or more regulatory elements (e.g., operably linked to the protein-coding sequence). Suitably, a lentiviral genome may comprise from 5' to 3': a 5' LTR, a RRE, a protein-coding sequence, and a 3' LTR. Suitably, a lentiviral genome may comprise from 5' to 3': a 5' LTR, a retroviral psi packaging element, a RRE, a protein-coding sequence, and a 3' LTR. Suitably, a lentiviral genome may comprise from 5' to 3': a 5' LTR, a retroviral psi packaging element, a RRE, a cPPT, a protein-coding sequence, and a 3' LTR. Preferably, lentiviral genome may comprise from 5' to 3': a 5' LTR, a PBS, a retroviral psi packaging element, a RRE, a cPPT, a protein-coding sequence, and a 3' LTR.
[0253] The lentiviral vector of the present invention may be replication-defective. Typically, at least part of one or more protein coding regions essential for replication may be removed from the lentiviral genome. This makes the lentiviral vector "replication-defective" or "replication-incompetent". Suitably, one or more of gag, pol, rev, and env genes are deleted (at least partially) in a replication-defective lentiviral vector. Suitably, each of the gag, pol, rev, and env genes are deleted (at least partially) in a replication-defective lentiviral vector. Optionally, the lentiviral vector lacks a functional gag-pol and / or env gene and / or other genes essential for replication.
[0254] The lentiviral vector of the present invention may be derived from any lentivirus. As used herein "lentivirus-derived" or "lentivirus-based" means that the lentiviral genome comprises one or more elements from said lentivirus. For example, the coding regions of viral proteins may be deleted, but one or more cis-acting element(s) may be retained from said lentivirus.
[0255] The lentiviral vector may be derived from a primate lentivirus. Examples of "primate" lentiviruses include, but are not limited to, human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV). Thelentiviral vector may be derived from a non-primate lentivirus (i.e., derived from a lentivirus which does not primarily infect primates, especially humans). Examples of "non-primate" lentiviruses include, but are not limited to, the prototype "slow virus" visna / maedi virus (VMV), caprine arthritis-encephalitis virus (CAEV), equine infectious anaemia virus (EIAV), feline immunodeficiency virus (FIV), and bovine immunodeficiency virus (BIV).
[0256] Suitably, the lentiviral vector of the present invention is a HIV-derived lentiviral vector. As used herein " HIV-derived" or " HIV-based" means that the lentiviral genome comprises one or more element(s) from HIV. For example, the coding regions of HIV viral proteins may be deleted, and one or more HIV cis-acting element may retained in the lentiviral genome (see, for example, Johnson (2021) Molecular Therapy-Methods & Clinical Development 21: 451-465). A HIV-derived lentiviral genome may comprise from 5' to 3': a 5' LTR, one or more HIV-derived cis-acting elements (e.g., RRE and / or cPPT), and a 3' LTR.
[0257] Suitably, the lentiviral vector of the present invention is a HIV-l-derived lentiviral vector. The prototype lentiviral vector system is based on HIV-1 (see, for example, Merten et al., Production of lentiviral vectors, Mol Ther Methods Clin Dev, 3, 16017 (2016)). It has been shown that sequences that extend into the gag open reading frame may be important for packaging of HIV-1. Therefore, HIV-1 vectors often contain the relevant portion of gag in which the translational initiation codon has been mutated. In addition, HIV-1 vectors often also contain a portion of the env gene that includes the RRE. Rev binds to RRE, which permits the transport of full-length or singly spliced mRNAs from the nucleus to the cytoplasm. In the absence of rev and / or a RRE, full-length HIV-1 RNAs may accumulate in the nucleus. Alternatively, a constitutive transport element from certain simple retroviruses such as Mason-Pfizer monkey virus can be used to relieve the requirement for rev and a RRE. A HIV-l-derived lentiviral genome may comprise from 5' to 3': a 5' LTR, one or more HIV-l-derived cis-acting elements (e.g., a PBS, a retroviral psi packaging element, a RRE and / or a cPPT), and a 3' LTR.
[0258] The lentiviral vector of the present invention may be a self-inactivating lentiviral vector. As used herein, "selfinactivating" or " SIN" lentiviral vectors may comprise lentiviral genomes in which the lentiviral enhancer and promoter sequences have been deleted (see, for example, Zufferey et al., Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery, J Virol, 72, 9873-9880 (1998); Miyoshi et al., Development of a self-inactivating lentivirus vector, J Virol, 72, 8150-8157 (1998)). SIN lentiviral vectors can be generated and transduce non-dividing cells in vivo with an efficacy similar to that of wild-type vectors. The transcriptional inactivation of the long terminal repeat (LTR) in the SIN provirus can prevent mobilisation by replication-competent virus. This can also enable the regulated expression of genes from internal promoters by eliminating any cis-acting effects of the LTR.
[0259] The lentiviral vector of the present invention may be integration competent. As used herein, an "integration competent" lentiviral vector is capable of integrating into the genome of a host cell. In contrast to integrationcompetent lentiviral vectors, integration defective lentiviral vectors (IDLVs) can be produced, for example by packaging the lentiviral vector with catalytically inactive integrase (such as an HIV integrase bearing the D64V mutation in the catalytic site) or by modifying or deleting essential att sequences from the lentiviral genome LTR, or by a combination of the above (see, for example, Wanisch et al., Integration-deficient lentiviral vectors: a slow coming of age, Mol Ther, 17, 1316-1332 (2009)).
[0260] In one embodiment, the lentiviral vector of the present invention may be replication-defective and integrating. In a preferred embodiment, the lentiviral vector of the present invention may be replicationdefective, integrating, and self-inactivating. In an even more preferred embodiment, the lentiviral vector of the present invention may be replication-defective, integrating, self-inactivating, and HIV-derived.
[0261] The lentiviral vector of the present invention may be a lentiviral particle. A "lentiviral particle" refers to an enveloped lentiviral genome. Lentiviral particles may be generated by co-transfection of a plasmid containing a lentiviral genome (e.g., a "transfer vector") with helper plasmids (e.g., "packaging vectors" encoding gag-pol and / or rev, and "envelope vectors" encoding env) into host cells and harvesting of the lentivirus-containing supernatant afterwards.
[0262] The lentiviral vector of the present invention may be pseudotyped. Pseudotyping lentiviral vectors with naturally occurring or engineered lentiviral envelopes can allow targeted transduction of specific cell types (see, for example, Joglekar etal., Pseudotyped Lentiviral Vectors: One Vector, Many Guises, Hum Gene Ther Methods, 28, 291-301 (2017)). Suitably, the lentiviral vector is pseudotyped to allow transduction of HSPCs and / or of differentiated hematopoietic cells. In some embodiments, the lentiviral vector is a Vesicular stomatitis virus G protein (VSV-G)-pseudotyped lentiviral vector. Vesicular stomatitis virus G protein (VSV-G) is a commonly used envelope protein for pseudotyping. VSV-G is a trimeric protein that binds phosphatidylserine and low-density lipoprotein receptors on a cell surface to endocytose into the cell.
[0263] In some embodiments, the lentiviral vector of the present invention: (i) is a CD47highlentiviral vector; and / or(ii) is an MHC-Ifreelentiviral vector. In preferred embodiments, the lentiviral vector of the present invention isa CD47highand MHC-Ifreelentiviral vector. Each of these features individually or in combination reduces immune responses to the viral vector following administration.
[0264] CD47highlentiviral vectors
[0265] The lentiviral vector of the present invention may be a CD47highlentiviral vector. As used herein, a "CD47highlentiviral vector" refers to a lentiviral vector with increased levels of CD47 (Cluster of Differentiation 47) CD47 (or a variant or fragment thereof) on its surface. A CD47highlentiviral vector has reduced uptake by professional phagocytes. In some embodiments the surface of a CD47hlghlentiviral vector comprises a higher1
[0266] level of CD47 protein than a control lentiviral vector produced in HEK293T cells. The skilled person knows how to obtain suitable HEK293T cells and how to perform a suitable control experiment to compare levels of CD47 protein on lentiviral vectors.
[0267] CD47 (Cluster of Differentiation 47), also known as integrin associated protein (IAP), is a transmembrane protein that in humans is encoded by the CD47 gene. Phagocytosis is physiologically inhibited by CD47, which is a ubiquitously expressed ligand of signal regulatory protein a (SIRP-a) receptor that is expressed by professional phagocytes. CD47 may be incorporated into lentiviral vectors when they bud from producer cells.
[0268] The lentiviral vector of the present invention may comprise one or more CD47 polypeptides (or a variant or fragment thereof) on its surface. The amount of CD47 (or a variant or fragment thereof) on the surface may be enough to reduce uptake by professional phagocytes. Any suitable assay to quantify the amount of CD47 polypeptides (or variants or fragments thereof) present on the surface of the lentiviral vector may be used. The skilled person knows suitable assays to quantify the amount of CD47 polypeptides (or variants or fragments thereof) present on the surface of the lentiviral vector.
[0269] In some embodiments, the density of CD47 polypeptides (or variant or fragments thereof) may be determined by immunostaining for CD47 and total internal reflection fluorescence microscopy, for example as described in US 2010 / 0316570 Al, materials and methods of the examples section. The CD47 polypeptides (or variant or fragments thereof) may be present at a density of at least about 20 molecules / μm2, at least about 25 molecules / μm2, at least about 30 molecules / μm2, at least about 35 molecules / μm2, at least about 40 molecules / μm2, at least about 45 molecules / μm2, at least about 50 molecules / μm2, at least about 60 molecules / μm2, at least about 70 molecules / μm2, at least about 80 molecules / μm2, at least about 90 molecules / μm2, at least about 100 molecules / μm2, at least about 150 molecules / μm2, at least about 200 molecules / μm2, at least about 250 molecules / μm2, at least about 300 molecules / μm2, at least about 350 molecules / μm2, at least about 400 molecules / μm2, at least about 450 molecules / μm2, at least about 500 molecules / μm2, at least about 600 molecules / μm2, at least about 700 molecules / μm2, at least about 800 molecules / μm2, at least about 900 molecules / μm2or at least about 1000 molecules / μm2. The CD47 polypeptides (or fragments thereof) may be present at a density of about 1000 molecules / μm2or less, about 500 molecules / μm2or less or about 250 molecules / μm2or less. The CD47 polypeptides (or fragments thereof) may be present at a density of from about 20 molecules / μm2to about 1000 molecules / μm2, from about 20 molecules / μm2to about 500 molecules / μm2or from about 20 molecules / μm2to about 250 molecules / pm2. In a preferred embodiment, the CD47 polypeptides (or fragments thereof) are present at a density of from about 90 molecules / μm2to about 900 molecules / μm2.
[0270] In some embodiments, the amount of CD47 polypeptides (or variant or fragments thereof) may be determined by immunostaining for CD47 and electron microscopy, as described in Milani etal., Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates, Sci Transl Med, 11(493), eaav7325 (2019)). The CD47 polypeptides (or variants or fragments thereof) may be detected in an amount of at least about 10 gold particles / lentiviral particle, at least about 15 gold particles / lentiviral particle or at least about 20 gold particles / lentiviral particle. The CD47 polypeptides (or variants or fragments thereof) may be detected in an amount of about 100 gold particles / lentiviral particle or less, about 80 gold particles / lentiviral particle or less or about 60 gold particles / lentiviral particle or less. The CD47 polypeptides (or fragments thereof) may be detected in an amount of from about 10 to about 100 gold particles / lentiviral particle, from about 15 to about 80 gold particles / lentiviral particle or, in a preferred embodiment, from about 20 to about 60 gold particles / lentiviral particle.
[0271] The lentiviral vector of the present invention may be obtained from a CD47highproducer cell. As used herein, a "CD47highproducer cell" refers to a producer cell with increased levels of CD47 (or a fragment thereof) on its surface.
[0272] A CD47highproducer cell may be genetically engineered to increase expression of CD47 (or a variant or fragment thereof) on the cell surface. For example, the producer cell may comprise a vector encoding CD47 (or a variant or fragment thereof) or may be edited to introduce a nucleotide sequence encoding CD47 (or a variant or fragment thereof) into its genome. Suitably, the producer cell is transduced with a viral vector encoding a CD47 polypeptide (or a variant or fragment thereof).
[0273] A CD47highproducer cell may have a higher concentration of CD47 (or a variant or fragment thereof) on its surface than an unmodified producer cell. Suitably, the producer cell has at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold or at least about 30-fold more CD47 on its cell surface than an unmodified producer cell. Suitably, the producer cell has from about 5-fold to about 30-fold more CD47 (or a fragment thereof) on its cell surface than an unmodified producer cell.
[0274] Suitably, the lentiviral vector of the present invention has a higher concentration of CD47 (or a variant or fragment thereof) on its surface than a lentiviral vector obtained from an unmodified producer cell. Suitably, the lentiviral vector has at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold or at least about 50-fold more CD47 (or a variant or fragment thereof) on its surface than a lentiviral vector obtained from an unmodified producer cell. Suitably, the lentiviral vector has from about 5-fold to about 30-fold more CD47 (or a variant or fragment thereof) on its surface than a lentiviral vector obtained from an unmodified producer cell.
[0275] CD47 is a member of the immunoglobulin (Ig) superfamily of membrane proteins, with a single IgV-like domain at its N-terminus, a highly hydrophobic stretch with five membrane-spanning segments and an alternatively spliced cytoplasmic C-terminus ranging in length from 3 to 36 amino acids. Mouse, rat, bovine and human CD47 molecules have been cloned and show about 70% overall amino acid identity (see, for example, Brown etal., Integrin-associated protein (CD47) and its ligands, Trends Cell Biol, 11, 130-135 (2001)).
[0276] The CD47 polypeptide (or a variant or fragment thereof) may be a human CD47 polypeptide (or a variant or fragment thereof). A CD47 polypeptide may have an amino acid sequence of UniProtKB Q08722.
[0277] Exemplary CD47 polypeptides are provided as the sequences set forth in SEQ ID NOs: 4-7. Suitably, a CD47 polypeptide comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to any of the sequences set forth in SEQ ID NOs: 4-7. Suitably, a CD47 polypeptide comprises or consists of the amino acid sequence set forth in any of SEQ ID NOs: 4-7.
[0278] Exemplary CD47 amino acid sequences:
[0279] MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRNN
[0280] (SEQ ID NO: 4)
[0281] MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRKAVEEPLNAFKESKGMMNDE
[0282] (SEQ ID NO: 5)
[0283] MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTWIPCFVTNMEAQNTTEVYVKWKFKG RDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGE TIIELKYRWSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVI
[0284] TVIVIVGAILFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQLLGLVYMKFV
[0285] (SEQ ID NO: 6)
[0286] MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTWIPCFVTNMEAQNTTEVYVKWKFKG RDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGE TIIELKYRWSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVI TVIVIVGAILFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRKAVEEPL
[0287] N
[0288] (SEQ ID NO: 7)
[0289] Exemplary CD47 polypeptides excluding the signal peptide are provided as the sequences set forth in SEQ ID NOs: 8-11. Suitably, a CD47 polypeptide comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to any of the sequences set forth in SEQ ID NOs: 8-11. Suitably, a CD47 polypeptide comprises or consists of the amino acid sequence of any of the sequences set forth in SEQ ID NOs: 8-11.
[0290] Exemplary CD47 amino acid sequences excluding signal peptide:
[0291] QLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRNN
[0292] (SEQ ID NOs: 8)
[0293] QLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRKAVEEPLNAFKESKGMMNDE
[0294] (SEQ ID NOs: 9)
[0295] QLLFNKTKSVEFTFCNDTWIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTD FSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRWSWFSPNEN
[0296] ILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSL KNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAWGLSLCIAACIPM HGPLLISGLSILALAQLLGLVYMKFV
[0297] (SEQ ID NOs: 10)
[0298] QLLFNKTKSVEFTFCNDTWIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTD FSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRWSWFSPNEN ILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSL KNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAWGLSLCIAACIPM HGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRKAVEEPLN
[0299] (SEQ ID NOs: 11)
[0300] The skilled person would be able to generate variants and / or fragments of CD47, for example based on conservative substitutions and / or the known structural and functional features of CD47. These are described, e.g., in Fenalti et al., Structure of the human marker of self 5-transmembrane receptor CD47, Nature Communications, 12, 1-14 (2021).
[0301] Suitably, a fragment of CD47 and / or CD47 variant retains the ability to inhibit phagocytosis. Suitably, a CD47 fragment and / or CD47 variant may comprise the extracellular domain of CD47. The extracellular domain of human CD47 may interact with SIRP-a and inhibit phagocytosis. Optionally, a CD47 fragment and / or CD47 variant comprises the transmembrane domain of CD47. The domains may be linked by inter-domain linker(s). The fragment and / or variant may have at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% of the activity of a full-length CD47 polypeptide.
[0302] Suitably, a variant of the sequence set forth in SEQ ID NO: 4 may comprise one or more substitutions selected from V5I, C14W, C15R, F22L, S27F, F30L, F32Y, T36S, V38L, V38I, F42V, T44A, N50S, T51A, T52S, T52A, V56I, R63K, A71T, S75Y, T76A, P78L, P78S, P78A, S82R, S82N, S83T, K85N, K85E, V88A, V88L, V88I, Q90R, L91F, K93N, M100I, M100V, D101G, K102R, K102T, S107L, I126F, 1127V, K130Q, R132H, S138F, V146I, 1150V, 1153V, S169A, G170R, G170S, G171S, D173Y, 1177V, A178G, V181I, V185A, 1186V, V188A, I189T, 1191V, V198I, A207S, T215I, I219M, Y226C, A231S, T235A, S236F, A240V, A240T, 1241V, V243I, I244T, V246L, Y249F, A252S, A252T, V254A, S257T, I264M, I264L, M266I, M266T, M266V, V287I, V292A, N295S, N295D, Q296L, P302S, N304S and N304D. These are considered to be tolerated, benign, and / or likely benign variations as predicted by SIFT, PolyPhen, CADD, REVEL and MetaLR.
[0303] Suitably, a variant of the sequence set forth in SEQ ID NO: 5 may comprise one or more substitutions selected from P3L, A6P, F22L, S27F, F30L, F32Y, T36S, V38L, V38I, F42V, N50S, T51A, T52S, T52A, V56I, R63K, A71T, S75Y, T76A, P78L, P78S, P78A, S82R, S82N, S83T, K85N, K85E, V88A, V88L, V88I, Q90R, L91F, K93N, M100I,M100V, D101G, K102R, K102T, S107L, I126F, 1127V, K130Q, R132H, S138F, V146I, 1150V, 1153V, S169A, G170R, G170S, G171S, 1177V, A178G, V181I, I186V, V188A, I189T, 1191V, V198I, A207S, T215I, I219M, Y226C, A231S, T235A, A240V, A240T, 1241V, V243I, I244T, V246L, Y249F, A252S, A252T, V254A, I264M, I264L, M266I, M266T, M266V, V287I, V292A, N295S, N295D and Q296L. These are considered to be tolerated, benign, and / or likely benign variations as predicted by SIFT, PolyPhen, CADD, REVEL, and MetaLR.
[0304] An exemplary CD47 fragment is the sequence set forth in SEQ ID NO: 12. Suitably, a CD47 fragment comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequence set forth in SEQ ID NO: 12. Suitably, a CD47 fragment comprises or consists of the amino acid sequence set forth in SEQ ID NO: 12.
[0305] Exemplary CD47 fragment:
[0306] MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTWIPCFVTNMEAQNTTEVYVKWKFKG RDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGE
[0307] TIIELKYRVVSWFSPN
[0308] (SEQ ID NO: 12)
[0309] An exemplary CD47 fragment excluding the signal peptide is the sequence set forth in SEQ ID NO: 13. Suitably, a CD47 fragment comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% identity to the sequence set forth in SEQ ID NO: 13. Suitably, a CD47 fragment comprises or consists of the amino acid sequence set forth in SEQ ID NO: 13.
[0310] Exemplary CD47 fragment excluding signal peptide:
[0311] QLLFNKTKSVEFTFCNDTWIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTD
[0312] FSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRWSWFSPN
[0313] (SEQ ID NO: 13)
[0314] MHC-Ilowor MHC-Ifreelentiviral vectors
[0315] The lentiviral vector of the present invention may be an MHC-I10” lentiviral vector or an MHC-Ifreelentiviral vector. In preferred embodiments, the lentiviral vector of the present invention is an MHC-Ifreelentiviral vector.
[0316] As used herein, the term " MHC-I10” lentiviral vector" refers to a lentiviral vector with reduced levels of one or more MHC-I molecules on its surface (i.e., reduced levels of surface-exposed MHC-I molecules). The number of surface-exposed MHC-I molecules may be reduced such that the immune response to the MHC-I is decreased to a therapeutically relevant degree.
[0317] As used herein, the term " MHC-Ifreelentiviral vector" refers to a lentiviral vector which is substantially devoid of (or free of) one or more MHC-I molecules on its surface (i.e., substantially devoid of (or free of) surface-exposed MHC-I molecules). Specifically, the surface of the lentiviral vector may not comprise MHC-I.
[0318] The major histocompatibility complex class I (MHC-I) is a heterodimeric membrane protein that is displayed on the outer leaflet of the cell membrane (see, for example, Penn et al., Major histocompatibility complex (MHC), in eLS (2005)). MHC-I functions to bind and display peptide fragments of proteins to the extracellular environment, where they may be recognised by CD8+ cytotoxic T cells. Peptide fragments generated from normal cellular proteins will not activate cytotoxic T cells due to central and peripheral tolerance mechanisms. However, foreign peptides (e.g., those originating from viral proteins) will cause activation of an immune response to destroy the cell. An allogeneic MHC-I protein itself may be recognised by the immune system. For example, antibodies may bind MHC-I epitopes directly. As a result, lentiviral vectors that comprise MHC-I molecules originating from an allogeneic source may be targeted and neutralised by the immune system.
[0319] The term " MHC-I molecules" may refer to human MHC-I molecules. Human MHC-I is also referred to as human leukocyte antigen class I (HLA-I) and is expressed on almost all nucleated cells. HLA-I consists of two polypeptide chains, an HLA-I heavy chain (a chain) and R2 microglobulin (B2M or fc chain). The HLA-I a chain and B2M are linked non-covalently. The HLA-I a chain is polymorphic. Six HLA-I a chains have been identified to date, including three classical, highly polymorphic a chains (HLA-A, HLA-B and HLA-C) and three non-classical, less polymorphic (HLA-E, HLA-F and HLA-G) a chains. The MHC-I molecules may comprise or consist of HLA-A, HLA-B and HLA-C molecules, which comprise an invariant B2M sequence.
[0320] The term " MHC-I molecules" also includes variant MHC-I sequences, such as polymorphisms of HLA-I a chain sequences and / or B2M sequences. For example, variant MHC-I sequences may include HLA-I a chain sequences and / or B2M sequences with single nucleotide polymorphisms (SNPs) or multiple SNPs. Such variant MHC-I sequences with SNPs or multiple SNPs are known in the art.
[0321] Any suitable assay to quantify the amount of MHC-I molecules present on the surface of the lentiviral vector may be used.
[0322] In some embodiments, the amount of MHC-I molecules may be determined by immunostaining for MHC-I and electron microscopy, for example as described in Milani et al., Genome editing for scalable productionof alloantigen-free lentiviral vectors for in vivo gene therapy, EMBO Mol Med, 9, 1558-1573 (2017), on page 1570. The MHC-I molecules may be detected in an amount of less than about 10 gold particles / lentiviral particle, less than about 9 gold particles / lentiviral particle, less than about 8 gold particles / lentiviral particle, less than about 7 gold particles / lentiviral particle, less than about 6 gold particles / lentiviral particle, less than about 5 gold particles / lentiviral particle, less than about 4 gold particles / lentiviral particle, less than about 3 gold particles / lentiviral particle, less than about 2 gold particles / lentiviral particle, less than about 1 gold particle / lentiviral particle or about 0 gold particles / lentiviral particle. Preferably, the MHC-I molecules may be undetectable (e.g., the amount of gold particles detected may not be significantly higher than background levels).
[0323] The lentiviral vector of the present invention may be obtained from an MHC-I10” producer cell or an MHC-Ifreeproducer cell. In preferred embodiments, the lentiviral vector of the present invention is obtained from an MHC-Ifreeproducer cell. As used herein, the term " MHC-I10” producer cell" refers to a producer cell with reduced levels of one or more MHC-I molecule on its surface. As used herein, the term " MHC-Ifreeproducer cell" refers to a producer cell which is substantially devoid of or free of one or more MHC-I molecule(s) on its surface. Specifically, the surface of the lentiviral vector may not comprise MHC-I molecules.
[0324] An MHC-I10” or MHC-Ifreeproducer cell may be genetically engineered to decrease expression of MHC-I on the cell surface. For example, the cell may comprise a genetically engineered disruption of a gene encoding 82-microglobulin and / or a genetically engineered disruption of a gene encoding an MHC-I a chain.
[0325] Methods for genetic engineering to decrease protein expression are known in the art. For example, this may be achieved by targeted gene knockout. To decrease protein expression, the gene encoding the protein itself or its regulatory sequence (e.g., its promoter) may be knocked out. Knockout may be achieved by deletion of a section of the coding nucleic acid sequence, which may delete a section of the protein essential for expression or stability, or alter the reading frame of the coding sequence or by base-editing. Suitable methods for targeted gene knockout include use of zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and CRISPR / Cas-based RNA-guided nucleases (see, e.g., Gaj et al., ZFN, TALEN, and CRISPR / Cas-based methods for genome engineering, Trends Biotechnol, 31, 397-405 (2013)). For example, the CRISPR / Cas9 RNA-guided nuclease may be used to catalyse a double strand break at a specific locus in the genome if provided with appropriate RNA guides designed to bind that locus. Cas9 and the guide RNA may be delivered to a target cell by transfection of vectors encoding the protein and RNA. Cells attempt to repair any double strand breaks in their DNA using the non- homologous end joining (NHEJ) pathway. This is an error-prone mechanism which inserts random nucleotides and often disrupts the reading frame of the targeted gene. Alternatively, the genetic engineering to decrease protein expression may be accomplished using RNAi techniques, microRNA or antisense RNA to suppress expression of the target gene.
[0326] Once the targeted gene knockout or suppression of expression approach has been carried out, the resulting population of cells may be screened to select and enrich for those cells exhibiting the phenotype of interest, for example decreased expression of surface-exposed MHC-I. Suitable techniques for screening and enrichment are known in the art and include flow cytometry and fluorescence-activated cell sorting (FACS).
[0327] In some embodiments, the producer cell comprises a genetically engineered disruption of a gene encoding R2-microglobulin. R2-microglobulin stabilises MHC-I, thus cells deficient in R2-microglobulin will exhibit decreased expression of MHC-I on the surface of the cell. The cell may comprise genetically engineered disruptions in all copies of the gene encoding R2-microglobulin.
[0328] In another embodiment, the cell comprises a genetically engineered disruption of one or more genes encoding an MHC-I a chain. The cell may comprise genetically engineered disruptions in all copies of the gene encoding an MHC-I a chain.
[0329] The cell may comprise both genetically engineered disruptions of genes encoding R2-microglobulin and genetically engineered disruptions of genes encoding an MHC-I a chain.
[0330] Decreased expression of MHC-I on the surface of the cell may refer to a decrease in the number of MHC-I molecules that are expressed on the surface of the cell that has been genetically engineered, in comparison to the number of MHC-I molecules that are expressed on the surface of a cell lacking the genetic engineering, but under otherwise substantially identical conditions. The expression of MHC-I on the surface of the cell may be decreased such that the number of surface-exposed MHC-I molecules is, for example, less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposed MHC-I molecules that are displayed in the absence of the genetic engineering. In some embodiments, the expression of MHC-I on the surface of the cell is decreased such that the number of surface-exposed MHC-I molecules is 0% of the number of surface-exposed MHC-I molecules that are displayed in the absence of the genetic engineering.
[0331] The expression of MHC-I on the surface of the cell is preferably decreased such that the cell is substantially devoid of surface-exposed MHC-I molecules. In this context, "substantially devoid" means that there is a substantial decrease in the number of MHC-I molecules that are expressed on the surface of the cell that has been genetically engineered, in comparison to the number of MHC-I molecules that are expressed on the surface of a cell lacking the genetic engineering, such that the immune response to MHC-I on lentiviral vectors produced by the cell is decreased to a therapeutically useful degree.
[0332] Suitably, the lentiviral vector of the present invention has a lower concentration of MHC-I molecules on its surface than a lentiviral vector obtained from an unmodified producer cell. Suitably, the lentiviral vector has less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposedMHC-I molecules that are displayed on a lentiviral vector obtained from an unmodified producer cell. In some embodiments, the lentiviral vector has less than about 20% of the number of surface-exposed MHC-I molecules that are displayed on a lentiviral vector obtained from an unmodified producer cell.
[0333] In some embodiments, the lentiviral vector of the present invention is substantially devoid of MHC-I molecules on its surface. In this context, "substantially devoid" means that there is no detectable immune response due to the molecules on the surface of the lentiviral vector.
[0334] In some embodiments, the lentiviral vector of the present invention is free of MHC-I molecules on its surface. In this context, "free" means that there are no detectable molecules (e.g., by immunostaining and electron microscopy) on the surface of the lentiviral vector. As used herein, "not detectable" refers to levels which are not statistically significantly different compared to background levels.
[0335] In some embodiments, the lentiviral vector of the present invention has decreased HLA-A, HLA-B and / or HLA-C molecules on its surface. Suitably, the lentiviral vector has less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposed HLA-A molecules that are displayed on a lentiviral vector obtained from an unmodified producer cell. Suitably, the lentiviral vector has less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposed HLA-B molecules that are displayed on a lentiviral vector obtained from an unmodified producer cell. Suitably, the lentiviral vector has less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposed HLA-C molecules that are displayed on a lentiviral vector obtained from an unmodified producer cell.
[0336] In some embodiments, the lentiviral vector of the present invention is substantially devoid of HLA-A, HLA-B and / or HLA-C molecules on its surface. In some embodiments, the lentiviral vector of the present invention is substantially devoid of HLA-A, HLA-B and HLA-C molecules on its surface. In some embodiments, the lentiviral vector of the present invention is free of HLA-A, HLA-B and / or HLA-C molecules on its surface. In some embodiments, the lentiviral vector of the present invention is free of HLA-A, HLA-B and HLA-C molecules on its surface.
[0337] As described above, an HLA-I molecule consists of two polypeptide chains, an HLA-I heavy chain (α chain) and β2 microglobulin (β2M or β chain). The HLA-I α chain and β2M are linked non-covalently.
[0338] The skilled person would readily be able to determine amino acid and nucleic acid sequences of HLA-I α chains. For example, the HLA-I α chains may be identified in a genome sequence using their location within the major histocompatibility complex region of the chromosome (see, for example, Penn et al. (2005) Major histocompatibility complex (MHC). eLS).
[0339] HLA-A α chains may have an amino acid sequence of UniProtKB P04439. Exemplary HLA-A α chains are provided by the sequences set forth in SEQ ID NOs: 14 and 15. Suitably, an HLA-A α chain comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequences set forth in SEQ ID NO: 14 or 15. Suitably, a HLA-A α chain comprises or consists of the amino acid sequence set forth in SEQ ID NO: 14 or 15.
[0340] MAVMAPRTLLLLLSGALALTQTWAGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDS
[0341] DAASQRMEPRAPWIEQEGPEYWDQETRNVKAQSQTDRVDLGTLRGYYNQSEAGSHTIQIMYG
[0342] CDVGSDGRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITKRKWEAAHEAEQLRAYLDG
[0343] TCVEWLRRYLENGKETLQRTDPPKTHMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQ
[0344] TQDTELVETRPAGDGTFQKWAAVWPSGEEQRYTCHVQHEGLPKPLTLRWELSSQPTIPIVG
[0345] IIAGLVLLGAVITGAWAAVMWRRKSSDRKGGSYTQAASSDSAQGSDVSLTACKV
[0346] (SEQ ID NO: 14)
[0347] MAVMAPRTLLLLLSGALALTQTWAGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDS DAASQRMEPRAPWIEQEGPEYWDQETRNVKAQSQTDRVDLGTLRGYYNQSEAGSHTIQIMYG CDVGSDGRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITKRKWEAAHAAEQQRAYLEG RCVEWLRRYLENGKETLQRTDPPKTHMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQ TQDTELVETRPAGDGTFQKWAAVWPSGEEQRYTCHVQHEGLPKPLTLRWELSSQPTIPIVG IIAGLVLLGAVITGAWAAVMWRRKSSGGEGVKDRKGGSYTQAASSDSAQGSDVSLTACKV
[0348] (SEQ ID NO: 15)
[0349] HLA-B α chains may have an amino acid sequence of UniProtKB P01889. An exemplary HLA-B α chain is provided by the sequence set forth in SEQ ID NO: 16. Suitably, an HLA-B α chain comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequence set forth in SEQ ID NO: 16. Suitably, a HLA-B α chain comprises or consists of the amino acid sequence set forth in SEQ ID NO: 16.
[0350] MLVMAPRTVLLLLSAALALTETWAGSHSMRYFYTSVSRPGRGEPRFISVGYVDDTQFVRFDS
[0351] DAASPREEPRAPWIEQEGPEYWDRNTQIYKAQAQTDRESLRNLRGYYNQSEAGSHTLQSMYG
[0352] CDVGPDGRLLRGHDQYAYDGKDYIALNEDLRSWTAADTAAQITQRKWEAAREAEQRRAYLEG
[0353] ECVEWLRRYLENGKDKLERADPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQ
[0354] TQDTELVETRPAGDRTFQKWAAVWPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTVPIVG
[0355] IVAGLAVLAVWIGAWAAVMCRRKSSGGKGGSYSQAACSDSAQGSDVSLTA
[0356] (SEQ ID NO: 16)
[0357] HLA-C α chains may have an amino acid sequence of UniProtKB P10321. Exemplary HLA-C α chains are provided by the sequences set forth in SEQ ID NOs: 17 and 18. Suitably, an HLA-C α chain comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequences set forth in SEQ ID NO: 17 or 18. Suitably, a HLA-C α chain comprises or consists of the amino acid sequence of SEQ ID NO: 17 or 18.
[0358] MRVMAPRALLLLLSGGLALTETWACSHSMRYFDTAVSRPGRGEPRFISVGYVDDTQFVRFDS DAASPRGEPRAPWVEQEGPEYWDRETQKYKRQAQADRVSLRNLRGYYNQSEDGSHTLQRMSG CDLGPDGRLLRGYDQSAYDGKDYIALNEDLRSWTAADTAAQITQRKLEAARAAEQLRAYLEG TCVEWLRRYLENGKETLQRAEPPKTHVTHHPLSDHEATLRCWALGFYPAEITLTWQRDGEDQ TQDTELVETRPAGDGTFQKWAAVWPSGQEQRYTCHMQHEGLQEPLTLSWEPSSQPTIPIMG IVAGLAVLWLAVLGAWTAMMCRRKSSGGKGGSCSQAACSNSAQGSDESLITCKA
[0359] (SEQ ID NO: 17)
[0360] MRVMAPRALLLLLSGGLALTETWACSHSMRYFDTAVSRPGRGEPRFISVGYVDDTQFVRFDS DAASPRGEPRAPWVEQEGPEYWDRETQKYKRQAQADRVSLRNLRGYYNQSEDGSHTLQRMSG CDLGPDGRLLRGYDQSAYDGKDYIALNEHLRSCTAADTAAQITQRKLEAARAAEQLRAYLEG TCVEWLRRYLENGKETLQRAEPPKTHVTHHPLSDHEATLRCWALGFYPAEITLTWQRDGEDQ TQDTELVETRPAGDGTFQKWAAVWPSGQEQRYTCHMQHEGLQEPLTLRWGGKGGSCSQAAC SNSAQGSDESLITCKA
[0361] (SEQ ID NO: 18)
[0362] Amino acid and nucleic acid sequences encoding β2M are also known in the art. For example, a nucleic acid sequence of a human β2M is deposited as GenBank Accession No. NM_004048.
[0363] An HLA β chain may be that of UniProtKB P61769. An exemplary HLA β chain is provided by the sequence set forth in SEQ ID NO: 19. Suitably, an HLA β chain comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequence set forth in SEQ ID NO: 19. Suitably, an HLA β chain comprises or consists of the amino acid sequence set forth in SEQ ID NO: 19.
[0364] MSRSVALAVLALLSLSGLEAIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKN GERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM
[0365] (SEQ ID NO: 19)
[0366] The lentiviral vector of the present invention may be a CD47hlghand MHC-Ifreelentiviral vector or a CD47hlghand MHC-I10” lentiviral vector. In preferred embodiments, the lentiviral vector of the present invention is a CD47hlghand MHC-Ifreelentiviral vector.
[0367] The lentiviral vector of the present invention may be obtained from a CD47hlghand MHC-Ifreeproducer cell or a CD47hlghand MHC-I10” producer cell. In preferred embodiments, the lentiviral vector of the present invention is obtained from a CD47hlghand MHC-Ifreeproducer cell.
[0368] Reverse orientation
[0369] In one aspect, the invention provides a lentiviral vector comprising a nucleotide sequence of a nucleic acid of interest, such as a gene of interest, operably linked to a promoter, wherein the nucleotide sequence of the nucleic acid of interest, such as the gene of interest and the promoter are in a reverse orientation in the lentiviral vector. Reverse orientation can be useful in case expression of the transgene is unwanted in producer cells or if it is difficult to get rid of the co-produced protein (e.g., because it is toxic) during LV purification.
[0370] In one aspect, the invention provides a lentiviral vector comprising an expression cassette comprising a nucleotide sequence of a nucleic acid of interest, such as a gene of interest, operably linked to a promoter, wherein the expression cassette is in a reverse orientation in the lentiviral vector.
[0371] As used herein, "reverse orientation" in a lentiviral vector refers to the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, and the promoter, and / or the expression cassette, being incorporated into the lentiviral vector such that the direction of transcription from the promoter is oriented towards a 5' long terminal repeat (LTR) of the lentiviral vector. The nucleotide sequence of the nucleic acid of interest, such as the gene of interest, or the expression cassette may be in an antisense orientation compared to transcription of the lentiviral vector genome, for example which may occur in lentiviral vector producer cells during vector production.
[0372] The reverse orientation may allow transcription of the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, from the promoter when the lentiviral vector is in a cell in which the promoter is active. The reverse orientation may prevent transcription of the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, from a second promoter that is upstream of the 5'LTR. The second promoter may, for example, only be present in the plasmid transcribing the lentiviral vector genome in producer cells during vector production.
[0373] Regulatory elements of lentiviral vectors
[0374] The lentiviral vector of the present invention may comprise one or more regulatory elements which can act pre- or post-transcriptionally. Suitably, the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, is operably linked to one or more regulatory elements which may act pre- or post-transcriptionally. In one embodiment, the one or more regulatory elements may facilitate expression of the nucleic acid of interest, such as the gene of interest, in all cells. In another embodiment, the one or more regulatory elements may facilitate expression of the nucleic acid of interest, such as the gene of interest, in HSPCs and / or in differentiated hematopoietic cells.
[0375] As used herein, the term "regulatory element" refers to any nucleotide sequence that facilitates expression of a polypeptide. For example, such a regulatory element acts to increase expression of a transcript or to enhance mRNA stability. Suitable regulatory elements include, for example, promoters, enhancer elements, post-transcriptional regulatory elements, polyadenylation sequences and Kozak sequences, as further defined herein.
[0376] Exemplary embodiments of regulatory elements of the viral vector of the invention in general have already been described herein. These exemplary embodiments of regulatory elements of the viral vector of the invention in general can also be embodiments of the viral vector of the invention when the viral vector of the invention is a lentiviral vector.
[0377] The following passages provide further exemplary embodiments of regulatory elements of lentiviral vectors according to the present invention specifically.
[0378] Other cis-acting elements
[0379] Lentiviral vectors of the present invention may also comprise additional cis-acting elements, such as a rev response element (RRE), which enables the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell; a retroviral psi packaging element, which is involved in regulating the essential process of packaging the retroviral RNA genome into the viral capsid during replication; a primer binding site (PBS), where reverse transcription is initiated; the TAT activation region (TAR); splice donor and acceptor sites; and central and terminal polypurine tracts, which allow initiation of plus-strand synthesis.
[0380] Cis-acti ng elements of lentiviral vectors of the invention may include one or more of a rev response element (RRE); a retroviral psi packaging element; a primer binding site (PBS); a TAT activation region (TAR); splice donor and acceptor sites; and central and terminal polypurine tracts.
[0381] The following passages provide exemplary embodiments of cis-acting elements of lentiviral vectors.
[0382] Long terminal repeats (LTRs) of lentiviral vectors
[0383] The lentiviral vector of the present invention may comprise one or more long terminal repeats (LTRs). LTRs are responsible for proviral integration and transcription. Typically, a naturally occurring LTR comprises U3, R, and U5 regions.
[0384] In a lentivirus genome, the elements are typically flanked at both ends by regions called long terminal repeats (LTRs). The LTRs are responsible for integration and transcription. LTRs may also serve as enhancer-promoter sequences and can control the expression of the lentiviral genes. The LTRs themselves are identical or nearidentical sequences that can typically be divided into three regions: U3, R and U5. LTRs may be naturally occurring or may be modified. For example, U3 and U5 modifications are described in Iwakuma et al., SelfInactivating Lentiviral Vectors with U3 and U5 Modifications, Virology, 261, 120-132 (1999).
[0385] Suitable LTR sequences are well known to the skilled person (see, for example, Freeh et al., Common Modular Structure of Lentivirus LTRs, Virology, 224, 256-267 (1996)).
[0386] In some embodiments, a LTR comprises or consists of a nucleotide sequence that has at least 70% sequence identity to the sequence set forth in SEQ ID NO: 20 or a fragment thereof. Suitably, a LTR comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 20 or a fragment thereof.
[0387] In some embodiments, a LTR comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 20 or a fragment thereof.
[0388] TGGAAGGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTC TGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCC TCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTA ACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAG
[0389] (SEQ ID NO: 20)
[0390] The lentiviral vector of the present invention may comprise one or more self-inactivating long terminal repeats (SIN-LTR). A " SIN-LTR" may comprise a deletion that abolishes transcription of the full-length virus after it has incorporated into a host cell. For example, a 3' SIN-LTR may comprise a deletion in the U3 region removing the promoter / enhancer elements (see, for example, Zufferey et al., Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery, J Virol, 72, 9873-9880 (1998)). This deletion is copied into the 5' LTR after reverse transcription, thereby making the gene expression in target cells dependent on an internal promoter of choice.
[0391] Suitable SIN-LTR sequences are well known to the skilled person (see, for example, Zufferey et al., SelfInactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery, J Virol, 72, 9873-9880 (1998); Miyoshi et al., Development of a self-inactivating lentivirus vector, J Virol, 72, 8150-8157 (1998)).
[0392] In some embodiments, the 5' LTR comprises or consists of a nucleotide sequence that has at least 70% sequence identity to the sequence set forth in SEQ ID NO: 21 or a fragment thereof. Suitably, the 5' LTR comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 21 or a fragment thereof.
[0393] In some embodiments, the 5' LTR comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 21 or a fragment thereof.
[0394] GGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACT GCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTG ACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAG
[0395] (SEQ ID NO: 21)
[0396] In some embodiments, the 5' LTR and / or the 3' LTR comprises or consists of a nucleotide sequence that has at least 70% sequence identity to the sequence set forth in SEQ ID NO: 20 or a fragment thereof. Suitably, the 5' LTR and / or the 3' LTR comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 20 or a fragment thereof.
[0397] In some embodiments, the 5' LTR and / or the 3' LTR comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 20 or a fragment thereof.
[0398] In some embodiments, the 5' LTR and the 3' LTR comprise or consist of a nucleotide sequence that has at least 70% sequence identity to the sequence set forth in SEQ ID NO: 20 or a fragment thereof. Suitably, the5' LTR and the 3' LTR comprise or consist of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 20 or a fragment thereof.
[0399] Primer binding site (PBS) of lentiviral vectors
[0400] The lentiviral vector of the present invention may comprise a primer binding site (PBS). A PBS is a cis-acting element where a primer may bind to initiate reverse transcription of the RNA genome (see, for example, Lanchy et al., Contacts between Reverse Transcriptase and the Primer Strand Govern the Transition from Initiation to Elongation of HIV-1 Reverse Transcription, J Biol Chem, 273, 24425-24432 (1998)).
[0401] Suitable lentiviral PBSs are well known to the skilled person.
[0402] In some embodiments, a PBS comprises or consists of a nucleotide sequence that has at least 70% sequence identity to the sequence set forth in SEQ ID NO: 22 or a fragment thereof. Suitably, a PBS comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the sequence set forth in SEQ ID NO: 22 or a fragment thereof.
[0403] In some embodiments, a PBS comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 22 or a fragment thereof.
[0404] TGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGAC TCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAA TTTTGACTAGCGGAGGCTAGAAGGAGAGAG
[0405] (SEQ ID NO: 22)
[0406] Retroviral psi packaging element of the lentiviral vector
[0407] The lentiviral vector of the present invention may comprise a retroviral psi packaging element. A retroviral psi packaging element is a cis-acting element that is involved in regulating the process of packaging the retroviral RNA genome into the viral capsid during replication (see, for example, McBride et al., Efficient Encapsidation of Human Immunodeficiency VirusType 1 Vectors and Further Characterization of cis Elements Required for Encapsidation, J Virol, 71, 4544-4554 (1997)). A retroviral psi packaging element may form part of the 5' region of the gag gene.
[0408] Suitable retroviral psi packaging elements are well known to the skilled person.
[0409] In some embodiments, a retroviral psi packaging element comprises or consists of a nucleotide sequence that has at least 70% sequence identity to the sequence set forth in SEQ ID NO: 23 or a fragment thereof. Suitably, a retroviral psi packaging element comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 23 or a fragment thereof.
[0410] In some embodiments, a retroviral psi packaging element comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 23 or a fragment thereof.
[0411] ATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGCGATGGGAAAAAATTCGG TTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCT AGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGG GACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTAGATCATTATATAATACAGTA GCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAA GATAGAGGAAGAGCAAAACAAAAGTAAGACCACCGCACAGCAAGCGGCCGCTGAT
[0412] (SEQ ID NO: 23)
[0413] Rev response element (R E) oflentiviral vectors
[0414] The lentiviral vector of the present invention may comprise a rev response element (RRE). A RRE is a cis-acting element that enables the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell (see, for example, Pollard et al., The HIV-l Rev Protein, Annu Rev of Microbiol, 52, 491-532 (1998)).
[0415] Suitable RRE sequences will be well known to the skilled person.
[0416] In some embodiments, a RRE comprises or consists of a nucleotide sequence that has at least 70% sequence identity to the sequence set forth in SEQ ID NO: 24 or a fragment thereof. Suitably, a RRE comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the sequence set forth in SEQ ID NO: 24 or a fragment thereof.
[0417] In some embodiments, a RRE comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 24 or a fragment thereof.
[0418] GGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGAC
[0419] GCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGA
[0420] GGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG
[0421] GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTT
[0422] (SEQ ID NO: 24)
[0423] Central polypurine tract (cPPT) oflentiviral vectors
[0424] The lentiviral vector of the present invention may comprise a central polypurine tract (cPPT). A cPPT may allow initiation of plus-strand synthesis (see, for example, Follenzi et al., Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences, Nat Genet, 25, 217-222 (2000)).
[0425] Suitable cPPT sequences are well known to the skilled person.
[0426] In some embodiments, a cPPT comprises or consists of a nucleotide sequence that has at least 70% sequence identity to the sequence set forth in SEQ ID NO: 25 or a fragment thereof. Suitably, a cPPT comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 25 or a fragment thereof.
[0427] In some embodiments, a cPPT comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 25 or a fragment thereof.
[0428] AACTTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAA TAG C AAC AGAC AT AC AAAC T AAAGAAT T AC AAAAAC AAAT T AC AAAAAT T C AAAAT T T T AT C
[0429] (SEQ ID NO: 25)
[0430] Other elements oflentiviral vectors
[0431] The lentiviral vector of the present invention may comprise other suitable elements.
[0432] In some embodiments, the lentiviral vector of the present invention comprises an element that is a delta ENVl and optionally comprises or consists of a nucleotide sequence that has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 26 or a fragment thereof. In some embodiments, the lentiviral vector of the present invention comprises an element that is a delta ENVl and optionally comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 26 or a fragment thereof.
[0433] T CTT CAGACCT GGAGGAGGAGATAT GAGGGACAATT GGAGAAGT GAATTATATAAATATAAA
[0434] GTAGTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAG
[0435] AGAAAAAAGAGCAGT GGGAATA
[0436] (SEQ ID NO: 26 - Exemplary delta ENV1)
[0437] In some embodiments, the lentiviral vector of the present invention comprises an element that is a delta ENV2 and optionally comprises or consists of a nucleotide sequence that has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 27 or a fragment thereof. In some embodiments, the lentiviral vector of the present invention comprises an element that is a delta ENV2 and optionally comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 1 or a fragment thereof.
[0438] GGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATA AATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAAT
[0439] TACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACA AGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTT GCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACCCA CCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAG
[0440] AC AGAGAC AGAT C CAT T C GAT T AGT GAAC G GAT C
[0441] (SEQ ID NO: 27 - Exemplary delta ENV2)
[0442] Exemplary lentiviral genomes
[0443] The lentiviral vector of the present invention may comprise a lentiviral genome (also referred to herein as the "lentiviral genome of the present invention" or the "lentiviral genome of the invention") comprising from 5' to 3': a 5' LTR, one or more cis-acting elements, and a 3' LTR.
[0444] For example, in a preferred embodiment, the lentiviral vector of the present invention may comprise a lentiviral genome of the present invention comprising from 5' to 3': a 5' LTR, a PBS, a retroviral psi packaging element, a RRE, a cPPT, an expression cassette, a WPRE, and a 3' LTR.
[0445] The expression cassette in the lentiviral genome of the present invention may, for example comprise a nucleotide sequence of the nucleic acid of interest, such as a gene of interest, operably linked to a promoter, and optionally operably linked to a polyadenylation sequence.
[0446] The lentiviral genome of the present invention may further comprise any other suitable elements, such as any other elements described herein or one or more spacer sequence(s). The spacer sequence(s) may comprise, for example, at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10), at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine or at least ten nucleotide bases.
[0447] Retroviral vectors (RV)
[0448] In one embodiment, the viral vector of the present invention is a retroviral vector (also abbreviated as " RV" herein). In a preferred embodiment, the retroviral vector of the present invention is selected from the group consisting of gamma retrovirus and alpha retrovirus.
[0449] In one embodiment, the retroviral vector may be in the form of a retroviral particle. In other embodiments, the retroviral vector may comprise a retroviral genome, optionally wherein the retroviral genome is enveloped. As used herein, the term "retroviral genome" refers to a genome that comprises at least one element derived or derivable from a retroviral genome.
[0450] The term "element derived or derivable from a retroviral genome" as used herein refers to an element of a component of a reference retrovirus genome that may differ, e.g., in sequence, from the corresponding element of the component in the reference retrovirus genome, but that fulfils the same function, to the same or a similar extent, as the corresponding element of the component in the reference retrovirus genome. Typically, there are three components of a retrovirus genome: (1) the regulatory cassette comprising regulatory elements, in particular enhancer, promoter and / or auxiliary elements that control expression of genes as an episome or as a chromosomal integrant; (2) the nucleic acid of interest, such as the gene of interest; and (3) the protein envelope and / or capsid.
[0451] The basic genes required for retrovirus survival and function are the gag, pol, and env genes: gag encodes structural proteins; pol encodes enzymes required for reverse transcription and integration into the host cell genome; and env encodes the viral envelope glycoprotein.
[0452] Retroviruses may also have additional cis-acting elements, such as a rev response element (RRE), which enables the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell; a retroviral psi packaging element, which is involved in regulating the essential process of packaging the retroviral RNA genome into the viral capsid during replication; a primer binding site (PBS), where reverse transcription is initiated; the TAT activation region (TAR); splice donor and acceptor sites; and central and terminal polypurine tracts, which allow initiation of plus-strand synthesis.
[0453] In a retrovirus genome, the elements are typically flanked at both ends by regions called long terminal repeats (LTRs). The LTRs are responsible for integration and transcription. LTRs may also serve as enhancer-promoter sequences and can control the expression of the retroviral genes. The LTRs themselves are identical or nearidentical sequences that can typically be divided into three regions: U3, R and U5. LTRs may be naturally occurring or may be modified. For example, U3 and U5 modifications are described in Iwakuma et al., SelfInactivating Lentiviral Vectors with U3 and U5 Modifications, Virology, 261, 120-132 (1999).
[0454] The retroviral vector of the present invention may comprise a minimal retroviral genome. As used herein, a "minimal retroviral genome" means that the retroviral genome has been manipulated so as to remove the non-essential elements and to retain the essential elements in order to provide the required functionality to infect, transduce and deliver a nucleotide sequence of interest to a target host cell.
[0455] The retroviral vector of the present invention may be replication-defective. Typically, at least part of one or more protein coding regions essential for replication may be removed from the retroviral genome. This makes the retroviral vector "replication-defective" or "replication-incompetent". Suitably, one or more of gag, pol, rev, and env genes are deleted (at least partially) in a replication-defective retroviral vector. Suitably, each of the gag, pol, rev, and env genes are deleted (at least partially) in a replication-defective retroviral vector. Optionally, the retroviral vector lacks a functional gag-pol and / or env gene and / or other genes essential for replication.
[0456] The retroviral vector of the present invention may be derived from any retrovirus. As used herein "retrovirus-derived" or "retrovirus-based" means that the retroviral genome comprises one or more elements from said retrovirus. For example, the coding regions of viral proteins may be deleted, but one or more cis-acting element(s) may be retained from said retrovirus.
[0457] The retroviral vector of the present invention may be a self-inactivating retroviral vector. As used herein, "self-inactivating" or " SIN" retroviral vectors may comprise retroviral genomes in which the retroviral enhancer and promoter sequences have been deleted (see, for example, Zufferey et al., Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery, J Virol, 72, 9873-9880 (1998); Miyoshi et al., Development of a self-inactivating lentivirus vector, J Virol, 72, 8150-8157 (1998)). SIN retroviral vectors can be generated and transduce non-dividing cells in vivo with an efficacy similar to that of wild-type vectors. The transcriptional inactivation of the long terminal repeat (LTR) in the SIN provirus can prevent mobilisation by replication-competent virus. This can also enable the regulated expression of genes from internal promoters by eliminating any cis-acting effects of the LTR.
[0458] The retroviral vector of the present invention may be integration competent. As used herein, an "integration competent" retroviral vector is capable of integrating into the genome of a host cell. In contrast to integrationcompetent retroviral vectors, integration defective retroviral vectors (IDLVs) can be produced, for example by packaging the retroviral vector with catalytically inactive integrase (such as an HIV integrase bearing the D64V mutation in the catalytic site) or by modifying or deleting essential att sequences from the retroviral genome LTR, or by a combination of the above (see, for example. Wanisch et al., Integration-deficient lentiviral vectors: a slow coming of age, Mol Ther, 17, 1316-1332 (2009)).
[0459] The retroviral vector of the present invention may be replication-defective and integrating. The retroviral vector of the present invention may be replication-defective, integrating, and self-inactivating, in a preferred embodiment, the retroviral vector of the present invention may be replication-defective, integrating, and self-inactivating.
[0460] The retroviral vector of the present invention may be a retroviral particle. A "retroviral particle" refers to an enveloped retroviral genome. Retroviral particles may be generated by co-transfection of a plasmid containing a retroviral genome (e.g., a "transfer vector") with helper plasmids (e.g., "packaging vectors" encoding gag-pol and / or rev, and "envelope vectors" encoding env) into host cells and harvesting of the retrovirus-containing supernatant afterwards.
[0461] The retroviral vector of the present invention may be typed. Pseudotyping retroviral vectors with naturally occurring or engineered retroviral envelopes can allow targeted transduction of specific cell types (see, for example, Joglekar et al., Pseudotyped Lentiviral Vectors: One Vector, Many Guises, Hum Gene Ther Methods, 28, 291-301 (2017)). Suitably, the retroviral vector is pseudotyped to allow transduction of HSPCs and / or of differentiated hematopoietic cells. In some embodiments, the retroviral vector is a Vesicular stomatitis virus G protein (VSV-G)-pseudotyped retroviral vector. Vesicular stomatitis virus G protein (VSV-G) is a commonly used envelope protein for pseudotyping. VSV-G is a trimeric protein that binds phosphatidylserine and low-density lipoprotein receptors on a cell surface to endocytose into the cell.
[0462] In some embodiments, the retroviral vector of the present invention: (i) is a CD47hlghretroviral vector; and / or (ii) is an MHC-Ifreeretroviral vector. In preferred embodiments, the retroviral vector of the present invention is a CD47hlghand MHC-Ifreeretroviral vector. Each of these features individually or in combination reduces immune responses to the viral vector following administration.
[0463] CD47highretroviral vectors
[0464] The retroviral vector of the present invention may be a CD47hlghretroviral vector. As used herein, a " CD47hlghretroviral vector" refers to a retroviral vector with increased levels of CD47 (Cluster of Differentiation 47) CD47 (or a variant or fragment thereof) on its surface. A CD47hlghretroviral vector has reduced uptake by professional phagocytes. In some embodiments the surface of a CD47hlghretroviral vector comprises a higherlevel of CD47 protein than a control retroviral vector produced in HEK293T cells. The skilled person knows how to obtain suitable HEK293T cells and how to perform a suitable control experiment to compare levels of CD47 protein on retroviral vectors.
[0465] CD47 (Cluster of Differentiation 47), also known as integrin associated protein (IAP), is a transmembrane protein that in humans is encoded by the CD47 gene. Phagocytosis is physiologically inhibited by CD47, which is a ubiquitously expressed ligand of signal regulatory protein a (SIRP-a) receptor that is expressed by professional phagocytes. CD47 may be incorporated into retroviral vectors when they bud from producer cells.
[0466] The retroviral vector of the present invention may comprise one or more CD47 polypeptides (or a variant or fragment thereof) on its surface. The amount of CD47 (or a variant or fragment thereof) on the surface may be enough to reduce uptake by professional phagocytes. Any suitable assay to quantify the amount of CD47 polypeptides (or variants or fragments thereof) present on the surface of the retroviral vector may be used. The skilled person knows suitable assays to quantify the amount of CD47 polypeptides (or variants or fragments thereof) present on the surface of the retroviral vector.
[0467] In some embodiments, the density of CD47 polypeptides (or variant or fragments thereof) may be determined by immunostaining for CD47 and total internal reflection fluorescence microscopy, for example as described in US 2010 / 0316570 Al. The CD47 polypeptides (or variant or fragments thereof) may be present at a density of at least about 20 molecules / μm2, at least about 25 molecules / μm2, at least about 30 molecules / μm2, at least about 35 molecules / μm2, at least about 40 molecules / μm2, at least about 45 molecules / μm2, at least about 50 molecules / μm2, at least about 60 molecules / μm2, at least about 70 molecules / μm2, at least about 80 molecules / μm2, at least about 90 molecules / μm2, at least about 100 molecules / μm2, at least about 150 molecules / μm2, at least about 200 molecules / μm2, at least about 250 molecules / μm2, at least about 300 molecules / μm2, at least about 350 molecules / μm2, at least about 400 molecules / μm2, at least about 450 molecules / μm2, at least about 500 molecules / μm2, at least about 600 molecules / μm2, at least about 700 molecules / μm2, at least about 800 molecules / μm2, at least about 900 molecules / μm2or at least about 1000 molecules / μm2. The CD47 polypeptides (or fragments thereof) may be present at a density of about 1000 molecules / μm2or less, about 500 molecules / μm2or less or about 250 molecules / μm2or less. The CD47 polypeptides (or fragments thereof) may be present at a density of from about 20 molecules / μm2to about 1000 molecules / μm2, from about 20 molecules / μm2to about 500 molecules / μm2or from about 20 molecules / μm2to about 250 molecules / pm2. In a preferred embodiment, the CD47 polypeptides (or fragments thereof) are present at a density of from about 90 molecules / μm2to about 900 molecules / μm2.
[0468] In some embodiments, the amount of CD47 polypeptides (or variant or fragments thereof) may be determined by immunostaining for CD47 and electron microscopy, as described in Milani etal., Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates, Sci Transl Med, 11(493), eaav7325 (2019). The CD47 polypeptides (or variants or fragments thereof) may be detected in an amount of at least about 10 gold particles / retroviral particle, at least about 15 gold particles / retroviral particle or at least about 20 gold particles / retroviral particle. The CD47 polypeptides (or variants or fragments thereof) may be detected in an amount of about 100 gold particles / retroviral particle or less, about 80 gold particles / retroviral particle or less or about 60 gold particles / retroviral particle or less. The CD47 polypeptides (or fragments thereof) may be detected in an amount of from about 10 to about 100 gold particles / retroviral particle, from about 15 to about 80 gold particles / retroviral particle or, in a preferred embodiment, from about 20 to about 60 gold particles / retroviral particle.
[0469] The retroviral vector of the present invention may be obtained from a CD47hlghproducer cell. As used herein, a " CD47hlghproducer cell" refers to a producer cell with increased levels of CD47 (or a fragment thereof) on its surface.
[0470] A CD47highproducer cell may be genetically engineered to increase expression of CD47 (or a variant or fragment thereof) on the cell surface. For example, the producer cell may comprise a vector encoding CD47 (or a variant or fragment thereof) or may be edited to introduce a nucleotide sequence encoding CD47 (or a variant or fragment thereof) into its genome. Suitably, the producer cell is transduced with a viral vector encoding a CD47 polypeptide (or a variant or fragment thereof).
[0471] A CD47highproducer cell may have a higher concentration of CD47 (or a variant or fragment thereof) on its surface than an unmodified producer cell. Suitably, the producer cell has at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold or at least about 30-fold more CD47 on its cell surface than an unmodified producer cell. Suitably, the producer cell has from about 5-fold to about 30-fold more CD47 (or a fragment thereof) on its cell surface than an unmodified producer cell.
[0472] Suitably, the retroviral vector of the present invention has a higher concentration of CD47 (or a variant or fragment thereof) on its surface than a retroviral vector obtained from an unmodified producer cell. Suitably, the retroviral vector has at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold or at least about 50-fold more CD47 (or a variant or fragment thereof) on its surface than a retroviral vector obtained from an unmodified producer cell. Suitably, the retroviral vector has from about 5-fold to about 30-fold more CD47 (or a variant or fragment thereof) on its surface than a retroviral vector obtained from an unmodified producer cell.
[0473] CD47 is a member of the immunoglobulin (Ig) superfamily of membrane proteins, with a single IgV-like domain at its N-terminus, a highly hydrophobic stretch with five membrane-spanning segments and an alternatively spliced cytoplasmic C-terminus ranging in length from 3 to 36 amino acids. Mouse, rat, bovine and human CD47 molecules have been cloned and show about 70% overall amino acid identity (see, for example, Brown etal., Integrin-associated protein (CD47) and its ligands, Trends Cell Biol, 11, 130-135 (2001)).
[0474] The CD47 polypeptide (or a variant or fragment thereof) may be a human CD47 polypeptide (or a variant or fragment thereof). A CD47 polypeptide may have an amino acid sequence of UniProtKB Q08722.
[0475] Exemplary CD47 polypeptides are provided as the sequences set forth in SEQ ID NOs: 4-7. Suitably, a CD47 polypeptide comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to any of the sequences set forth in SEQ ID NOs: 4-7. Suitably, a CD47 polypeptide comprises or consists of the amino acid sequence set forth in any of SEQ ID NOs: 4-7.
[0476] Exemplary CD47 polypeptides excluding the signal peptide are provided as the sequences set forth in SEQ ID NOs: 8-11. Suitably, a CD47 polypeptide comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to any of the sequences set forth in SEQ ID NOs: 8-11. Suitably, a CD47 polypeptide comprises or consists of the amino acid sequence of any of the sequences set forth in SEQ ID NOs: 8-11.
[0477] The skilled person would be able to generate variants and / or fragments of CD47, for example based on conservative substitutions and / or the known structural and functional features of CD47. These are described, e.g., in Fenalti et al., Structure of the human marker of self 5-transmembrane receptor CD47, Nature Communications, Nature Communications, 12, 1-14 (2021).
[0478] Suitably, a fragment of CD47 and / or CD47 variant retains the ability to inhibit phagocytosis. Suitably, a CD47 fragment and / or CD47 variant may comprise the extracellular domain of CD47. The extracellular domain of human CD47 may interact with SIRP-a and inhibit phagocytosis. Optionally, a CD47 fragment and / or CD47 variant comprises the transmembrane domain of CD47. The domains may be linked by inter-domain linker(s). The fragment and / or variant may have at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% of the activity of a full-length CD47 polypeptide.
[0479] Suitably, a variant of the sequence set forth in SEQ ID NO: 4 may comprise one or more substitutions selected from V5I, C14W, C15R, F22L, S27F, F30L, F32Y, T36S, V38L, V38I, F42V, T44A, N50S, T51A, T52S, T52A, V56I, R63K, A71T, S75Y, T76A, P78L, P78S, P78A, S82R, S82N, S83T, K85N, K85E, V88A, V88L, V88I, Q90R, L91F, K93N, M100I, M100V, D101G, K102R, K102T, S107L, I126F, 1127V, K130Q, R132H, S138F, V146I, 1150V, 1153V, S169A, G170R, G170S, G171S, D173Y, 1177V, A178G, V181I, V185A, 1186V, V188A, I189T, 1191V, V198I, A207S, T215I, I219M, Y226C, A231S, T235A, S236F, A240V, A240T, 1241V, V243I, I244T, V246L, Y249F, A252S, A252T, V254A, S257T, I264M, I264L, M266I, M266T, M266V, V287I, V292A, N295S, N295D, Q296L, P302S, N304S and N304D. These are considered to be tolerated, benign, and / or likely benign variations as predicted by SIFT, PolyPhen, CADD, REVEL and MetaLR.
[0480] Suitably, a variant of the sequence set forth in SEQ ID NO: 5 may comprise one or more substitutions selected from P3L, A6P, F22L, S27F, F30L, F32Y, T36S, V38L, V38I, F42V, N50S, T51A, T52S, T52A, V56I, R63K, A71T, S75Y, T76A, P78L, P78S, P78A, S82R, S82N, S83T, K85N, K85E, V88A, V88L, V88I, Q90R, L91F, K93N, M100I, M100V, D101G, K102R, K102T, S107L, I126F, 1127V, K130Q, R132H, S138F, V146I, 1150V, 1153V, S169A, G170R, G170S, G171S, 1177V, A178G, V181I, I186V, V188A, I189T, 1191V, V198I, A207S, T215I, I219M, Y226C, A231S, T235A, A240V, A240T, 1241V, V243I, I244T, V246L, Y249F, A252S, A252T, V254A, I264M, I264L, M266I, M266T, M266V, V287I, V292A, N295S, N295D and Q296L. These are considered to be tolerated, benign, and / or likely benign variations as predicted by SIFT, PolyPhen, CADD, REVEL, and MetaLR.
[0481] An exemplary CD47 fragment is the sequence set forth in SEQ ID NO: 12. Suitably, a CD47 fragment comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequence set forth in SEQ ID NO: 12. Suitably, a CD47 fragment comprises or consists of the amino acid sequence set forth in SEQ ID NO: 12.
[0482] An exemplary CD47 fragment excluding the signal peptide is the sequence set forth in SEQ ID NO: 13. Suitably, a CD47 fragment comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% identity to the sequence set forth in SEQ ID NO: 13. Suitably, a CD47 fragment comprises or consists of the amino acid sequence set forth in SEQ ID NO: 13.
[0483] MHC-Ilowor MHC-Ifreeretroviral vectors
[0484] The retroviral vector of the present invention may be an MHC-I10” retroviral vector or an MHC-Ifreeretroviral vector. In preferred embodiments, the retroviral vector of the present invention is an MHC-Ifreeretroviral vector.
[0485] As used herein, the term " MHC-I10” retroviral vector" refers to a retroviral vector with reduced levels of one or more MHC-I molecules on its surface (i.e., reduced levels of surface-exposed MHC-I molecules). The number of surface-exposed MHC-I molecules may be reduced such that the immune response to the MHC-I is decreased to a therapeutically relevant degree.
[0486] As used herein, the term " MHC-Ifreeretroviral vector" refers to a retroviral vector which is substantially devoid of (or free of) one or more MHC-I molecules on its surface (i.e., substantially devoid of (or free of) surface-exposed MHC-I molecules). Specifically, the surface of the retroviral vector may not comprise MHC-I.
[0487] The major histocompatibility complex class I (MHC-I) is a heterodimeric membrane protein that is displayed on the outer leaflet of the cell membrane (see, for example, Penn et al., (2005) Major histocompatibility complex (MHC). eLS). MHC-I functions to bind and display peptide fragments of proteins to the extracellular environment, where they may be recognised by CD8+ cytotoxic T cells. Peptide fragments generated from normal cellular proteins will not activate cytotoxic T cells due to central and peripheral tolerance mechanisms. However, foreign peptides (e.g., those originating from viral proteins) will cause activation of an immune response to destroy the cell. An allogeneic MHC-I protein itself may be recognised by the immune system. For example, antibodies may bind MHC-I epitopes directly. As a result, retroviral vectors that comprise MHC-I molecules originating from an allogeneic source may be targeted and neutralised by the immune system.
[0488] The term " MHC-I molecules" may refer to human MHC-I molecules. Human MHC-I is also referred to as human leukocyte antigen class I (HLA-I) and is expressed on almost all nucleated cells. HLA-I consists of two polypeptide chains, an HLA-I heavy chain (a chain) and R2 microglobulin (B2M or fc chain). The HLA-I a chain and B2M are linked non-covalently. The HLA-I a chain is polymorphic. Six HLA-I a chains have been identified to date, including three classical, highly polymorphic a chains (HLA-A, HLA-B and HLA-C) and three non-classical, less polymorphic (HLA-E, HLA-F and HLA-G) a chains. The MHC-I molecules may comprise or consist of HLA-A, HLA-B and HLA-C molecules, which comprise an invariant B2M sequence.
[0489] The term " MHC-I molecules" also includes variant MHC-I sequences, such as polymorphisms of HLA-I a chain sequences and / or B2M sequences. For example, variant MHC-I sequences may include HLA-I a chain sequences and / or B2M sequences with single nucleotide polymorphisms (SNPs) or multiple SNPs. Such variant MHC-I sequences with SNPs or multiple SNPs are known in the art.
[0490] Any suitable assay to quantify the amount of MHC-I molecules present on the surface of the retroviral vector may be used.
[0491] In some embodiments, the amount of MHC-I molecules may be determined by immunostaining for MHC-I and electron microscopy, for example as described in Milani et al., Genome editing for scalable productionof alloantigen-free lentiviral vectors for in vivo gene therapy, EMBO Mol Med, 9, 1558-1573 (2017). The MHC-I molecules may be detected in an amount of less than about 10 gold particles / retroviral particle, less than about 9 gold particles / retroviral particle, less than about 8 gold particles / retroviral particle, less than about 7 gold particles / retroviral particle, less than about 6 gold particles / retroviral particle, less than about 5 gold particles / retroviral particle, less than about 4 gold particles / retroviral particle, less than about 3 gold particles / retroviral particle, less than about 2 gold particles / retroviral particle, less than about 1 gold particle / retroviral particle or about 0 gold particles / retroviral particle The MHC-I molecules may be undetectable (e.g., the amount of gold particles detected may not be significantly higher than background levels).
[0492] The retroviral vector of the present invention may be obtained from an MHC-I10” producer cell or an MHC-lfreeproducer cell. In preferred embodiments, the retroviral vector of the present invention is obtained from an MHC-Ifreeproducer cell. As used herein, the term " MHC-I10” producer cell" refers to a producer cell with reduced levels of one or more MHC-I molecule on its surface. As used herein, the term " MHC-Ifreeproducer cell" refers to a producer cell which is substantially devoid of or free of one or more MHC-I molecule(s) on its surface. Specifically, the surface of the retroviral vector may not comprise MHC-I molecules.
[0493] An MHC-I10” or MHC-Ifreeproducer cell may be genetically engineered to decrease expression of MHC-I on the cell surface. For example, the cell may comprise a genetically engineered disruption of a gene encoding 82-microglobulin and / or a genetically engineered disruption of a gene encoding an MHC-I a chain.
[0494] Methods for genetic engineering to decrease protein expression are known in the art. For example, this may be achieved by targeted gene knockout. To decrease protein expression, the gene encoding the protein itself or its regulatory sequence (e.g., its promoter) may be knocked out. Knockout may be achieved by deletion of a section of the coding nucleic acid sequence, which may delete a section of the protein essential for expression or stability, or alter the reading frame of the coding sequence or by base-editing. Suitable methods for targeted gene knockout include use of zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and CRISPR / Cas-based RNA-guided nucleases (see, e.g., Gaj et al., ZFN, TALEN, and CRISPR / Cas-based methods for genome engineering, Trends Biotechnol, 31, 397-405 (2013)). For example, the CRISPR / Cas9 RNA-guided nuclease may be used to catalyse a double strand break at a specific locus in the genome if provided with appropriate RNA guides designed to bind that locus. Cas9 and the guide RNA may be delivered to a target cell by transfection of vectors encoding the protein and RNA. Cells attempt to repair any double strand breaks in their DNA using the non- homologous end joining (NHEJ) pathway. This is an error-prone mechanism which inserts random nucleotides and often disrupts the reading frame of the targeted gene. Alternatively, the genetic engineering to decrease protein expression may be accomplished using RNAi techniques, microRNA or antisense RNA to suppress expression of the target gene.
[0495] Once the targeted gene knockout or suppression of expression approach has been carried out, the resulting population of cells may be screened to select and enrich for those cells exhibiting the phenotype of interest, for example decreased expression of surface-exposed MHC-I. Suitable techniques for screening and enrichment are known in the art and include flow cytometry and fluorescence-activated cell sorting (FACS).
[0496] In some embodiments, the producer cell comprises a genetically engineered disruption of a gene encoding R2-microglobulin. R2-microglobulin stabilises MHC-I, thus cells deficient in R2-microglobulin will exhibit decreased expression of MHC-I on the surface of the cell. The cell may comprise genetically engineered disruptions in all copies of the gene encoding R2-microglobulin.
[0497] In another embodiment, the cell comprises a genetically engineered disruption of one or more genes encoding an MHC-I a chain. The cell may comprise genetically engineered disruptions in all copies of the gene encoding an MHC-I a chain.
[0498] The cell may comprise both genetically engineered disruptions of genes encoding R2-microglobulin and genetically engineered disruptions of genes encoding an MHC-I a chain.
[0499] Decreased expression of MHC-I on the surface of the cell may refer to a decrease in the number of MHC-I molecules that are expressed on the surface of the cell that has been genetically engineered, in comparison to the number of MHC-I molecules that are expressed on the surface of a cell lacking the genetic engineering, but under otherwise substantially identical conditions. The expression of MHC-I on the surface of the cell may be decreased such that the number of surface-exposed MHC-I molecules is, for example, less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposed MHC-I molecules that are displayed in the absence of the genetic engineering. In some embodiments, the expression of MHC-I on the surface of the cell is decreased such that the number of surface-exposed MHC-I molecules is 0% of the number of surface-exposed MHC-I molecules that are displayed in the absence of the genetic engineering.
[0500] The expression of MHC-I on the surface of the cell is preferably decreased such that the cell is substantially devoid of surface-exposed MHC-I molecules. In this context, "substantially devoid" means that there is a substantial decrease in the number of MHC-I molecules that are expressed on the surface of the cell that has been genetically engineered, in comparison to the number of MHC-I molecules that are expressed on the surface of a cell lacking the genetic engineering, such that the immune response to MHC-I on retroviral vectors produced by the cell is decreased to a therapeutically useful degree.
[0501] Suitably, the retroviral vector of the present invention has a lower concentration of MHC-I molecules on its surface than a retroviral vector obtained from an unmodified producer cell. Suitably, the retroviral vector has less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposedMHC-I molecules that are displayed on a retroviral vector obtained from an unmodified producer cell. In some embodiments, the retroviral vector has less than about 20% of the number of surface-exposed MHC-I molecules that are displayed on a retroviral vector obtained from an unmodified producer cell.
[0502] In some embodiments, the retroviral vector of the present invention is substantially devoid of MHC-I molecules on its surface. In this context, "substantially devoid" means that there is no detectable immune response due to the molecules on the surface of the retroviral vector.
[0503] In some embodiments, the retroviral vector of the present invention is free of MHC-I molecules on its surface. In this context, "free" means that there are no detectable molecules (e.g., by immunostaining and electron microscopy) on the surface of the retroviral vector. As used herein, "not detectable" refers to levels which are not statistically significantly different compared to background levels.
[0504] In some embodiments, the retroviral vector of the present invention has decreased HLA-A, HLA-B and / or HLA-C molecules on its surface. Suitably, the retroviral vector has less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposed HLA-A molecules that are displayed on a retroviral vector obtained from an unmodified producer cell. Suitably, the retroviral vector has less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposed HLA-B molecules that are displayed on a retroviral vector obtained from an unmodified producer cell. Suitably, the retroviral vector has less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposed HLA-C molecules that are displayed on a retroviral vector obtained from an unmodified producer cell.
[0505] In some embodiments, the retroviral vector of the present invention is substantially devoid of HLA-A, HLA-B and / or HLA-C molecules on its surface. In some embodiments, the retroviral vector of the present invention is substantially devoid of HLA-A, HLA-B and HLA-C molecules on its surface. In some embodiments, the retroviral vector of the present invention is free of HLA-A, HLA-B and / or HLA-C molecules on its surface. In some embodiments, the retroviral vector of the present invention is free of HLA-A, HLA-B and HLA-C molecules on its surface.
[0506] As described above, an HLA-I molecule consists of two polypeptide chains, an HLA-I heavy chain (α chain) and β2 microglobulin (β2M or β chain). The HLA-I α chain and β2M are linked non-covalently.
[0507] The skilled person would readily be able to determine amino acid and nucleic acid sequences of HLA-I α chains. For example, the HLA-I α chains may be identified in a genome sequence using their location within the major histocompatibility complex region of the chromosome (see, for example, Penn et al., (2005) Major histocompatibility complex (MHC)).
[0508] HLA-A α chains may have an amino acid sequence of UniProtKB P04439. Exemplary HLA-A α chains are provided by the sequences set forth in SEQ ID NOs: 14 and 15. Suitably, an HLA-A α chain comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequences set forth in SEQ ID NO: 14 or 15. Suitably, a HLA-A α chain comprises or consists of the amino acid sequence set forth in SEQ ID NO: 14 or 15.
[0509] HLA-B α chains may have an amino acid sequence of UniProtKB P01889. An exemplary HLA-B α chain is provided by the sequence set forth in SEQ ID NO: 16. Suitably, an HLA-B α chain comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequence set forth in SEQ ID NO: 16. Suitably, a HLA-B α chain comprises or consists of the amino acid sequence set forth in SEQ ID NO: 16.
[0510] HLA-C α chains may have an amino acid sequence of UniProtKB P10321. Exemplary HLA-C α chains are provided by the sequences set forth in SEQ ID NOs: 17 and 18. Suitably, an HLA-C α chain comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequences set forth in SEQ ID NO: 17 or 18. Suitably, a HLA-C α chain comprises or consists of the amino acid sequence of SEQ ID NO: 17 or 18.
[0511] Amino acid and nucleic acid sequences encoding β2M are also known in the art. For example, a nucleic acid sequence of a human β2M is deposited as GenBank Accession No. NM_004048.
[0512] An HLA β chain may be that of UniProtKB P61769. An exemplary HLA β chain is provided by the sequence set forth in SEQ ID NO: 19. Suitably, an HLA β chain comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequence set forth in SEQ ID NO: 19. Suitably, an HLA β chain comprises or consists of the amino acid sequence set forth in SEQ ID NO: 19.
[0513] The retroviral vector of the present invention may be a CD47hlghand MHC-Ifreeretroviral vector or a CD47hlghand MHC-I10” retroviral vector. In preferred embodiments, the retroviral vector of the present invention is a CD47hlghand MHC-Ifreeretroviral vector.
[0514] The retroviral vector of the present invention may be obtained from a CD47hlghand MHC-Ifreeproducer cell or a CD47hlghand MHC-I10” producer cell. In preferred embodiments, the retroviral vector of the present invention is obtained from a CD47hlghand MHC-Ifreeproducer cell.
[0515] Reverse orientation
[0516] In one aspect, the invention provides a retroviral vector comprising a nucleotide sequence of a nucleic acid of interest, such as a gene of interest, operably linked to a promoter, wherein the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, and the promoter are in a reverse orientation in the retroviral vector. Reverse orientation can be useful in case expression of the transgene is unwanted in producer cells or if it is difficult to get rid of the co-produced protein (e.g., because it is toxic) during retroviral vector purification.
[0517] In one aspect, the invention provides a retroviral vector comprising an expression cassette comprising a nucleotide sequence of a nucleic acid of interest, such as a gene of interest, operably linked to a promoter, wherein the expression cassette is in a reverse orientation in the retroviral vector.
[0518] As used herein, "reverse orientation" in a retroviral vector refers to the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, and the promoter, and / or the expression cassette, being incorporated into the retroviral vector such that the direction of transcription from the promoter is oriented towards a 5' long terminal repeat (LTR) of the retroviral vector. The nucleotide sequence of the nucleic acid of interest, such as the gene of interest, or the expression cassette may be in an antisense orientation compared to transcription of the retroviral vector genome, for example which may occur in retroviral vector producer cells during vector production.
[0519] The reverse orientation may allow transcription of the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, from the promoter when the retroviral vector is in a cell in which the promoter is active. The reverse orientation may prevent transcription of the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, from a second promoter that is upstream of the 5'LTR. The second promoter may, for example, only be present in the plasmid transcribing the retroviral vector genome in producer cells during vector production.
[0520] Regulatory elements of retroviral vectors
[0521] The retroviral vector of the present invention may comprise one or more regulatory elements which can act pre- or post-transcriptionally. Suitably, the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, is operably linked to one or more regulatory elements which may act pre- or post-
[0522] transcriptionally. In one embodiment, the one or more regulatory elements may facilitate expression of the nucleic acid of interest, such as the gene of interest, in all cells. In another embodiment, the one or more regulatory elements may facilitate expression of the nucleic acid of interest, such as the gene of interest, in HSPCs and / or in differentiated hematopoietic cells.
[0523] As used herein, the term "regulatory element" refers to any nucleotide sequence that facilitates expression of a polypeptide. For example, such a regulatory element acts to increase expression of a transcript or to enhance mRNA stability. Suitable regulatory elements include, for example, promoters, enhancer elements, post-transcriptional regulatory elements, polyadenylation sequences and Kozak sequences, as further defined herein.
[0524] Exemplary embodiments of regulatory elements of the viral vector of the invention in general have already been described herein. These exemplary embodiments of regulatory elements of the viral vector of the invention in general can also be embodiments of the viral vector of the invention when the viral vector of the invention is a retroviral vector.
[0525] The following passages provide further exemplary embodiments of regulatory elements of retroviral vectors according to the present invention specifically.
[0526] Other cis-acting elements of retroviral vectors
[0527] Retroviral vectors of the invention may also have additional cis-acting elements, such as a rev response element (RRE), which enables the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell; a retroviral psi packaging element, which is involved in regulating the essential process of packaging the retroviral RNA genome into the viral capsid during replication; a primer binding site (PBS), where reverse transcription is initiated; splice donor and acceptor sites; and central and terminal polypurine tracts, which allow initiation of plus-strand synthesis.
[0528] The following passages provide exemplary embodiments of cis-acting elements of retroviral vectors.
[0529] Long terminal repeats (LTRs) of retroviral vectors
[0530] The retroviral vector of the present invention may comprise one or more LTRs. LTRs are responsible for proviral integration and transcription. Typically, a naturally occurring LTR comprises U3, R, and U5 regions.
[0531] In a retrovirus genome, the elements are typically flanked at both ends by regions called long terminal repeats (LTRs). The LTRs are responsible for integration and transcription. LTRs may also serve as enhancer-promotersequences and can control the expression of the retroviral genes. The LTRs themselves are identical or nearidentical sequences that can typically be divided into three regions: U3, R and U5. LTRs may be naturally occurring or may be modified.
[0532] Suitable LTR sequences are well known to the skilled person.
[0533] The retroviral vector of the present invention may comprise one or more self-inactivating long terminal repeats (SIN-LTR). A " SIN-LTR" may comprise a deletion that abolishes transcription of the full-length virus after it has incorporated into a host cell. For example, a 3' SIN-LTR may comprise a deletion in the U3 region removing the promoter / enhancer elements. This deletion is copied into the 5' LTR after reverse transcription, thereby making the gene expression in target cells dependent on an internal promoter of choice.
[0534] Suitable SIN-LTR sequences are well known to the skilled person.
[0535] Primer binding site (PBS) of retroviral vectors
[0536] The retroviral vector of the present invention may comprise a primer binding site (PBS). A PBS is a cis-acting element where a primer may bind to initiate reverse transcription of the RNA genome (see, for example, Lanchy et al., Contacts between Reverse Transcriptase and the Primer Strand Govern the Transition from Initiation to Elongation of HIV-1 Reverse Transcription, J Biol Chem, 273, 24425-24432 (1998)).
[0537] Suitable retroviral PBSs are well known to the skilled person.
[0538] Retroviral psi packaging element of retroviral vectors
[0539] The retroviral vector of the present invention may comprise a retroviral psi packaging element. A retroviral psi packaging element is a cis-acting element that is involved in regulating the process of packaging the retroviral RNA genome into the viral capsid during replication (see, for example, McBride et al., Efficient Encapsidation of Human Immunodeficiency VirusType 1 Vectors and Further Characterization of cis Elements Required for Encapsidation, J Virol, 71, 4544-4554 (1997)). A retroviral psi packaging element may form part of the 5' region of the gag gene.
[0540] Suitable retroviral psi packaging elements are well known to the skilled person.
[0541] In some embodiments, a retroviral psi packaging element comprises or consists of a nucleotide sequence that has at least 70% sequence identity to the sequence set forth in SEQ ID NO: 23 or a fragment thereof. Suitably, a retroviral psi packaging element comprises or consists of a nucleotide sequence that has at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 23 or a fragment thereof.
[0542] In some embodiments, a retroviral psi packaging element comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 23 or a fragment thereof.
[0543] Rev response element (RRE) of retroviral vectors
[0544] The retroviral vector of the present invention may comprise a rev response element (RRE). A RRE is a cisacting element that enables the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell (see, for example, Pollard et al., The HIV-l Rev Protein, Annu Rev of Microbiol, 52, 491-532 (1998)).
[0545] Suitable RRE sequences will be well known to the skilled person.
[0546] Central polypurine tract (cPPT) of retroviral vectors
[0547] The retroviral vector of the present invention may comprise a central polypurine tract (cPPT). A cPPT may allow initiation of plus-strand synthesis (see, for example, Follenzi et al., Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-l pol sequences, Nat Genet, 25, 217-222 (2000)).
[0548] Suitable cPPT sequences are well known to the skilled person.
[0549] Other elements of retroviral vectors
[0550] The retroviral vector of the present invention may comprise other suitable elements.
[0551] In some embodiments, the retroviral vector of the present invention comprises an element that is a delta ENV1.
[0552] In some embodiments, the retroviral vector of the present invention comprises an element that is a delta ENV2.
[0553] Virus-like particle (VLP) vectors
[0554] In one embodiment, the viral vector of the present invention is a virus-like particle (VLP) vector. As used herein, the term "virus-like particle (VLP) vector" refers to a particle that closely resembles a virus, but is non-infectious because it does not contain genetic material capable of causing viral infection. More specifically, as used herein, a VLP vector is a structure that comprises one or more different viral structural proteins with the ability to self-assemble, thereby mimicking the form and size of a virus particle, but a VLP vector lacks genetic material for infecting host cells.
[0555] In one embodiment, the VLP vector may be derived or derivable from a virus selected from the group consisting of lentivirus, adeno-associated virus, adenovirus and retrovirus. As used herein, the term "derived or derivable from a virus" in the context of a VLP vector means that the VLP vector comprises an element of a component, in particular structural proteins, from one or more viruses. The element of a component of the virus may differ, e.g., in sequence, from the corresponding element of the component in the virus, but fulfils the same function, to the same or a similar extent, as the corresponding element of the component in the virus.
[0556] In one embodiment, a VLP vector comprises one or more element(s) of a component from one virus, such as one or more structural proteins from one virus. In another embodiment, a VLP vector comprises elements of components from two or more viruses, such as different structural proteins from two or more viruses, and may then be referred to as a chimeric VLP vector.
[0557] In one embodiment, the VLP vector of the present invention may be derived or derivable from a virus selected from the group consisting of adeno-associated virus and adenovirus.
[0558] In a preferred embodiment, the VLP vector of the present invention may be derived or derivable from a virus selected from the group consisting of lentivirus and retrovirus.
[0559] In an even more preferred embodiment, the VLP vector of the present invention in derived or derivable from lentivirus.
[0560] CD47highVLP vectors
[0561] The VLP vector of the present invention may be a CD47hlghVLP vector. As used herein, a " CD47hlghVLP vector" refers to a VLP vector with increased levels of CD47 (Cluster of Differentiation 47) CD47 (or a variant or fragment thereof) on its surface. A CD47hlghVLP vector has reduced uptake by professional phagocytes. In some embodiments the surface of a CD47hlghVLP vector comprises a higher level of CD47 protein than a control VLP vector produced in HEK293T cells. The skilled person knows how to obtain suitable HEK293T cells and how to perform a suitable control experiment to compare levels of CD47 protein on VLP vectors.
[0562] CD47 (Cluster of Differentiation 47), also known as integrin associated protein (IAP), is a transmembrane protein that in humans is encoded by the CD47 gene. Phagocytosis is physiologically inhibited by CD47, which is a ubiquitously expressed ligand of signal regulatory protein a (SIRP-a) receptor that is expressed by professional phagocytes. CD47 may be incorporated into VLP vectors when they bud from producer cells.
[0563] The VLP vector of the present invention may comprise one or more CD47 polypeptides (or a variant or fragment thereof) on its surface. The amount of CD47 (or a variant or fragment thereof) on the surface may be enough to reduce uptake by professional phagocytes. Any suitable assay to quantify the amount of CD47 polypeptides (or variants or fragments thereof) present on the surface of the VLP vector may be used. The skilled person knows suitable assays to quantify the amount of CD47 polypeptides (or variants or fragments thereof) present on the surface of the VLP vector.
[0564] In some embodiments, the density of CD47 polypeptides (or variant or fragments thereof) may be determined by immunostaining for CD47 and total internal reflection fluorescence microscopy, for example as described in US 2010 / 0316570 Al. The CD47 polypeptides (or variant or fragments thereof) may be present at a density of at least about 20 molecules / μm2, at least about 25 molecules / μm2, at least about 30 molecules / μm2, at least about 35 molecules / μm2, at least about 40 molecules / μm2, at least about 45 molecules / μm2, at least about 50 molecules / μm2, at least about 60 molecules / μm2, at least about 70 molecules / μm2, at least about 80 molecules / μm2, at least about 90 molecules / μm2, at least about 100 molecules / μm2, at least about 150 molecules / μm2, at least about 200 molecules / μm2, at least about 250 molecules / μm2, at least about 300 molecules / μm2, at least about 350 molecules / μm2, at least about 400 molecules / μm2, at least about 450 molecules / μm2, at least about 500 molecules / μm2, at least about 600 molecules / μm2, at least about 700 molecules / μm2, at least about 800 molecules / μm2, at least about 900 molecules / μm2or at least about 1000 molecules / μm2. The CD47 polypeptides (or fragments thereof) may be present at a density of about 1000 molecules / μm2or less, about 500 molecules / μm2or less or about 250 molecules / μm2or less. The CD47 polypeptides (or fragments thereof) may be present at a density of from about 20 molecules / μm2to about 1000 molecules / μm2, from about 20 molecules / μm2to about 500 molecules / μm2or from about 20 molecules / μm2to about 250 molecules / pm2. In a preferred embodiment, the CD47 polypeptides (or fragments thereof) are present at a density of from about 90 molecules / μm2to about 900 molecules / μm2.
[0565] In some embodiments, the amount of CD47 polypeptides (or variant or fragments thereof) may be determined by immunostaining for CD47 and electron microscopy, as described in Milani etal., Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates, Sci Transl Med, 11(493), eaav7325 (2019). The CD47 polypeptides (or variants or fragments thereof) may be detected in an amount of at least about 10 gold particles / VLP, at least about 15 gold particles / VLP or at least about 20 gold particles / VLP. The CD47 polypeptides (or variants or fragments thereof) may be detected in an amount ofabout 100 gold particles / VLP or less, about 80 gold particles / VLP or less or about 60 gold particles / VLP or less. The CD47 polypeptides (or fragments thereof) may be detected in an amount of from about 10 to about 100 gold particles / VLP, from about 15 to about 80 gold particles / VLP or, in a preferred embodiment, from about 20 to about 60 gold particles / VLP.
[0566] The VLP vector of the present invention may be obtained from a CD47hlghproducer cell. As used herein, a " CD47hlghproducer cell" refers to a producer cell with increased levels of CD47 (or a fragment thereof) on its surface.
[0567] A CD47highproducer cell may be genetically engineered to increase expression of CD47 (or a variant or fragment thereof) on the cell surface. For example, the producer cell may comprise a vector encoding CD47 (or a variant or fragment thereof) or may be edited to introduce a nucleotide sequence encoding CD47 (or a variant or fragment thereof) into its genome. Suitably, the producer cell is transduced with a viral vector encoding a CD47 polypeptide (or a variant or fragment thereof).
[0568] A CD47highproducer cell may have a higher concentration of CD47 (or a variant or fragment thereof) on its surface than an unmodified producer cell. Suitably, the producer cell has at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold or at least about 30-fold more CD47 on its cell surface than an unmodified producer cell. Suitably, the producer cell has from about 5-fold to about 30-fold more CD47 (or a fragment thereof) on its cell surface than an unmodified producer cell.
[0569] Suitably, the VLP vector of the present invention has a higher concentration of CD47 (or a variant or fragment thereof) on its surface than a VLP vector obtained from an unmodified producer cell. Suitably, the VLP vector has at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold or at least about 50-fold more CD47 (or a variant or fragment thereof) on its surface than a VLP vector obtained from an unmodified producer cell. Suitably, the VLP vector has from about 5-fold to about 30-fold more CD47 (or a variant or fragment thereof) on its surface than a VLP vector obtained from an unmodified producer cell.
[0570] CD47 is a member of the immunoglobulin (Ig) superfamily of membrane proteins, with a single IgV-like domain at its N-terminus, a highly hydrophobic stretch with five membrane-spanning segments and an alternatively spliced cytoplasmic C-terminus ranging in length from 3 to 36 amino acids. Mouse, rat, bovine and human CD47 molecules have been cloned and show about 70% overall amino acid identity (see, for example, Brown etal., Integrin-associated protein (CD47) and its ligands, Trends Cell Biol, 11, 130-135 (2001)).
[0571] The CD47 polypeptide (or a variant or fragment thereof) may be a human CD47 polypeptide (or a variant or fragment thereof). A CD47 polypeptide may have an amino acid sequence of UniProtKB Q08722.
[0572] Exemplary CD47 polypeptides are provided as the sequences set forth in SEQ ID NOs: 4-7. Suitably, a CD47 polypeptide comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to any of the sequences set forth in SEQ ID NOs: 4-7. Suitably, a CD47 polypeptide comprises or consists of the amino acid sequence set forth in any of SEQ ID NOs: 4-7.
[0573] Exemplary CD47 polypeptides excluding the signal peptide are provided as the sequences set forth in SEQ ID NOs: 8-11. Suitably, a CD47 polypeptide comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to any of the sequences set forth in SEQ ID NOs: 8-11. Suitably, a CD47 polypeptide comprises or consists of the amino acid sequence of any of the sequences set forth in SEQ ID NOs: 8-11.
[0574] The skilled person would be able to generate variants and / or fragments of CD47, for example based on conservative substitutions and / or the known structural and functional features of CD47. These are described, e.g., in Fenalti et al., Structure of the human marker of self 5-transmembrane receptor CD47, Nature Communications, Nature Communications, 12, 1-14 (2021).
[0575] Suitably, a fragment of CD47 and / or CD47 variant retains the ability to inhibit phagocytosis. Suitably, a CD47 fragment and / or CD47 variant may comprise the extracellular domain of CD47. The extracellular domain of human CD47 may interact with SIRP-a and inhibit phagocytosis. Optionally, a CD47 fragment and / or CD47 variant comprises the transmembrane domain of CD47. The domains may be linked by inter-domain linker(s). The fragment and / or variant may have at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% of the activity of a full-length CD47 polypeptide.
[0576] Suitably, a variant of the sequence set forth in SEQ ID NO: 4 may comprise one or more substitutions selected from V5I, C14W, C15R, F22L, S27F, F30L, F32Y, T36S, V38L, V38I, F42V, T44A, N50S, T51A, T52S, T52A, V56I, R63K, A71T, S75Y, T76A, P78L, P78S, P78A, S82R, S82N, S83T, K85N, K85E, V88A, V88L, V88I, Q90R, L91F, K93N, M100I, M100V, D101G, K102R, K102T, S107L, I126F, 1127V, K130Q, R132H, S138F, V1461, 1150V, 1153V, S169A, G170R, G170S, G171S, D173Y, 1177V, A178G, V181I, V185A, 1186V, V188A, I189T, 1191V, V198I, A207S, T215I, I219M, Y226C, A231S, T235A, S236F, A240V, A240T, 1241V, V243I, I244T, V246L, Y249F, A252S, A252T, V254A, S257T, I264M, I264L, M266I, M266T, M266V, V287I, V292A, N295S, N295D, Q296L, P302S, N304S andN304D. These are considered to be tolerated, benign, and / or likely benign variations as predicted by SIFT, PolyPhen, CADD, REVEL and MetaLR.
[0577] Suitably, a variant of the sequence set forth in SEQ ID NO: 5 may comprise one or more substitutions selected from P3L, A6P, F22L, S27F, F30L, F32Y, T36S, V38L, V38I, F42V, N50S, T51A, T52S, T52A, V56I, R63K, A71T, S75Y, T76A, P78L, P78S, P78A, S82R, S82N, S83T, K85N, K85E, V88A, V88L, V88I, Q90R, L91F, K93N, M100I, M100V, D101G, K102R, K102T, S107L, I126F, 1127V, K130Q, R132H, S138F, V146I, 1150V, 1153V, S169A, G170R, G170S, G171S, 1177V, A178G, V181I, 1186V, V188A, I189T, 1191V, V198I, A207S, T215I, I219M, Y226C, A231S, T235A, A240V, A240T, 1241V, V243I, I244T, V246L, Y249F, A252S, A252T, V254A, I264M, I264L, M266I, M266T, M266V, V287I, V292A, N295S, N295D and Q296L. These are considered to be tolerated, benign, and / or likely benign variations as predicted by SIFT, PolyPhen, CADD, REVEL, and MetaLR.
[0578] An exemplary CD47 fragment is the sequence set forth in SEQ ID NO: 12. Suitably, a CD47 fragment comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequence set forth in SEQ ID NO: 12. Suitably, a CD47 fragment comprises or consists of the amino acid sequence set forth in SEQ ID NO: 12.
[0579] An exemplary CD47 fragment excluding the signal peptide is the sequence set forth in SEQ ID NO: 13. Suitably, a CD47 fragment comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% identity to the sequence set forth in SEQ ID NO: 13. Suitably, a CD47 fragment comprises or consists of the amino acid sequence set forth in SEQ ID NO: 13.
[0580] MHC-Ilowor MHC-IfreeVLP vectors
[0581] The VLP vector of the present invention may be an MHC-I10” VLP vector or an MHC-IfreeVLP vector. In preferred embodiments, the VLP vector of the present invention is an MHC-IfreeVLP vector.
[0582] As used herein, the term " MHC-I10” VLP vector" refers to a VLP vector with reduced levels of one or more MHC-I molecules on its surface (i.e., reduced levels of surface-exposed MHC-I molecules). The number of surface-exposed MHC-I molecules may be reduced such that the immune response to the MHC-I is decreased to a therapeutically relevant degree.
[0583] As used herein, the term " MHC-IfreeVLP vector" refers to a VLP vector which is substantially devoid of (or free of) one or more MHC-I molecules on its surface (i.e., substantially devoid of (or free of) surface-exposed MHC-I molecules). Specifically, the surface of the VLP vector may not comprise MHC-I.
[0584] The major histocompatibility complex class I (MHC-I) is a heterodimeric membrane protein that is displayed on the outer leaflet of the cell membrane (see, for example, Penn et al., (2005) Major histocompatibility complex (MHC)). MHC-I functions to bind and display peptide fragments of proteins to the extracellular environment, where they may be recognised by CD8+ cytotoxic T cells. Peptide fragments generated from normal cellular proteins will not activate cytotoxic T cells due to central and peripheral tolerance mechanisms. However, foreign peptides (e.g., those originating from viral proteins) will cause activation of an immune response to destroy the cell. An allogeneic MHC-I protein itself may be recognised by the immune system. For example, antibodies may bind MHC-I epitopes directly. As a result, VLP vectors that comprise MHC-I molecules originating from an allogeneic source may be targeted and neutralised by the immune system.
[0585] The term " MHC-I molecules" may refer to human MHC-I molecules. Human MHC-I is also referred to as human leukocyte antigen class I (HLA-I) and is expressed on almost all nucleated cells. HLA-I consists of two polypeptide chains, an HLA-I heavy chain (a chain) and 82 microglobulin (82M or 8 chain). The HLA-I a chain and 82M are linked non-covalently. The HLA-I a chain is polymorphic. Six HLA-I a chains have been identified to date, including three classical, highly polymorphic a chains (HLA-A, HLA-B and HLA-C) and three non-classical, less polymorphic (HLA-E, HLA-F and HLA-G) a chains. The MHC-I molecules may comprise or consist of HLA-A, HLA-B and HLA-C molecules, which comprise an invariant 82M sequence.
[0586] The term " MHC-I molecules" also includes variant MHC-I sequences, such as polymorphisms of HLA-I a chain sequences and / or 82M sequences. For example, variant MHC-I sequences may include HLA-I a chain sequences and / or 82M sequences with single nucleotide polymorphisms (SNPs) or multiple SNPs. Such variant MHC-I sequences with SNPs or multiple SNPs are known in the art.
[0587] Any suitable assay to quantify the amount of MHC-I molecules present on the surface of the VLP vector may be used.
[0588] In some embodiments, the amount of MHC-I molecules may be determined by immunostaining for MHC-I and electron microscopy, for example as described in Milani et al., Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy, EMBO Mol Med, 9, 1558-1573 (2017). The MHC-I molecules may be detected in an amount of less than about 10 gold particles / VLP, less than about 9 gold particles / VLP, less than about 8 gold particles / VLP, less than about 7 gold particles / VLP, less than about 6 gold particles / VLP, less than about 5 gold particles / VLP, less than about 4 gold particles / VLP, less than about 3 gold particles / VLP, less than about 2 gold particles / VLP, less than about 1 gold particle / VLP or about 0 gold particles / VLP. The MHC-I molecules may be undetectable (e.g., the amount of gold particles detected may not be significantly higher than background levels).
[0589] The VLP vector of the present invention may be obtained from an MHC-I10” producer cell or an MHC-Ifreeproducer cell. In preferred embodiments, the VLP vector of the present invention is obtained from an MHC-lfreeproducer cell. As used herein, the term " MHC-I10” producer cell" refers to a producer cell with reduced levels of one or more MHC-I molecule on its surface. As used herein, the term " MHC-Ifreeproducer cell" refers to a producer cell which is substantially devoid of or free of one or more MHC-I molecule(s) on its surface. Specifically, the surface of the VLP vector may not comprise MHC-I molecules.
[0590] An MHC-I10” or MHC-Ifreeproducer cell may be genetically engineered to decrease expression of MHC-I on the cell surface. For example, the cell may comprise a genetically engineered disruption of a gene encoding R2-microglobulin and / or a genetically engineered disruption of a gene encoding an MHC-I a chain.
[0591] Methods for genetic engineering to decrease protein expression are known in the art. For example, this may be achieved by targeted gene knockout. To decrease protein expression, the gene encoding the protein itself or its regulatory sequence (e.g., its promoter) may be knocked out. Knockout may be achieved by deletion of a section of the coding nucleic acid sequence, which may delete a section of the protein essential for expression or stability, or alter the reading frame of the coding sequence or by base-editing. Suitable methods for targeted gene knockout include use of zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and CRISPR / Cas-based RNA-guided nucleases (see, e.g., Gaj et al., ZFN, TALEN, and CRISPR / Cas-based methods for genome engineering, Trends Biotechnol, 31, 397-405 (2013)). For example, the CRISPR / Cas9 RNA-guided nuclease may be used to catalyse a double strand break at a specific locus in the genome if provided with appropriate RNA guides designed to bind that locus. Cas9 and the guide RNA may be delivered to a target cell by transfection of vectors encoding the protein and RNA. Cells attempt to repair any double strand breaks in their DNA using the non- homologous end joining (NHEJ) pathway. This is an error-prone mechanism which inserts random nucleotides and often disrupts the reading frame of the targeted gene. Alternatively, the genetic engineering to decrease protein expression may be accomplished using RNAi techniques, microRNA or antisense RNA to suppress expression of the target gene.
[0592] Once the targeted gene knockout or suppression of expression approach has been carried out, the resulting population of cells may be screened to select and enrich for those cells exhibiting the phenotype of interest, for example decreased expression of surface-exposed MHC-I. Suitable techniques for screening and enrichment are known in the art and include flow cytometry and fluorescence-activated cell sorting (FACS).
[0593] In some embodiments, the producer cell comprises a genetically engineered disruption of a gene encoding R2-microglobulin. R2-microglobulin stabilises MHC-I, thus cells deficient in R2-microglobulin will exhibit decreased expression of MHC-I on the surface of the cell. The cell may comprise genetically engineered disruptions in all copies of the gene encoding R2-microglobulin.
[0594] In another embodiment, the cell comprises a genetically engineered disruption of one or more genes encoding an MHC-I a chain. The cell may comprise genetically engineered disruptions in all copies of the gene encoding an MHC-I a chain.
[0595] The cell may comprise both genetically engineered disruptions of genes encoding R2-microglobulin and genetically engineered disruptions of genes encoding an MHC-I a chain.
[0596] Decreased expression of MHC-I on the surface of the cell may refer to a decrease in the number of MHC-I molecules that are expressed on the surface of the cell that has been genetically engineered, in comparison to the number of MHC-I molecules that are expressed on the surface of a cell lacking the genetic engineering, but under otherwise substantially identical conditions. The expression of MHC-I on the surface of the cell may be decreased such that the number of surface-exposed MHC-I molecules is, for example, less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposed MHC-I molecules that are displayed in the absence of the genetic engineering. In some embodiments, the expression of MHC-I on the surface of the cell is decreased such that the number of surface-exposed MHC-I molecules is 0% of the number of surface-exposed MHC-I molecules that are displayed in the absence of the genetic engineering.
[0597] The expression of MHC-I on the surface of the cell is preferably decreased such that the cell is substantially devoid of surface-exposed MHC-I molecules. In this context, "substantially devoid" means that there is a substantial decrease in the number of MHC-I molecules that are expressed on the surface of the cell that has been genetically engineered, in comparison to the number of MHC-I molecules that are expressed on the surface of a cell lacking the genetic engineering, such that the immune response to MHC-I on VLP vectors produced by the cell is decreased to a therapeutically useful degree.
[0598] Suitably, the VLP vector of the present invention has a lower concentration of MHC-I molecules on its surface than a VLP vector obtained from an unmodified producer cell. Suitably, the VLP vector has less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposed MHC-I molecules that are displayed on a VLP vector obtained from an unmodified producer cell. In some embodiments, the VLP vector has less than about 20% of the number of surface-exposed MHC-I molecules that are displayed on a VLP vector obtained from an unmodified producer cell.
[0599] In some embodiments, the VLP vector of the present invention is substantially devoid of MHC-I molecules on its surface. In this context, "substantially devoid" means that there is no detectable immune response due to the molecules on the surface of the VLP vector.
[0600] In some embodiments, the VLP vector of the present invention is free of MHC-I molecules on its surface. In this context, "free" means that there are no detectable molecules (e.g., by immunostaining and electronmicroscopy) on the surface of the VLP vector. As used herein, "not detectable" refers to levels which are not statistically significantly different compared to background levels.
[0601] In some embodiments, the VLP vector of the present invention has decreased HLA-A, HLA-B and / or HLA-C molecules on its surface. Suitably, the VLP vector has less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposed HLA-A molecules that are displayed on a VLP vector obtained from an unmodified producer cell. Suitably, the VLP vector has less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposed HLA-B molecules that are displayed on a VLP vector obtained from an unmodified producer cell. Suitably, the VLP vector has less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the number of surface-exposed HLA-C molecules that are displayed on a VLP vector obtained from an unmodified producer cell.
[0602] In some embodiments, the VLP vector of the present invention is substantially devoid of HLA-A, HLA-B and / or HLA-C molecules on its surface. In some embodiments, the VLP vector of the present invention is substantially devoid of HLA-A, HLA-B and HLA-C molecules on its surface. In some embodiments, the VLP vector of the present invention is free of HLA-A, HLA-B and / or HLA-C molecules on its surface. In some embodiments, the VLP vector of the present invention is free of HLA-A, HLA-B and HLA-C molecules on its surface.
[0603] As described above, an HLA-I molecule consists of two polypeptide chains, an HLA-I heavy chain (α chain) and β2 microglobulin (β2M or β chain). The HLA-I α chain and β2M are linked non-covalently.
[0604] The skilled person would readily be able to determine amino acid and nucleic acid sequences of HLA-I α chains. For example, the HLA-I α chains may be identified in a genome sequence using their location within the major histocompatibility complex region of the chromosome (see, for example, Penn et al., (2005) Major histocompatibility complex (MHC)).
[0605] HLA-A α chains may have an amino acid sequence of UniProtKB P04439. Exemplary HLA-A α chains are provided by the sequences set forth in SEQ ID NOs: 14 and 15. Suitably, an HLA-A α chain comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequences set forth in SEQ ID NO: 14 or 15. Suitably, a HLA-A α chain comprises or consists of the amino acid sequence set forth in SEQ ID NO: 14 or 15.
[0606] HLA-B α chains may have an amino acid sequence of UniProtKB P01889. An exemplary HLA-B α chain is provided by the sequence set forth in SEQ ID NO: 16. Suitably, an HLA-B α chain comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%or about 100% sequence identity to the sequence set forth in SEQ ID NO: 16. Suitably, a HLA-B α chain comprises or consists of the amino acid sequence set forth in SEQ ID NO: 16.
[0607] HLA-C α chains may have an amino acid sequence of UniProtKB P10321. Exemplary HLA-C α chains are provided by the sequences set forth in SEQ ID NOs: 17 and 18. Suitably, an HLA-C α chain comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequences set forth in SEQ ID NO: 17 or 18. Suitably, a HLA-C α chain comprises or consists of the amino acid sequence of SEQ ID NO: 17 or 18.
[0608] Amino acid and nucleic acid sequences encoding β2M are also known in the art. For example, a nucleic acid sequence of a human β2M is deposited as GenBank Accession No. NM_004048.
[0609] An HLA β chain may be that of UniProtKB P61769. An exemplary HLA β chain is provided by the sequence set forth in SEQ ID NO: 19. Suitably, an HLA β chain comprises an amino acid sequence that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% sequence identity to the sequence set forth in SEQ ID NO: 19. Suitably, an HLA β chain comprises or consists of the amino acid sequence set forth in SEQ ID NO: 19.
[0610] The VLP vector of the present invention may be a CD47highand MHC-IfreeVLP vector or a CD47highand MHC-IlowVLP vector. In preferred embodiments, the VLP vector of the present invention is a CD47highand MHC-IfreeVLP vector.
[0611] The VLP vector of the present invention may be obtained from a CD47hlghand MHC-Ifreeproducer cell or a CD47hlghand MHC-I10” producer cell. In preferred embodiments, the VLP vector of the present invention is obtained from a CD47hlghand MHC-Ifreeproducer cell.
[0612] Reverse orientation
[0613] In one aspect, the invention provides a VLP vector comprising a nucleotide sequence of a nucleic acid of interest, such as a gene of interest, operably linked to a promoter, wherein the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, and the promoter are in a reverse orientation in the VLP vector. Reverse orientation can be useful in case expression of the transgene is unwanted in producer cells or if it is difficult to get rid of the co-produced protein (e.g., because it is toxic) during VLP vector purification.
[0614] In one aspect, the invention provides a VLP vector comprising an expression cassette comprising a nucleotide sequence of a nucleic acid of interest, such as the gene of interest, operably linked to a promoter, wherein the expression cassette is in a reverse orientation in the VLP vector.
[0615] As used herein, "reverse orientation" in a VLP vector may refer to the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, and the promoter, and / or the expression cassette, being incorporated into the VLP vector such that the direction of transcription from the promoter is oriented towards a 5' long terminal repeat (LTR) of the VLP vector. The nucleotide sequence of the nucleic acid of interest, such as the gene of interest, or the expression cassette may be in an antisense orientation compared to transcription of the VLP vector genome, for example which may occur in VLP vector producer cells during vector production.
[0616] The reverse orientation may allow transcription of the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, from the promoter when the VLP vector is in a cell in which the promoter is active. The reverse orientation may prevent transcription of the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, from a second promoter that is upstream of the 5'LTR. The second promoter may, for example, only be present in the plasmid transcribing the VLP vector genome in producer cells during vector production.
[0617] Regulatory elements of VLP vectors
[0618] The VLP vector of the present invention may comprise one or more regulatory elements which can act pre-or post-transcriptionally. Suitably, the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, is operably linked to one or more regulatory elements which may act pre- or post-transcriptionally. In one embodiment, the one or more regulatory elements may facilitate expression of the nucleic acid of interest, such as the gene of interest, in all cells. In another embodiment, the one or more regulatory elements may facilitate expression of the nucleic acid of interest, such as the gene of interest, in HSPCs and / or in differentiated hematopoietic cells.
[0619] As used herein, the term "regulatory element" refers to any nucleotide sequence that facilitates expression of a polypeptide. For example, such a regulatory element acts to increase expression of a transcript or to enhance mRNA stability. Suitable regulatory elements include, for example, promoters, enhancer elements, post-transcriptional regulatory elements, polyadenylation sequences and Kozak sequences, as further defined herein.
[0620] Exemplary embodiments of regulatory elements of the viral vector of the invention in general have already been described herein. These exemplary embodiments of regulatory elements of the viral vector of the
[0621] invention in general can also be embodiments of the viral vector of the invention when the viral vector of the invention is a VLP vector.
[0622] The following passages provide further exemplary embodiments of regulatory elements of VLP vectors according to the present invention specifically.
[0623] Other cis-acting elements of VLP vectors
[0624] VLP vectors of the invention may also comprise additional cis-acting elements, such as a rev response element (RRE), which enables the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell; a retroviral psi packaging element, which is involved in regulating the essential process of packaging the retroviral RNA genome into the viral capsid during replication; a primer binding site (PBS), where reverse transcription is initiated; the TAT activation region (TAR); splice donor and acceptor sites; and central and terminal polypurine tracts, which allow initiation of plus-strand synthesis.
[0625] Cis-acting elements of VLP vectors of the invention may include one or more of a rev response element (RRE); a retroviral psi packaging element; a primer binding site (PBS); a TAT activation region (TAR); splice donor and acceptor sites; and central and terminal polypurine tracts.
[0626] The following passages provide exemplary embodiments of cis-acting elements of VLP vectors.
[0627] Long terminal repeats (LTRs) of the VLP vectors
[0628] The VLP vector of the present invention may comprise one or more LTRs. LTRs are responsible for proviral integration and transcription. Typically, a naturally occurring LTR comprises U3, R, and U5 regions.
[0629] In a VLP genome, the elements may be flanked at both ends by regions called long terminal repeats (LTRs). The LTRs can then be responsible for integration and transcription. LTRs may also serve as enhancer-promoter sequences and can control the expression of the genes in a VLP vector. The LTRs themselves can be identical or near-identical sequences that can typically be divided into three regions: U3, R and U5. LTRs may be naturally occurring virus LTRs or may be modified.
[0630] Suitable LTR sequences are well known to the skilled person.
[0631] The VLP vector of the present invention may comprise one or more self-inactivating long terminal repeats (SIN-LTR). A " SIN-LTR" may comprise a deletion that abolishes transcription of the full-length VLP genome after it has incorporated into a host cell. For example, a 3' SIN-LTR may comprise a deletion in the U3 regionremoving the promoter / enhancer elements. This deletion is copied into the 5' LTR after reverse transcription, thereby making the gene expression in target cells dependent on an internal promoter of choice.
[0632] Suitable SIN-LTR sequences are well known to the skilled person.
[0633] Primer binding site (PBS) of VLP vectors
[0634] The VLP vector of the present invention may comprise a primer binding site (PBS). A PBS is a cis-acting element where a primer may bind to initiate reverse transcription of the RNA genome (see, for example, Lanchy et al., Contacts between Reverse Transcriptase and the Primer Strand Govern the Transition from Initiation to Elongation of HIV-1 Reverse Transcription, J Biol Chem, 273, 24425-24432 (1998)).
[0635] Suitable PBSs for VLPs are well known to the skilled person.
[0636] Retroviral psi packaging element of VLP vectors
[0637] The VLP vector of the present invention may comprise a retroviral psi packaging element. A retroviral psi packaging element is a cis-acting element that is involved in regulating the process of packaging the VLP genome into the viral capsid during replication (see, for example, McBride et al., Efficient Encapsidation of Human Immunodeficiency Virus Type 1 Vectors and Further Characterization of cis Elements Required for Encapsidation, J Virol, 71, 4544-4554 (1997)). A retroviral psi packaging element may form part of the 5' region of the gag gene.
[0638] Suitable retroviral psi packaging elements are well known to the skilled person.
[0639] In some embodiments, a retroviral psi packaging element comprises or consists of a nucleotide sequence that has at least 70% sequence identity to the sequence set forth in SEQ ID NO: 23 or a fragment thereof. Suitably, a retroviral psi packaging element comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 23 or a fragment thereof.
[0640] In some embodiments, a retroviral psi packaging element comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 23 or a fragment thereof.
[0641] Rev response element (RRE) of VLP vectors
[0642] The VLP vector of the present invention may comprise a rev response element (RRE). A RRE is a cis-acting element that enables the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell (see, for example, Pollard et al., The HIV-1 Rev Protein, Annu Rev of Microbiol, 52, 491-532 (1998)).
[0643] Suitable RRE sequences will be well known to the skilled person.
[0644] Central polypurine tract (cPPT) of VLP vectors
[0645] The VLP vector of the present invention may comprise a central polypurine tract (cPPT). A cPPT may allow initiation of plus-strand synthesis (see, for example, Follenzi et al., Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences, Nat Genet, 25, 217-222 (2000)).
[0646] Suitable cPPT sequences are well known to the skilled person.
[0647] Other elements of VLP vectors
[0648] The VLP vector of the present invention may comprise other suitable elements. The skilled person knows which other elements may be suitably included in a VLP vector for gene delivery.
[0649] In some embodiments, the VLP vector of the present invention comprises an element that is a delta ENV1.
[0650] In some embodiments, the VLP vector of the present invention comprises an element that is a delta ENV2.
[0651] Adeno-associated viral (AAV) vectors
[0652] In one embodiment, the viral vector may be an adeno-associated viral (AAV) vector, such as AAV9 or AAV-PHP.eB (see, for example, Kimura & Harashima, 2022. Neural Regen Res. 17(4): 785-787).
[0653] In one embodiment, the AAV vector is or is derived from an adeno-associated virus serotype selected from the group consisting of AAV type 1, AAV type 2, AAV type 3 (including types 3A and 3B), AAV type 4, AAV type 5, AAV type 6, AAV type 7, AAV type 8, AAV type 9, AAV type 10, AAV type 11, AAV type 12, and AAV type 13. In a preferred embodiment, the AAV vector is or is derived from an adeno-associated virus serotype selected from AAV type 2, AAV type 5, AAV type 6, AAV type 8 and / or AAV type 9. In an even more preferred embodiment, the AAV vector is or is derived from an adeno-associated virus with the serotype AAV type 6.
[0654] Reverse orientation
[0655] In one aspect, the invention provides an AAV vector comprising a nucleotide sequence of a nucleic acid of interest, such as a gene of interest, operably linked to a promoter, wherein the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, and the promoter are in a reverse orientation in the AAV vector. Reverse orientation can be useful in case expression of the transgene is unwanted in producer cells or if it is difficult to get rid of the co-produced protein (e.g., because it is toxic) during AAV vector purification.
[0656] In one aspect, the invention provides an AAV vector comprising an expression cassette comprising a nucleotide sequence of a nucleic acid of interest, such as a gene of interest, operably linked to a promoter, wherein the expression cassette is in a reverse orientation in the AAV vector.
[0657] The reverse orientation may allow transcription of the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, from the promoter when the AAV vector is in a cell in which the promoter is active. The reverse orientation may prevent transcription of the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, from a second promoter. The second promoter may, for example, only be present in the plasmid transcribing the AAV vector genome in producer cells during vector production.
[0658] Regulatory elements of AAV vectors
[0659] The AAV vector of the present invention may comprise one or more regulatory elements which can act pre-or post-transcriptionally. Suitably, the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, is operably linked to one or more regulatory elements which may act pre- or post-transcriptionally. In one embodiment, the one or more regulatory elements may facilitate expression of the nucleic acid of interest, such as the gene of interest, in all cells. In another embodiment, the one or more regulatory elements may facilitate expression of the nucleic acid of interest, such as the gene of interest, in HSPCs and / or in differentiated hematopoietic cells.
[0660] As used herein, the term "regulatory element" refers to any nucleotide sequence that facilitates expression of a polypeptide. For example, such a regulatory element acts to increase expression of a transcript or to enhance mRNA stability. Suitable regulatory elements include, for example, promoters, enhancer elements, post-transcriptional regulatory elements, polyadenylation sequences and Kozak sequences, as further defined herein.
[0661] Exemplary embodiments of regulatory elements of the viral vector of the invention in general have already been described herein. These exemplary embodiments of regulatory elements of the viral vector of the invention in general can also be embodiments of the viral vector of the invention when the viral vector of the invention is an AAV vector.
[0662] The following passages provide further exemplary embodiments of regulatory elements of AAV vectors according to the present invention specifically.
[0663] Other cis-acting elements of AAV vectors
[0664] AAV vectors of the invention may also comprise additional cis-acting elements, such as inverted terminal repeats (ITRs).
[0665] The following passages provide exemplary embodiments of cis-acting elements of AAV vectors.
[0666] Inverted terminal repeats (ITRs) of AAV vectors
[0667] An AAV vector of the present invention may comprise inverted terminal repeats (ITRs). As used herein, the term " ITR" refers to two palindromic nucleic acid sequences that are each about 120 nucleotides to about 250 nucleotides in length and capable of forming a hairpin. Typically, the nucleic acid sequence between the ITRs is packaged into the AAV vector. Typically, the nucleic acid sequence outside of the ITRs is not packaged into the AAV vector.
[0668] An ITR may be from any serotype of AAV. An ITR typically includes a replication protein binding element (RBE) and a terminal resolution sequence (TRS). As used herein, the term " ITR" encompasses both wild-type parvoviral ITRs and engineered ITRs. For example, a wild-type parvoviral ITR sequence may be altered by insertion, deletion, truncation, or missense mutations, as long as the ITR functions to mediate virus packaging, replication, integration, and / or provirus rescue, and the like. ITRs are inherently unstable due to their secondary structure, palindromic nature, and high GC content. This instability can cause partial loss of an ITR during routine plasmid propagation, with complete ITR loss abolishing AAV packaging. Thus, in a preferred embodiment, the ITR has been altered, e.g., by insertion, deletion, truncation, or missense mutations, to improve stability.
[0669] As used herein, the term “S' ITR" means the ITR located at the 5' boundary of the nucleic acid molecule, and the term "3' ITR" means the ITR located at the 3' boundary of the nucleic acid molecule.
[0670] Other elements of AAV vectors
[0671] The AAV vector of the present invention may comprise other suitable elements. The skilled person knows which other elements may be suitably included in an AAV vector for gene delivery.
[0672] Adenoviral vectors (AdV)
[0673] In one embodiment, the viral vector of the present invention is an adenoviral (AdV) vector. In one embodiment, the viral vector of the present invention is not an adenoviral (AdV) vector.
[0674] The AdV vector of the present invention is or is derived from any adenovirus serotype. In one embodiment, the AdV vector of the present invention is or is derived from a human adenovirus serotype 5 (Ad5).
[0675] Reverse orientation
[0676] In one aspect, the invention provides an AdV vector comprising a nucleotide sequence of a nucleic acid of interest, such as a gene of interest, operably linked to a promoter, wherein the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, and the promoter are in a reverse orientation in the AdV vector. Reverse orientation can be useful in case expression of the transgene is unwanted in producer cells or if it is difficult to get rid of the co-produced protein (e.g., because it is toxic) during AdV vector purification.
[0677] In one aspect, the invention provides an AdV vector comprising an expression cassette comprising a nucleotide sequence of a nucleic acid of interest, such as a gene of interest, operably linked to a promoter, wherein the expression cassette is in a reverse orientation in the AdV vector.
[0678] The reverse orientation may allow transcription of the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, from the promoter when the AdV vector is in a cell in which the promoter is active. The reverse orientation may prevent transcription of the nucleotide sequence of the nucleic acid of interest, such as the gene of interest, from a second promoter. The second promoter may, for example, only be present in the plasmid transcribing the AdV vector genome in producer cells during vector production.
[0679] Regulatory elements of AdV vectors
[0680] The AdV vector of the present invention may comprise one or more regulatory elements which can act pre-or post-transcriptionally. Suitably, the nucleic acid sequence of the nucleic acid of interest, such as the gene of interest, is operably linked to one or more regulatory elements which may act pre- or post-transcriptionally. In one embodiment, the one or more regulatory elements may facilitate expression of the nucleic acid of interest, such as the gene of interest, in all cells. In another embodiment, the one or more regulatory elements may facilitate expression of the nucleic acid of interest, such as the gene of interest, in HSPCs and / or in differentiated hematopoietic cells.
[0681] As used herein, the term "regulatory element" refers to any nucleotide sequence that facilitates expression of a polypeptide. For example, such a regulatory element acts to increase expression of a transcript or toenhance mRNA stability. Suitable regulatory elements include, for example, promoters, enhancer elements, post-transcriptional regulatory elements, polyadenylation sequences and Kozak sequences, as further defined herein.
[0682] Exemplary embodiments of regulatory elements of the viral vector of the invention in general have already been described herein. These exemplary embodiments of regulatory elements of the viral vector of the invention in general can also be embodiments of the viral vector of the invention when the viral vector of the invention is an AdV vector.
[0683] Other elements of AdV vectors
[0684] The AdV vector of the present invention may comprise other suitable elements. The skilled person knows which other elements may be suitably included in an AdV vector for gene delivery.
[0685] Gene therapy
[0686] As used herein, the term "gene therapy" refers to the introduction of genes into cells. In particular, "gene therapy" refers to introduction of normal genes encoding functional proteins to correct for missing or defective genes that do not encode functional proteins. In other words, gene therapy as used herein refers to delivering a nucleic acid of interest, such as a gene of interest, to target cells such that the target cells express the nucleic acid of interest, such as the gene of interest. Gene therapy thereby treats, prevents or cures genetic disorders.
[0687] As used herein, the term “in vivo gene therapy" refers to the introduction of genes into cells in vivo, i.e., in the living body. As used herein, the term “ex vivo gene therapy" refers to the introduction of genes into cells ex vivo, i.e., outside the living body, and then transplanting the ex vivo modified cells into a subject.
[0688] Nucleic acid of interest
[0689] The vector of the present invention comprises one or more nucleic acid(s) of interest.
[0690] In one embodiment, the one or more nucleic acid(s) of interest encode one or more effector protein(s) capable of mediating gene editing that are selected from the group of zinc finger nucleases (ZFNs), zinc finger proteins (ZFPs), transcription activator-like effector nucleases (TALENs), and / or CRISPR / Cas proteins. In a preferred embodiment when the one or more nucleic acid(s) of interest encode one or more effector protein(s) capable of mediating gene editing, the one or more effector protein(s) capable of mediating geneediting are CRISPR / Cas proteins, more preferably Cas9, Casl3, Casl2, Casl2a protein, base editors or prime editors.
[0691] In a preferred embodiment, the one or more nucleic acid(s) of interest comprise one or more gene(s) of interest that encode one or more protein(s) of interest.
[0692] The terms "nucleic acid of interest" and "target nucleic acid" are used interchangeably herein. The terms "gene of interest", "transgene" and "target gene" are also used interchangeably herein.
[0693] The one or more nucleic acid(s) of interest, such as the one or more gene(s) of interest, may be operably linked to a promoter controlling expression of the nucleic acid of interest, such as the gene of interest. The promoters may be as defined herein.
[0694] As used herein, the term "operably linked" means that the components described are in a functional relationship that allows them to function in the intended manner. For, example, in the context of polynucleotide elements, a nucleic acid sequence is "operably linked" with another nucleic acid sequence when it is placed in a functional relationship with the other nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
[0695] In one embodiment, the one or more genes of interest are genes encoding functional proteins. These one or more genes of interest are intended to replace or compensate for missing or defective genes that do not encode functional proteins.
[0696] In one embodiment, the one or more genes of interest are involved in genetic disorders. For example, the one or more genes of interest are involved in genetic disorders associated with HSPCs and / or with differentiated hematopoietic cells. In one embodiment, the one or more genes of interest are involved in a genetic disorder selected from the group consisting of an immunodeficiency, a hemoglobinopathy, an osteochondrodysplasia, an inherited bone marrow failure syndrome, an inherited metabolic disorder, hematological cancers, and solid tumors. In a preferred embodiment, the one or more genes of interest are involved in a genetic disorder selected from the group consisting of adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID), autosomal recessive osteopetrosis (ARO), and Fanconi Anemia (FA). In an even more preferred embodiment, the one or more genes of interest are involved in FA.
[0697] In one embodiment, the vector of the invention does not comprise an optimized FVI 11 expression cassette expressibly linked to a megakaryocyte-specific promoter. In one embodiment, the one or more nucleic acid(s) of interest do not comprise a gene encoding Factor VIII. In one embodiment, the vector of the invention does not encode Factor VIII.
[0698] Target cells
[0699] In the present invention, the vector comprising the nucleic acid of interest as defined herein is delivered to target cells.
[0700] In one preferred embodiment, the target cells are HSPCs (i.e., hematopoietic stem cells and / or hematopoietic progenitor cells). In another embodiment, the target cells are differentiated hematopoietic cells, as further defined herein.
[0701] In one embodiment, the vector comprising the nucleic acid of interest as defined herein is delivered to hematopoietic stem cells (HSCs).
[0702] In another embodiment, the vector comprising the nucleic acid of interest as defined herein is delivered to hematopoietic progenitor cells (HPCs).
[0703] In a preferred embodiment, the vector comprising the nucleic acid of interest as defined herein is delivered to hematopoietic stem cells and hematopoietic progenitor cells.
[0704] In another embodiment, the vector comprising the nucleic acid of interest as defined herein is delivered to differentiated hematopoietic cells.
[0705] As used herein, the term "hematopoietic stem cell" (HSC) refers to cells that possess the long-term ability to self-renew and undergo successive stages of differentiation, ultimately giving rise to mature blood cells. HSCs are multipotent, meaning that they can differentiate into any type of hematopoietic cell, including but not limited to T cells, B cells, erythrocytes, megakaryocytes, platelets, basophils, mast cells, eosinophils, neutrophils, monocytes, macrophages, Kupffer cells, Langerhans cells, dendritic cells and osteoblasts. HSCs as described herein include, but are not limited to, e.g., " KSL" cells that are cKit+ Scal+ Lin-, " LK CD150" cells that are Lin- cKit+ CD150+, and " LK" cells that are Lin- cKit-.
[0706] As used herein, the term "hematopoietic progenitor cell" (HPC) refers to cells that may still have a short-term ability to self-renew, and that have the ability to undergo successive stages of differentiation, but that have already differentiated to or towards a state where they are lineage specific. For example, a lymphoid progenitor cell is a type of HPC that can give rise to, e.g., T cells, B cells and NK cells, but can no longer give rise to, e.g., platelets. HPCs are formed from HSCs during the pathway of differentiation. HPCs as described herein include, but are not limited to, e.g., multipotent progenitor cells (MPP), granulocyte-monocyte-lymphoid progenitor cells (GMLP), erythroid progenitor cells (EP), megakaryocyte-erythroid progenitor cells (MEP), granulocyte-monocyte progenitor cells (GMP), multi-lymphoid progenitors (MLP), early T-cell
[0707] precursors (ETP), B and NK progenitor cells (pre-BNK), common myeloid progenitors (CMP) and megakaryocyte progenitors (MKP).
[0708] As used herein, HSCs and HPCs are collectively referred to as "hematopoietic stem cells and / or hematopoietic progenitor cells" (HSPCs). HSCs and / or HPCs, i.e., HSPCs, can be targeted together, because they are typically found in the same compartments in the body of a subject. Thus, HSPCs as described herein include, but are not limited to, e.g., " KSL" cells that are cKit+ Scal+ Lin-, " LK CD150" cells that are Lin- cKit+ CD150+, and " LK" cells that are Lin- cKit-, as well as multipotent progenitor cells (MPP), granulocyte-monocyte-lymphoid progenitor cells (GMLP), erythroid progenitor cells (EP), megakaryocyte-erythroid progenitor cells (MEP), granulocyte-monocyte progenitor cells (GMP), multi-lymphoid progenitors (MLP), early T-cell precursors (ETP), B and NK progenitor cells (pre-BNK), common myeloid progenitors (CMP) and megakaryocyte progenitors (MKP).
[0709] As used herein, the term "differentiated hematopoietic cells" refers to cells that have differentiated from HSPCs. The term "differentiated hematopoietic cells" refers to cells that do not have the ability to differentiate into different cell types. Hematopoietic cells include, e.g., T cells, B cells, erythrocytes, megakaryocytes, platelets, basophils, mast cells, eosinophils, neutrophils, monocytes, macrophages, Kupffer cells, Langerhans cells, dendritic cells, myeloid cells, natural killer (NK) cells, granulocytes and osteoblasts. In a preferred embodiment of the present invention, the target cells are differentiated hematopoietic cells selected from T cells and / or macrophages. In an even more preferred embodiment of the present invention, the target cells are T cells.
[0710] As used herein, the term "hematopoietic cells" may be used as a collective term referring to both HSPCs (i.e., hematopoietic stem cells and / or hematopoietic progenitor cells) and differentiated hematopoietic cells.
[0711] As used herein, the terms "circulating HSCs", "circulating HPCs", "circulating HSPCs" and "circulating differentiated hematopoietic cells" refer to HSCs, HPCs, HSPCs and differentiated hematopoietic cells, respectively, that are present in the circulation of the body of a subject. For example, these circulating HSCs, circulating HPCs, circulating HSPCs and / or circulating differentiated hematopoietic cells can be detected by determining the counts of HSCs, HPCs, HSPCs and / or circulating differentiated hematopoietic cells in compartments other than the bone marrow, such as in the peripheral blood, spleen and / or liver. In one aspect, circulating HSCs, circulating HPCs, circulating HSPCs and / or circulating differentiated hematopoietic cells can be detected by determining the counts of HSCs, HPCs, HSPCs and / or circulating differentiated hematopoietic cells in peripheral blood. The skilled person knows of standard methods that can be used to determine the counts of HSCs, HPCs, HSPCs and / or circulating differentiated hematopoietic cells in a given sample. For example, the counts of HSCs, HPCs, HSPCs and / or circulating differentiated hematopoietic cells in a given sample can be determined using flow cytometry, such as a previously described multi-parametricflow cytometry analysis (see, e.g., Basso-Ricci, L. et al., Multiparametric Whole Blood Dissection: A one-shot comprehensive picture of the human hematopoietic system. Cytometry A, 91, 952-965 (2017)).
[0712] Diseases caused by deficient genes in hematopoietic cells, such as HSPCs and / or differentiated hematopoietic cells
[0713] The present invention may be useful in the treatment of certain diseases that are caused by deficiencies in genes in HSPCs and / or in differentiated hematopoietic cells. In particular, the nucleic acid of interest comprised in the vector of the present invention may replace or correct for deficiencies in genes in HSPCs and / or in differentiated hematopoietic cells.
[0714] In one embodiment, these diseases are selected from the group consisting of an immunodeficiency, a hemoglobinopathy, an osteochondrodysplasia, an inherited bone marrow failure syndrome, an inherited metabolic disorder, hematological cancers, and solid tumors.
[0715] In a preferred embodiment, these diseases are selected from the group consisting of adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID), autosomal recessive osteopetrosis (ARO), and Fanconi Anemia (FA).
[0716] In one embodiment, the disease is an immunodeficiency. In this embodiment, the disease is preferably adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID).
[0717] In another embodiment, the disease is an osteochondrodysplasia. In this embodiment, the disease is preferably autosomal recessive osteopetrosis (ARO).
[0718] In another embodiment, the disease is an inherited bone marrow failure syndrome. In this embodiment, the disease is preferably Fanconi anemia (FA).
[0719] In another embodiment, the disease is cancer. In this embodiment, the disease is preferably a hematological cancer or a solid tumor.
[0720] In an embodiment where the disease is a hematological cancer, the hematological cancer may be selected from the group consisting of leukemia or lymphoma. In a more specific embodiment, the hematological cancer includes cancers and malignancies including, but not limited to, e.g., one or more acute leukemias including but not limited to, e.g., B-cell acute Lymphoid Leukemia (" BALL"), T-cell acute Lymphoid Leukemia (" TALL"), acute lymphoid leukemia (ALL); one or more chronic leukemias including but not limited to, e.g., chronic myelogenous leukemia (CML), Chronic Lymphoid Leukemia (CLL). Additional cancers or hematologicconditions that may be treated by the in vivo gene therapy as described herein include, but are not limited to, e.g., B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, Follicular lymphoma, Hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, Marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and"preleukemia" which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells, and the like.
[0721] In an embodiment where the disease is not a hematological cancer, the disease may be a hyperproliferative condition or disorder (e.g., a cancer), e.g., solid tumor, a soft tissue tumor, or a metastatic lesion. In an embodiment where the disease is a solid tumor, the solid tumor may be selected from malignancies, e.g., sarcomas, adenocarcinomas, and carcinomas, of the various organ systems, such as those affecting liver, lung, breast, lymphoid, gastrointestinal (e.g., colon), genitourinary tract (e.g., renal, urothelial cells), prostate and pharynx. Adenocarcinomas include malignancies such as most colon cancers, rectal cancer, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus. In one embodiment, the cancer is a melanoma, e.g., an advanced stage melanoma.
[0722] In vivo nucleic acid transfer to hematopoietic cells such as HSPCs and / or differentiated hematopoietic cells may also be useful in the treatment of cancers, not limited to hematopoietic cancers, e.g., because successful in vivo gene therapy of hematopoietic cells such as HSPCs and / or differentiated hematopoietic cells can, for example, produce differentiated hematopoietic cells such as macrophages. Macrophages are found in tumors and where they release cytokines affecting the tumor microenvironment. Thus, macrophages modified by in vivo nucleic acid transfer to hematopoietic cells such as HSPCs and / or differentiated hematopoietic cells ccording to the present invention can reprogram the tumor microenvironment, for example, by macrophages that release cytokines that result in an anti-angiogenic effect, in direct toxicity to the tumor cells, and / or in the activation of T cells. Thus, the strategy for in vivo gene therapy of hematopoietic cells, in particular HSPCs and / or differentiated hematopoietic cells, ac described herein may also be useful in the treatment of cancers other than hematological cancers, such as solid tumors.
[0723] Metastatic lesions of the aforementioned cancers can also be treated or prevented using the methods and compositions of the invention. Examples of further cancers that can be treated include bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of theendometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin Disease, non-Hodgkin lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancerof the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers. Treatment of metastatic cancers, e.g., metastatic cancers that express PD-L1 (Iwai et al. (2005) Int. Immunol.
[0724] 17:133-144) can also be effected using the methods and compositions of the invention.
[0725] In another embodiment, the methods and compositions comprising the vector of the present invention can inhibit the growth of a cancer. Exemplary cancers whose growth can be inhibited include cancers typically responsive to immunotherapy. Non-limiting examples of cancers for treatment include melanoma (e.g., metastatic malignant melanoma), renal cancer (e.g. clear cell carcinoma), prostate cancer (e.g. hormone refractory prostate adenocarcinoma), breast cancer, colon cancer and lung cancer (e.g. non-small cell lung cancer). Additionally, refractory or recurrent malignancies can be treated using the molecules described herein.
[0726] As used herein, the term "cancer" includes all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness.
[0727] Further a disease that may be treated by the in vivo gene therapy as described herein includes, but is not limited to, e.g., atypical and / or non- classical cancers, malignancies, precancerous conditions or proliferative diseases.
[0728] Adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID)
[0729] Adenosine deaminase (ADA) deficiency causes severe combined immunodeficiency (ADA-SCID) through the accumulation of toxic adenosine metabolites that impair differentiation and function of T cells, B cells and natural killer (NK) cells.
[0730] ADA-SCID is caused by deficiencies in the gene encoding ADA.
[0731] The amino acid sequence of functional human ADA is as set forth in SEQ ID NO: 28.
[0732] MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPDFLAKFDYYMPAIAGCREAIKRIAY
[0733] EFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAIDLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGYHTLED
[0734] QALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIFKSTLDTDYQMTKRDMGFTEEEFKRL
[0735] NINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAGQNL
[0736] A variant of human ADA having the sequence as set forth in SEQ ID NO: 28 may be used, provided that the variant of human ADA is functional, i.e., functional enough to prevent onset or progression of ADA-SCID. A skilled person will be able to arrive at such variants of human ADA using methods known in the art. The variant of human ADA may, for example, have at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to human ADA as set forth in SEQ ID NO: 28.
[0737] Autosomal recessive osteopetrosis (ARO)
[0738] Autosomal recessive osteopetrosis (ARO) is a severe inherited bone disease caused by mutations in the T cell immune regulator 1 (TCIRG1) gene, leading to defective osteoclast function and impaired bone resorption. This condition requires early intervention to restrain disease progression, as BM failure in osteopetrotic (OC) patients severely limits treatment options. The underlying genetic defect impairs osteoclast resorption capacity, preventing the formation of a properly structured bone matrix.
[0739] The amino acid sequence of functional human TCIRG1 is as set forth in SEQ ID NO: 29.
[0740] MGSMFRSEEVALVQLFLPTAAAYTCVSRLGELGLVEFRDLNASVSAFQRRFVVDVRRCEELEKTFTFLQEEVRRAGLVLPPPK GRLPAPPPRDLLRIQEETERLAQELRDVRGNQQALRAQLHQLQLHAAVLRQGHEPQLAAAHTDGASERTPLLQAPGGPHQ DLRVNFVAGAVEPHKAPALERLLWRACRGFLIASFRELEQPLEHPVTGEPATWMTFLISYWGEQIGQKIRKITDCFHCHVFP FLQQEEARLGALQQLQQQSQELQEVLGETERFLSQVLGRVLQLLPPGQVQVHKMKAVYLALNQCSVSTTHKCLIAEAWCS VRDLPALQEALRDSSMEEGVSAVAHRIPCRDMPPTLIRTNRFTASFQGIVDAYGVGRYQEVNPAPYTIITFPFLFAVMFGDV GHGLLMFLFALAMVLAENRPAVKAAQNEIWQTFFRGRYLLLLMGLFSIYTGFIYNECFSRATSIFPSGWSVAAMANQSGW SDAFLAQHTMLTLDPNVTGVFLGPYPFGIDPIWSLAANHLSFLNSFKMKMSVILGVVHMAFGVVLGVFNHVHFGQRHRLL LETLPELTFLLGLFGYLVFLVIYKWLCVWAARAASAPSILIHFINMFLFSHSPSNRLLYPRQEVVQATL VLALAMVPILLLGTPL HLLHRHRRRLRRRPADRQEENKAGLLDLPDASVNGWSSDEEKAGGLDDEEEAELVPSEVLMHQAIHTIEFCLGCVSNTASY LRLWALSLAHAQLSEVLWAMVMRIGLGLGREVGVAAVVLVPIFAAFAVMTVAILLVMEGLSAFLHALRLHWVEFQNKFYS GTGYKLSPFTFAATDD
[0741] A variant of human TCIRG1 having the sequence as set forth in SEQ ID NO: 29 may be used, provided that the variant of human TCIRG1 is functional, i.e., functional enough to prevent onset or progression of ARO. A skilled person will be able to arrive at such variants of human TCIRG1 using methods known in the art. The variant of human TCIRG1 may, for example, have at least 70%, at least 80%, at least 90%, at least 95%, atleast 96%, at least 97%, at least 98% or at least 99% sequence identity to human TCIRG1 as set forth in SEQ
[0742] ID NO: 29.
[0743] Fanconi anemia (FA)
[0744] Fanconi anemia (FA) is a rare genetic disorder within the DNA repair deficiency syndromes, caused by mutations in the FA pathway. FA results in defective DNA damage response, hypersensitivity to endogenous and exogenous DNA cross-linkers, severe HSPC depletion, progressive BM failure, and increased cancer susceptibility. In FA, the HSPC compartment is directly affected, posing additional constraints for the collection and subsequent infusion of sufficient numbers of genetically corrected HSPCs in these patients.
[0745] FA can be caused by deficiencies in the gene encoding FANCA protein.
[0746] The amino acid sequence of functional human FANCA protein is as set forth in SEQ ID NO: 30.
[0747] MSDSWVPNSASGQDPGGRRRAWAELLAGRVKREKYNPERAQKLKESAVRLLRSHQDLNALLLEVEGPLCKKLSLSKVIDCD SSEAYANHSSSFIGSALQDQASRLGVPVGILSAGMVASSVGQICTAPAETSHPVLLTVEQRKKLSSLLEFAQYLLAHSMFSRLS FCQELWKIQSSLLLEAVWHLHVQGIVSLQELLESHPDMHAVGSWLFRNLCCLCEQMEASCQHADVARAMLSDFVQMFVL RGFQKNSDLRRTVEPEKMPQVTVDVLQRMLIFALDALAAGVQEESSTHKIVRCWFGVFSGHTLGSVISTDPLKRFFSHTLTQ ILTHSPVLKASDAVQMQREWSFARTHPLLTSLYRRLFVMLSAEELVGHLQEVLETQEVHWQRVLSFVSALVVCFPEAQQLL
[0748] EDWVARLMAQAFESCQLDSMVTAFLVVRQAALEGPSAFLSYADWFKASFGSTRGYHGCSKKALVFLFTFLSELVPFESPRYL QVHILHPPLVPSKYRSLLTDYISLAKTRLADLKVSIENMGLYEDLSSAGDITEPHSQALQDVEKAIMVFEHTGNIPVTVMEASIF RRPYYVSHFLPALLTPRVLPKVPDSRVAFIESLKRADKIPPSLYSTYCQACSAAEEKPEDAALGVRAEPNSAEEPLGQLTAALGE LRASMTDPSQRDVISAQVAVISERLRAVLGHNEDDSSVEISKIQLSINTPRLEPREHIAVDLLLTSFCQNLMAASSVAPPERQG PWAALFVRTMCGRVLPAVLTRLCQLLRHQGPSLSAPHVLGLAALAVHLGESRSALPEVDVGPPAPGAGLPVPALFDSLLTCR TRDSLFFCLKFCTAAISYSLCKFSSQSRDTLCSCLSPGLIKKFQFLMFRLFSEARQPLSEEDVASLSWRPLHLPSADWQRAALSL WTHRTFREVLKEEDVHLTYQDWLHLELEIQPEADALSDTERQDFHQWAIHEHFLPESSASGGCDGDLQAACTILVNALMD FHQSSRSYDHSENSDLVFGGRTGNEDIISRLQEMVADLELQQDUVPLGHTPSQEHFLFEIFRRRLQALTSGWSVAASLQRQ RELLMYKRILLRLPSSVLCGSSFQAEQPITARCEQFFHLVNSEMRNFCSHGGALTQDITAHFFRGLLNACLRSRDPSLMVDFIL AKCQTKCPLILTSALVWWPSLEPVLLCRWRRHCQSPLPRELQKLQEGRQFASDFLSPEAASPAPNPDWLSAAALHFAIQQV REENIRKQLKKLDCEREELLVFLFFFSLMGLLSSHLTSNSTTDLPKAFHVCAAILECLEKRKISWLALFQLTESDLRLGRLLLRVAP DQHTRLLPFAFYSLLSYFHEDAAIREEAFLHVAVDMYLKLVQLFVAGDTSTVSPPAGRSLELKGQGNPVELITKARLFLLQLIPR CPKKSFSHVAELLADRGDCDPEVSAALQSRQQAAPDADLSQEPHLF
[0749] A variant of human FANCA protein having the sequence as set forth in SEQ ID NO: 30 may be used, provided that the variant of human FANCA protein is functional, i.e., functional enough to prevent onset or progression of FA. A skilled person will be able to arrive at such variants of human FANCA protein using methods known in the art. The variant of human FANCA protein may, for example, have at least 70%, at least 80%, at least90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to human FANCA protein as set forth in SEQ ID NO: 30.
[0750] Subject
[0751] The terms "subject", "individual" or "patient" are used interchangeably in the present application to designate a living being that is subjected to a certain step. For example, the "subject", "individual" or "patient" is subjected to a medical use of the vector according to the present invention, as further defined herein.
[0752] Unless explicitly limited, the "subject", "individual" or "patient" can be of any age, sex and physical condition.
[0753] In a preferred embodiment, the "subject", "individual" or "patient" is a mammal. In an even more preferred embodiment, the "subject", "individual" or "patient" is a human subject.
[0754] In some embodiments, the subject is a newborn. In some embodiments, such subjects are optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0755] In other embodiments, the subject is not a newborn. In some embodiments, such subjects are administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling. In some preferred embodiments, such subjects are administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells. In some embodiments, such subjects are administered an inhibitor of IFNαR signalling. In some more preferred embodiments, such subjects are administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and an inhibitor of IFNαR signalling.
[0756] In some embodiments, the human subject is older than 19 years of age. As used herein, a human subject that is older than 19 years of age may be referred to as an "adult human subject".
[0757] In some embodiments, the human subject is older than 16 years of age and 19 years of age or younger. As used herein, a human subject that is older than 16 years of age and 19 years of age may be referred to as an "adolescent human subject".
[0758] In some embodiments, the human subject is selected from the group consisting of a human subject is older than 19 years of age and a human subject that is older than 16 years of age and 19 years of age or younger. In other words, in some embodiments, the human subject is selected from the group consisting of an adult human subject and an adolescent human subject, as defined herein.
[0759] In some embodiments, the human subject is older than 14 years of age and 16 years of age or younger. As used herein, a human subject that is older than 14 years of age and 16 years of age or younger may be referred to as a "juvenile human subject".
[0760] In some embodiments, the human subject is a human subject that is older than 1 year of age and 14 years of age or younger, is older than 3 years of age and 5 years of age or younger, or is older than 1 year of age and 3 years of age or younger. As used herein, a human subject that is older than 1 year of age and 14 years of age or younger, is older than 3 years of age and 5 years of age or younger, or is older than 1 year of age and 3 years of age or younger may be referred to as a "paediatric human subject".
[0761] In some embodiments, the human subject is selected from the group consisting of a human subject is older than 14 years of age and 16 years of age or younger, and a human subject that is older than 1 year of age and 14 years of age or younger, is older than 3 years of age and 5 years of age or younger, or is older than 1 year of age and 3 years of age or younger. In other words, in some embodiments, the human subject is selected from the group consisting of a juvenile human subject and a paediatric human subject, as defined herein.
[0762] In some embodiments, the human subject is older than 2 months of age and 1 year of age or younger. As used herein, a human subject that is older than 2 months of age and 1 year of age or younger may be referred to as an "infantile human subject" or as an "infant". The terms "infantile human subject" and "infant" are used interchangeably herein.
[0763] In some embodiments, the human subject is 2 months of age or younger. In some embodiments, the human subject is 28 days of age or younger. In some embodiments, the human subject is 14 days of age or younger. In some embodiments, the human subject is 7 days of age or younger. As used herein, a human subject that is 2 months of age or younger, such as 28 days of age or younger, 14 days of age or younger or 7 days of age or younger, may be referred to as a "neonatal human subject", as a "neonate" or as a "newborn". The terms "neonatal human subject", "neonate" and "newborn" are used interchangeably herein.
[0764] In some embodiments, the human subject is selected from the group consisting of a human subject that is older than 2 months of age and 1 year of age or younger, and a human subject that is 2 months of age or younger, such as 28 days of age or younger, 14 days of age or younger or 7 days of age or younger. In other words, in some embodiments, the human subject is selected from the group consisting of an infantile human subject and a neonatal human subject.
[0765] In some embodiments, the human subject is 12 months of age or younger, 11 months of age or younger, 10 months of age or younger, 9 months of age or younger, 8 months of age or younger, 7 months of age or
[0766] younger, 6 months of age or younger, 5 months of age or younger, 4 months of age or younger, 3 months of age or younger, 2 months of age or younger, 28 days of age or younger, 14 days of age or younger, or 7 days of age or younger. In some embodiments, such subjects are optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0767] In some embodiments, the human subject is older than 7 days of age, older than 14 days of age, older than 28 days of age, older than 2 months of age, older than 3 months of age, older than 4 months of age, older than 5 months of age, older than 6 months of age, older than 7 months of age, older than 8 months of age, older than 9 months of age, older than 10 months of age, older than 11 months of age, older than 12 months of age. In some embodiments, such subjects are administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling. In some embodiments, such subjects are administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells. In some embodiments, such subjects are administered an inhibitor of IFNαR signalling. In some embodiments, such subjects are administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and an inhibitor of IFNαR signalling.
[0768] In some embodiments: (a) the human subject is 12 months of age or younger and the subject is optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling; or (b) the human subject is older than 12 months of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0769] In some embodiments: (a) the human subject is 11 months of age or younger and the subject is optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling; or (b) the human subject is older than 11 months of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0770] In some embodiments: (a) the human subject is 10 months of age or younger and the subject is optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling; or (b) the human subject is older than 10 months of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0771] In some embodiments: (a) the human subject is 9 months of age or younger and the subject is optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling; or (b) the human subject is older than 9 months of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0772] In some embodiments: (a) the human subject is 8 months of age or younger and the subject is optionally or not administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling; or (b) the human subject is older than 8 months of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0773] In some embodiments: (a) the human subject is 7 months of age or younger and the subject is optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling; or (b) the human subject is older than 7 months of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0774] In some embodiments: (a) the human subject is 6 months of age or younger and the subject is optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling; or (b) the human subject is older than 6 months of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0775] In some embodiments: (a) the human subject is 5 months of age or younger and the subject is optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling; or (b) the human subject is older than 5 months of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0776] In some embodiments: (a) the human subject is 4 months of age or younger and the subject is optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling; or (b) the human subject is older than 4 months of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0777] In some embodiments: (a) the human subject is 3 months of age or younger and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling; or (b) the human subject is older than 3 months of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0778] In some embodiments: (a) the human subject is 2 months of age or younger and the subject is optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling; or (b) the human subject is older than 2 months of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0779] In some embodiments: (a) the human subject is 28 days of age or younger and the subject is optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor ofIFNαR signalling; or (b) the human subject is older than 28 days of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0780] In some embodiments: (a) the human subject is 14 days of age or younger and the subject is optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling; or (b) the human subject is older than 14 days of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0781] In some embodiments: (a) the human subject is 7 days of age or younger and the subject is optionally administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling; or (b) the human subject is older than 7 days of age and the subject is administered a mobilisation regimen for HSPCs and differentiated hematopoietic cells and / or an inhibitor of IFNαR signalling.
[0782] In one embodiment, the subject is a rodent, such as a mouse.
[0783] In one embodiment, the mouse subject is 8 weeks of age or older. As used herein, a mouse subject that is 8 weeks of age or older may be referred to as an "adult mouse".
[0784] In one embodiment, the mouse subject is between 1 and 2 weeks of age. As used herein, a mouse subject that is between 1 and 2 weeks of age may be referred to as a "young mouse".
[0785] In one embodiment, the mouse subject is a mouse subject immediately after birth that is 0 to 1 days of age. As used herein, a mouse subject after birth that is 0 to 1 days of age may be referred to as "neonatal mouse subject", "neonate" or "newborn". The terms "neonatal mouse subject", "neonate" and "newborn" are used interchangeably herein.
[0786] In one embodiment, the subject has not been administered an immune suppression regimen. In one embodiment, the subject has not been administered an immune suppression regimen comprising an inflammation suppressor. In one embodiment, the subject has not been administered an immune suppression regimen comprising an inflammatory signal inhibitor. In one embodiment, the subject has not been administered an immune suppression regimen comprising a dosing regimen of one or more of (i) an interleukin-1 (IL-1) signal inhibitor, optionally where the IL-1 signal inhibitor is anakinra; (ii) an IL- 6 signal inhibitor, optionally where the IL-6 signal inhibitor is tocilizumab; (ill) a corticosteroid, optionally where the corticosteroid is dexamethasone; and (iv) a calcineurin inhibitor, optionally where the calcineurin inhibitor is tacrolimus. In one embodiment, the subject has not been administered an immune suppression regimen comprising a dosing regimen of (i) an interleukin-1 (IL-1) signal inhibitor, optionally where the IL-1 signalinhibitor is anakinra; (ii) an IL- 6 signal inhibitor, optionally where the IL-6 signal inhibitor is tocilizumab; and (ill) a corticosteroid, optionally where the corticosteroid is dexamethasone.
[0787] In vivo administration
[0788] In the present invention, the method of treatment or medical use comprises in vivo administration of a vector as defined in the claims.
[0789] As used herein, the term “in vivo administration" means that a substance, such as the vector of the present invention, is administered directly into the living body. The term “in vivo administration" encompasses both systemic administration and local administration of a substance, such as the vector of the present invention, is administered directly into the living body. As used herein, “in vivo administration" includes but is not limited to intravenous administration, intraosseous administration, intra-arterial administration, subcutaneous administration, intramuscular administration, intrathecal administration and intraperitoneal administration. As used herein, the term "systemic administration" means that a substance, such as the vector of the present invention, is administered so that the entire body is affected. As used herein, the term "local administration" means that a substance, such as the vector of the present invention, is administered directly to a specific site of the body, so that only a certain part of the body is affected.
[0790] In one embodiment, the vector of the present invention is administered systemically. In one embodiment, the vector of the present invention is administered parenterally. In one embodiment, the vector of the present invention is administered by intravenous administration, intraosseous administration, intra-arterial administration, subcutaneous administration, intramuscular administration, intrathecal administration and intraperitoneal administration. In one embodiment, the vector of the present invention is administered intravenously.
[0791] In one embodiment, the method of the invention does not comprise administering to the subject an immune suppression regimen. In one embodiment, the method of the invention does not comprise administering to the subject an immune suppression regimen comprising an inflammation suppressor. In one embodiment, the method of the invention does not comprise administering to the subject an immune suppression regimen comprising an inflammatory signal inhibitor. In one embodiment, the method of the invention does not comprise administering to the subject an immune suppression regimen comprising a dosing regimen of one or more of (i) an interleukin-1 (IL-1) signal inhibitor, optionally where the IL-1 signal inhibitor is anakinra; (ii) an IL- 6 signal inhibitor, optionally where the IL-6 signal inhibitor is tocilizumab; (ill) a corticosteroid, optionally where the corticosteroid is dexamethasone; and (iv) a calcineurin inhibitor, optionally where the calcineurin inhibitor is tacrolimus. In one embodiment, the the method of the invention does not comprise administering to the subject an immune suppression regimen comprising a dosing regimen of (i) an interleukin-1 (IL-1) signal inhibitor, optionally where the IL-1 signal inhibitor is
[0792] anakinra; (ii) an IL- 6 signal inhibitor, optionally where the IL-6 signal inhibitor is tocilizumab; and (ill) a corticosteroid, optionally where the corticosteroid is dexamethasone.
[0793] Inhibitor of interferon-a receptor signalling
[0794] In one aspect of the present invention, an inhibitor of IFNαR signalling is for use in a method of increasing transduction efficiency of a vector in vivo and treating a disease in a subject. In this aspect, the method comprises (a) first, administering the inhibitor of IFNαR signalling to the subject, and (b) subsequently, administering a vector comprising a nucleic acid of interest to the subject by in vivo administration. In this aspect, the disease is treated by in vivo delivering said nucleic acid of interest to HSPCs (i.e., hematopoietic stem cells and / or hematopoietic progenitor cells) and / or differentiated hematopoietic cells.
[0795] In the present invention, an inhibitor of interferon-a receptor (IFNaR) signalling may be administered to the subject prior to administration of the vector to the subject.
[0796] As used herein, the term "inhibitor of interferon-a receptor (IFNaR) signalling" or "inhibitor of IFNαR signalling" refers to any compound that can attenuate or block signalling through IFNaR. In the context of the present invention, an inhibitor of IFNαR signalling acts as a vector transduction enhancer, because attenuating or blocking signalling through IFNaR interferes with IFNa-dependent immune responses triggered by vectors, in particular IFNa-dependent immune responses triggered by viral vectors. The underlying mechanism of the transduction enhancing effect of the inhibitor of IFNαR signalling is the reduction in immune response. Thus, any inhibitor of IFNαR signalling can be used to increase the transduction efficiency of the vector used in the present invention.
[0797] The inhibitor of IFNαR signalling may be selected from the group consisting of a small molecule and an antibody or fragment thereof that is capable of specifically binding to IFNaR and attenuating or blocking signalling through IFNaR. In one embodiment, the inhibitor of IFNαR signalling is selected from the group consisting of sifalimumab, rontalizumab, anifrolumab, QX006N, brepocitinib, baricitinib, upadacitinib, filgotinib, WD-890, ropsacitinib, deurefacitinib, arctigenin, tofacitinib.
[0798] In one embodiment, the inhibitor of IFNαR signalling is an antibody or fragment thereof that is capable of attenuating or blocking signalling through IFNaR. In one embodiment, the inhibitor of IFNαR signalling is selected from the group consisting of Sifalimumab, Rontalizumab, Anifrolumab, and QX006N, or antibody fragments thereof. In one embodiment, the inhibitor of IFNαR signalling is selected from the group consisting of Sifalimumab, Rontalizumab, Anifrolumab, and QX006N.
[0799] In a preferred embodiment, the inhibitor of IFNαR signalling is an antibody or fragment thereof that is capable of specifically binding to IFNaR and attenuating or blocking signalling through IFNaR. For example, the
[0800] inhibitor of IFNαR signalling may be Anifrolumab or QX006N, or antibody fragments thereof. In one embodiment, the inhibitor of IFNαR signalling is Anifrolumab or QX006N.
[0801] In an even more preferred embodiment, the inhibitor of IFNαR signalling is anifrolumab (CAS: 1326232-46-5; SEQ ID NOs: 31 and 32), which is a human monoclonal antibody that is a type I interferon (IFN) receptor antagonist. The sequences for the heavy chain and light chain of anifrolumab are well-known in the art. These can be found, for example, on the website " New Drug Approvals" (https: / / newdrugapprovals.org / ), on the page on anifrolumab (https: / / newdrugapprovals.org / 2021 / 08 / 08 / anifrolumab / ); or also, for example, on the " Drugbank" website on the page on anifrolumab (https: / / go.drugbank.com / drugs / DB11976), which has the DrugBank Accession Number DB11976.
[0802] A sequence for the variable domain of the heavy chain (VH) of anifrolumab is set forth in SEQ ID NO: 55: EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS
[0803] A sequence for the variable domain of the light chain (VI) of anifrolumab is set forth in SEQ ID NO: 56: EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFA VYYCQQYDSSAITFGQGTRLEIK
[0804] The sequence for the heavy chain of anifrolumab is set forth in SEQ ID NO: 31:
[0805] EVQLVQSGAE VKKPGESLKI SCKGSGYIFT NYWIAWVRQM PGKGLESMGI IYPGDSDIRY SPSFQGQVTI SADKSITTAY LQWSSLKASD TAMYYCARHD IEGFDYWGRG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APEFEGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA SIEKTISKAK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKLTVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK
[0806] The sequence for the light chain of anifrolumab is set forth in SEQ ID NO: 32:
[0807] EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSFFAWYQQK PGQAPRLLIY GASSRATGIP
[0808] DRLSGSGSGT DFTLTITRLE PEDFAVYYCQ QYDSSAITFG QGTRLEIKRT VAAPSVFIFP
[0809] PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
[0810] TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC.
[0811] In another embodiment, the inhibitor of IFNαR signalling is QX006N. QX006N is a humanized monoclonal antibody against human IFNaR (see e.g. Li, X., et aL, 2024. BioDrugs, 38(2), pp.313-321). QX006N is described in WO 2022 / 223714 Al, incorporated herein by reference.
[0812] A sequence for the variable domain of the heavy chain (VH) of QX006N is set forth in SEQ ID NO: 57:
[0813] EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYYMTWVRQAPGKGLEWVSVINVYGGTYYASWAKGRFTISRDNSKNTLYL QMNSLRAEDTAVYYCAREDVAVYMAIDLWGQGTLVTVSS
[0814] A sequence for the variable domain of the light chain (VI) of QX006N is set forth in SEQ ID NO: 58:
[0815] AIQMTQSPSSLSASVGDRVTITCQASQSISNQLSWYQQKPGKAPKLLIYDASSLASGVPSRFSGSRSGTKFTLTISSLQPEDFA TYYCLGIYGDGADDGIAFGGGTKVEIK
[0816] In another embodiment, the inhibitor of IFNαR signalling is MAR1-5A3, which is a mouse anti-mouse IFNAR-1 monoclonal antibody. Certain antibodies that are capable of specifically binding to IFNaR and attenuating or blocking signalling through IFNaR are described, e.g., in WO 2006 / 002177 A2 and WO 2022 / 223714 Al.
[0817] In another embodiment, the inhibitor of IFNαR signalling is an antibody or fragment thereof that is capable of specifically binding to IFNa and attenuating or blocking signalling through IFNaR. For example, the inhibitor of IFNαR signalling may be Sifalimumab or Rontalizumab, or antibody fragments thereof. In one embodiment, the inhibitor of IFNαR signalling is Sifalimumab or Rontalizumab.
[0818] In one embodiment, the inhibitor of IFNαR signalling is Sifalimumab. Sifalimumab is a human monoclonal antibody against IFNa (see e.g. Khamashta, M., et al., 2016. Annals of the rheumatic diseases, 75(11), pp.1909-1916).
[0819] A sequence for the variable domain of the heavy chain (VH) of Sifalimumab is set forth in SEQ ID NO: 59: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTST AYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS
[0820] A sequence for the variable domain of the light chain (VI) of Sifalimumab is set forth in SEQ ID NO: 60: EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFA VYYCQQYGSSPRTFGQGTKVEIK
[0821] The sequence for the heavy chain of Sifalimumab is set forth in SEQ ID NO: 61:
[0822] QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTST AYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
[0823] KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
[0824] KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0825] The sequence for the light chain of Sifalimumab is set forth in SEQ ID NO: 62:
[0826] EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFA VYYCQQYGSSPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
[0827] In one embodiment, the inhibitor of IFNαR signalling is Rontalizumab. Rontalizumab is a humanized monoclonal antibody against IFNa (see e.g. McBride, J. M., et aL, 2012. Arthritis & Rheumatism, 64(11), pp.3666-3676).
[0828] A sequence for the variable domain of the heavy chain (VH) of Rontalizumab is set forth in SEQ ID NO: 63: EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYIIHWVRQAPGKGLEWVASINPDYDITNYNQRFKGRFTISLDKSKRTAYLQ M NSLRAE DTAVYYCASW ISD F F DYWG QGTLVTVSS
[0829] A sequence for the variable domain of the light chain (VI) of Rontalizumab is set forth in SEQ ID NO: 64: DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKVLISYASNLESGVPSRFSGSGSGTDFTLTISSLQ PEDFATYYCQHSWGIPRTFGQGTKVEIK
[0830] The sequence for the heavy chain of Rontalizumab is set forth in SEQ ID NO: 65:
[0831] EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYIIHWVRQAPGKGLEWVASINPDYDITNYNQRFKGRFTISLDKSKRTAYLQ MNSLRAEDTAVYYCASWISDFFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
[0832] KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0833] The sequence for the light chain of Rontalizumab is set forth in SEQ ID NO: 66:
[0834] DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKVLISYASNLESGVPSRFSGSGSGTDFTLTISSLQ PEDFATYYCQHSWGIPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
[0835] In one embodiment, the inhibitor of IFNαR signalling is a full-length antibody. The term "full-length antibody" may refer to an immunoglobulin molecule that binds to a target molecule and contains four peptide chains: two heavy chains and two light chains which are connected to each other through disulphide bonds.
[0836] In one embodiment, the inhibitor of IFNαR signalling is an antibody fragment. An "antibody fragment" may be a fragment of an antibody, or a genetically engineered product of one of more fragments of an antibody, which fragment is involved in binding with the target molecule. Examples include an antigen-binding fragment (Fab), a fragment antibody (F(ab')2), a variable region (Fv), a single chain antibody (scFv), a singledomain antibody (sdAb), and a camelid antibody (VHH). In some embodiments, the antibody fragment is an antigen-binding fragment (Fab), a fragment antibody (F(ab')2), a single chain antibody (scFv), or a singledomain antibody (sdAb).
[0837] In one embodiment, the inhibitor of IFNαR signalling is administered to any subject, regardless of age, sex or physical condition.
[0838] In another embodiment, the inhibitor of IFNαR signalling is administered to any human subject, regardless of age, sex or physical condition.
[0839] In one embodiment, the inhibitor of IFNαR signalling is administered to a human subject that is older than 2 months of age and 1 year of age or younger. In a preferred embodiment, the inhibitor of IFNαR signalling is administered to a human subject that is older than 1 year of age and 14 years of age or younger. In an even more preferred embodiment, the inhibitor of IFNαR signalling is administered to a human subject that is older than 14 years of age and 16 years of age or younger. In a most preferred embodiment, the inhibitor of IFNαR signalling is administered to a human subject that is older than 16 years of age, optionally older than 19 years of age. In other words, the older a subject is, the more preferred it is that an inhibitor of IFNαR signalling is administered to the subject prior to administration of the vector of the present invention to the subject.
[0840] In one embodiment, the inhibitor of IFNαR signalling is administered to the subject between 1 and 5 hours prior to administration of the vector to the subject. In a preferred embodiment, the inhibitor of IFNαR signalling is administered to the subject 3 hours prior to administration of the vector to the subject.
[0841] In one embodiment, the inhibitor of IFNαR signalling is administered to the subject by systemic administration. In one embodiment, the inhibitor of IFNαR signalling is administered to the subject parenterally. In one embodiment, the inhibitor of IFNαR signalling is administered to the subject by intravenous administration, intraosseous administration, intra-arterial administration, subcutaneous administration, intramuscular administration, intrathecal administration or intraperitoneal administration. In a preferred embodiment, the inhibitor of IFNαR signalling is administered to the subject by intravenous administration.
[0842] Mobilisation regimen for HSPCs and differentiated hematopoietic cells
[0843] In the present invention, a mobilisation regimen for HSPCs and differentiated hematopoietic cells may be administered to the subject prior to administration of the vector to the subject.
[0844] As used herein, the term "mobilisation regimen for HSPCs and differentiated hematopoietic cells" refers to any compound or combination of compounds that can stimulate movement of HSPCs and / or differentiated hematopoietic cells from the bone marrow, preferably into the circulation. In other words, the term "mobilisation regimen for HSPCs and differentiated hematopoietic cells" refers to any compound or combination of compounds that can increase the number of circulating HSPCs and / or circulating differentiated hematopoietic cells.
[0845] As explained herein, the terms "circulating HSPCs" and "circulating differentiated hematopoietic cells" refer to HSPCs and differentiated hematopoietic cells, respectively, that are present in the circulation of the body of a subject. These circulating HSPCs and / or circulating differentiated hematopoietic cells can be detected, e.g., by determining the counts of HSPCs and / or differentiated hematopoietic cells in compartments other than the bone marrow, such as in the peripheral blood, spleen and / or liver. In a preferred aspect, circulating HSPCs and / or circulating differentiated hematopoietic cells can be detected by determining the counts of HSPCs and / or differentiated hematopoietic cells in peripheral blood. The skilled person knows of standard methods that can be used to determine the counts of HSPCs and / or differentiated hematopoietic cells in a given sample, as explained above.
[0846] In one embodiment, the mobilisation regimen for HSPCs and differentiated hematopoietic cells is a mobilisation regimen for HSPCs. In one embodiment, a mobilisation regimen for HSPCs is administered to the subject prior to administration of the vector to the subject. As used herein, the term "mobilisation regimen for HSPCs" refers to any compound or combination of compounds that can stimulate movement of HSPCs from the bone marrow, preferably into the circulation. In other words, the term "mobilisation regimen for HSPCs" refers to any compound or combination of compounds that can increase the number of circulating HSPCs.
[0847] In the context of the present invention, a mobilisation regimen for HSPCs and differentiated hematopoietic cells acts as a transduction enhancer, because it improves access of the in vivo administered vector to HSPCs and / or to differentiated hematopoietic cells.
[0848] In one embodiment, the mobilisation regimen for HSPCs and differentiated hematopoietic cells is administered to any subject, regardless of age, sex or physical condition.
[0849] In another embodiment, the mobilisation regimen for HSPCs and differentiated hematopoietic cells is administered to any human subject, regardless of age, sex or physical condition.
[0850] In one embodiment, the mobilisation regimen for HSPCs and differentiated hematopoietic cells is administered to a human subject that is older than 2 months of age and 1 year of age or younger. In a preferred embodiment, the mobilisation regimen for HSPCs and differentiated hematopoietic cells is administered to a human subject that is older than 1 year of age and 14 years of age or younger. In an even more preferred embodiment, the mobilisation regimen for HSPCs and differentiated hematopoietic cells is administered to a human subject that is older than 14 years of age and 16 years of age or younger. In a most preferred embodiment, the mobilisation regimen for HSPCs and differentiated hematopoietic cells is administered to a human subject that is older than 16 years of age, optionally older than 19 years of age. In other words, the older a subject is, the more preferred it is that an mobilisation regimen for HSPCs and differentiated hematopoietic cells of the present invention is administered to the subject prior to administration of the vector to the subject.
[0851] The skilled person knows which compounds may be used to stimulate movement of HSPCs and / or differentiated hematopoietic cells from the bone marrow into the circulation, i.e., compounds that may be used as a mobilisation regimen for HSPCs and differentiated hematopoietic cells. In one embodiment, the mobilisation regimen for HSPCs and differentiated hematopoietic cells comprises granulocyte-colony stimulating factor (G-CSF) and plerixafor.
[0852] In one embodiment, the mobilisation regimen for HSPCs and differentiated hematopoietic cells is administered to the subject over a period of up to 58 h prior to administration of the vector to the subject.
[0853] In a preferred embodiment, the mobilisation regimen for HSPCs and differentiated hematopoietic cells comprises the following steps:
[0854] a) administering multiple doses of G-CSF at regular intervals,
[0855] b) after administration of the last dose of G-CSF, administering plerixafor, and
[0856] c) after administration of plerixafor, administering the vector.
[0857] In a preferred embodiment, administering the mobilisation regimen for HSPCs and differentiated hematopoietic cells comprises the following steps:
[0858] a) administering at least 3 doses of G-CSF, wherein the doses of G-CSF are administered every 12 hours, b) 8 h after administration of the last dose of G-CSF, administering plerixafor, and
[0859] c) 2 h after administration of plerixafor, administering the vector.
[0860] In a preferred embodiment, administering the mobilisation regimen for HSPCs and differentiated hematopoietic cells comprises the following steps:
[0861] a) administering 5 doses of G-CSF, wherein the doses of G-CSF are administered every 12 hours, b) 8 h after administration of the last dose of G-CSF, administering plerixafor, and
[0862] c) 2 h after administration of plerixafor, administering the vector.
[0863] In another embodiment of a mobilisation regimen for HSPCs and differentiated hematopoietic cells, the compound used to stimulate circulation of these cells is selected from the group consisting of G-CSF, a CXCR4 antagonist and / or a VLA-4 antagonist.
[0864] In one embodiment, the mobilisation regimen for HSPCs and differentiated hematopoietic cells is administered to the subject by intravenous administration, intraosseous administration, intra-arterial administration, subcutaneous administration, intramuscular administration, intrathecal administration or intraperitoneal administration. In a preferred embodiment, the mobilisation regimen for HSPCs and differentiated hematopoietic cells is administered to the subject by subcutaneous administration.
[0865] In preferred embodiments, both an inhibitor of IFNαR signalling and a mobilisation regimen for HSPCs and differentiated hematopoietic cells may be administered to the subject prior to administration of the vector to the subject, as defined herein. In particular, as defined above, the older a subject is, the more preferred it is that both an inhibitor of IFNαR signalling and a mobilisation regimen for HSPCs and differentiated hematopoietic cells are administered to the subject prior to administration of the vector to the subject, as defined herein.
[0866] Vectors, kits and systems
[0867] In one aspect, the present invention provides a vector, as defined herein. The vector may be a transfer vector, as described herein. For example, the vector may be a plasmid and / or a viral genome may be operably linked to a promoter (e.g., a viral promoter, such as a PGK promoter or a CMV promoter), as defined herein.
[0868] In one aspect, the present invention provides a kit or system for producing the vector of the present invention.
[0869] The kit or system may be a virus packaging kit or system or a virus production kit or system. As used herein, a "virus packaging kit or system" may comprise one or more components, and optionally instructions, for packaging the viral vector of the present invention. As used herein, a "virus production kit or system" may comprise one or more components, and optionally instructions, for producing the viral vector of the present invention.
[0870] The kit or system may comprise a transfer vector encoding the nucleic acid of interest or viral genome of the present invention and optionally one or more helper vectors. The kit or system may further comprise host cells (e.g., packaging cells or producer cells, e.g., as defined herein) and / or other reagents (e.g., transfection reagent, culture medium, etc.). The kit or system may further comprise any other suitable components, and optionally instructions for packaging and / or producing the non-viral vector or viral vector of the present invention.
[0871] Cells
[0872] In one aspect, the present invention provides a cell comprising the vector of the present invention. The cell may be an isolated cell. Suitably, the cell is a mammalian cell, for example a human cell. The cell may be an isolated human cell.
[0873] Suitably, the cell may be a producer cell. As used herein, the term "producer cell" refers to a cell that produces viral particles, for example has been transiently transfected, stably transfected and / or transduced with all the elements necessary to produce the viral particles. Suitable producer cells will be well known to the skilled person and may include HEK293, COS-1, COS-7, CV-l, HeLa, CHO and A549 cell lines. In some embodiments, the producer cell is a HEK293 cell, or a derivative thereof (e.g., a HEK293T cell, a HEK293T Lenti-X, a HEK293T-Rex cell, a HEK293FT cell, a HEK293SF-3F6 cell, a HEK293SF-3F9 cell, a HEK293-EBNA1 cell or a SJ293TS cell).
[0874] Suitably, the cell may be a packaging cell. As used herein, the term "packaging cell" refers to a cell which contains some or all of the elements necessary for packaging a recombinant virus genome. Typically, such packaging cells contain one or more vectors which are capable of expressing viral structural proteins (e.g., gag-pol, rev, env) and / or one or more genes encoding the viral structural proteins have been integrated into the genome of the packaging cell. Cells comprising only some of the elements required for the production of enveloped viral particles are useful as intermediate reagents in the generation of viral particle producer cell lines, through subsequent steps of transient transfection, transduction or stable integration of each additional required element. These intermediate reagents are encompassed by the term "packaging cell". Suitable packaging cells will be well known to the skilled person.
[0875] Suitably, the cell may be an HSC, HPC, HSPC, and / or differentiated hematopoietic cell as defined herein. Preferably, the call may be an HSPC, as defined herein.
[0876] Method of production
[0877] In one aspect, the present invention provides a method of producing the vector of the present invention.
[0878] Suitable methods to produce non-viral vectors as defined herein and / or viral vectors as defined herein will be well known to the skilled person.
[0879] The method of production of a viral vector as defined herein may comprise: (a) introducing a transfer vector and one or more helper vectors into a host cell; (b) culturing the host cell under conditions suitable to produce viral vectors according to the present invention; and (c) obtaining the viral vectors from the host cell.
[0880] As used herein, a "transfer vector" may encode the viral genome of the present invention. Suitably, the transfer vector used to produce the viral genome within a host cell / packaging cell will have sufficient viral genetic information to allow packaging of a viral genome, in the presence of packaging components (e.g., gag-pol, rev, env), into a viral particle which is capable of infecting a target cell, but is incapable of independent replication to produce infectious viral particles within the final target cell.
[0881] The transfer vector used to produce the viral genome within a host cell / packaging cell may include transcriptional regulatory control sequences operably linked to the viral genome to direct transcription of the genome in a host cell / packaging cell. These regulatory sequences may be the natural sequences associated with the transcribed viral sequence (e.g., the 5' U3 region), or they may be a heterologous promoter, such as another viral promoter (e.g., the PGK promoter or the CMV promoter). The transfer vector may be a plasmid.
[0882] As used herein, a "helper vector" may encode one or more packaging components (e.g., gag-pol, rev, env). The nucleotide sequence encoding the packaging component(s) may be operably linked to a promoter (e.g., a CMV promoter or a RSV promoter) and / or a polyadenylation signal. The term "helper vector" may include "packaging vectors" (e.g., encoding gag-pol or rev) and "envelope vectors" (e.g., encoding an env gene, such as VSV-g). The helper vectors, packaging vectors and / or envelope vectors may be plasmids.
[0883] The transfer vector and one or more helper vectors may be introduced into the host cell by any suitable technique known in the art, such as transfection, transduction and / or transformation. Suitably, the helper vectors may be transiently transfected or transduced into the host cell or may be stably maintained (e.g., stably integrated into the cell genome) within the host cell. Alternatively, a combination of transient transfection or transduction and stable maintenance may be used to introduce the helper vectors into the host cell.
[0884] Suitably, the transfer vector and / or the helper vectors may be plasmids and introduced by transfection. Suitably, a four plasmid system may be used consisting of a transfer plasmid and three helper plasmids. In some embodiments of the viral vector of the present invention, the three helper plasmids may consist of: a first helper plasmid encoding a gag-pol gene; a second helper plasmid encoding a rev gene; and a third helperplasmid encoding an env gene. Alternatively, a three plasmid system may be used which consists of a transfer plasmid, one helper plasmid encoding a gag-pol gene and a rev gene; and one helper plasmid encoding an env gene. Alternatively, a two plasmid system may be used in which all helper functions (e.g. gag-pol, rev and env) are encoded by one helper plasmid.
[0885] Any suitable host cell may be used to produce the viral vector of the present invention. Suitable host cells include producer cells and packaging cells, such as those described below (e.g., HEK 293 or derivatives thereof). Suitable conditions for culturing the host cell will be well known to the skilled person. For example, the host cells may be incubated in chemically defined medium for from about 1 day to about 5 days (e.g. about 48 hours, about 72 hours or about 96 hours).
[0886] The viral vector may be obtained using any suitable methods known in the art. For example, the culture supernatant may be harvested and viral vector subsequently purified from the culture supernatant (e.g., by centrifugation, membrane filtration and / or chromatography). The method of production may further comprise any other suitable process steps, for example DNA reduction, concentration, formulation and / or sterilisation.
[0887] A host cell used to produce the viral vector of the present invention may comprise a heterologous polynucleotide. The term "heterologous" polynucleotide refers to a polynucleotide that is not naturally present in the cell, for example has been introduced into the cell by any suitable method, such as transduction or transfection. The heterologous polynucleotide may be, for example, a vector, such as an expression vector. The heterologous polynucleotide may be, for example, a plasmid.
[0888] Variants, derivatives analogues and fragments
[0889] In addition to the specific polypeptides and polynucleotides mentioned herein, the invention also encompasses variants, derivatives and fragments thereof.
[0890] In the context of the invention, a "variant" of any given sequence is a sequence in which the specific sequence of residues (whether amino acid or nucleic acid residues) has been modified in such a manner that the polypeptide or polynucleotide in question retains at least one or all of its endogenous functions. A variant sequence can be obtained by addition, deletion, substitution, modification, replacement and / or variation of at least one residue present in the naturally occurring polypeptide or polynucleotide.
[0891] The term "derivative" as used herein in relation to proteins or polypeptides of the invention includes any substitution of, variation of, modification of, replacement of, deletion of and / or addition of one (or more)amino acid residues from or to the sequence, providing that the resultant protein or polypeptide retains at least one or all of its endogenous functions.
[0892] Typically, amino acid substitutions may be made, for example from 1, 2 or 3, to 10 or 20 substitutions, provided that the modified sequence retains the required activity or ability. Amino acid substitutions may include the use of non-naturally occurring analogues.
[0893] Polypeptides used in the invention may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent polypeptide. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and / or the amphipathic nature of the residues as long as the endogenous function is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include asparagine, glutamine, serine, threonine and tyrosine.
[0894] Conservative substitutions may be made, for example according to the table below. Amino acids in the same block in the second column and in the same line in the third column may be substituted for each other:
[0895] Table A. Exemplary conservative amino acid substitutions
[0896]
[0897] The effect of additions, deletions, substitutions, modifications, replacements and / or variations may be predicted using any suitable prediction tool, for example SIFT (Vaser et al., SIFT missense predictions for genomes, Nat Protoc, 11, 1-9 (2016)), PolyPhen-2 (Adzhubei et al., Predicting functional effect of human missense mutations using PolyPhen-2, Curr Protoc Hum Genet, 76, 7-20 (2013)), CADD (Rentzsch etal., CADD-Splice-improving genome-wid...
Claims
CLAIMS1. A vector comprising a nucleic acid of interest for use in a method of treating a disease in a subject by in vivo delivering the nucleic acid of interest to HSPCs (i.e., hematopoietic stem cells and / or hematopoietic progenitor cells), wherein the method comprises in vivo administration of the vector.
2. The vector for use of claim 1, wherein the method further comprises administering an inhibitor of IFNαR signalling to the subject prior to administration of the vector to the subject.
3. The vector for use of claim 2, wherein the inhibitor of IFNαR signalling is administered to the subject between 1 and 5 hours prior to administration of the vector to the subject, optionally wherein the inhibitor of IFNαR signalling is administered to the subject 3 hours prior to administration of the vector to the subject.
4. The vector for use of any of claims 1-3, wherein the method further comprises administering a mobilisation regimen for HSPCs to the subject prior to administration of the vector to the subject.
5. The vector for use of claim 4, wherein the mobilisation regimen comprises granulocytecolony stimulating factor (G-CSF) and plerixafor, andwherein administering the mobilisation regimen comprises the following steps:a) administering multiple doses of G-CSF at regular intervals,b) after administration of the last dose of G-CSF, administering plerixafor, andc) after administration of plerixafor, administering the vector,optionally wherein administering the mobilisation regimen to the subject comprises the following steps:a) administering at least 3 and up to 5 doses of G-CSF, wherein the doses of G-CSF are administered every 12 hours,b) 8 h after administration of the last dose of G-CSF, administering plerixafor, and c) 2 h after administration of plerixafor, administering the vector.
6. An inhibitor of IFNαR signalling for use in a method of increasing transduction efficiency of a vector in vivo and treating a disease in a subject, wherein the inhibitor of IFNαR signalling is an anti-IFNaR blocking antibody or selected from the group consisting of Sifalimumab, Rontalizumab, Anifrolumab, and QX006N, and wherein the method comprises(a) first, administering the inhibitor of IFNαR signalling to the subject, and(b) subsequently, administering a vector comprising a nucleic acid of interest to the subject by in vivo administration,wherein the disease is treated by in vivo delivering said nucleic acid of interest to HSPCs (i.e., hematopoietic stem cells and / or hematopoietic progenitor cells).
7. The inhibitor of IFNαR signalling for use of claim 6, wherein the inhibitor of IFNαR signalling is selected from the group consisting of Sifalimumab, Rontalizumab, Anifrolumab, and QX006N.
8. The inhibitor of IFNαR signalling for use of claim 6 or 7, wherein the inhibitor of IFNαR signalling is administered to the subject between 1 and 5 hours prior to administration of the vector to the subject,optionally wherein the inhibitor of IFNαR signalling is administered to the subject 3 hours prior to administration of the vector to the subject.
9. The inhibitor of IFNαR signalling for use of any of claims 6-8, wherein the method further comprises administering a mobilisation regimen for HSPCs to the subject prior to administration of the vector to the subject.
10. The inhibitor of IFNαR signalling for use of claim 9, wherein the mobilisation regimen comprises G-CSF and plerixafor, andwherein administering the mobilisation regimen to the subject comprises the following steps:a) administering multiple doses of G-CSF at regular intervals,b) after administration of the last dose of G-CSF, administering plerixafor, andc) after administration of plerixafor, administering the vector,optionally wherein administering the mobilisation regimen to the subject comprises the following steps:a) administering at least 3 and up to 5 doses of G-CSF, wherein the doses of G-CSF are administered every 12 hours,b) 8 h after administration of the last dose of G-CSF, administering plerixafor, and c) 2 h after administration of plerixafor, administering the vector.
11. The vector for use of any of claims 1-5, or the inhibitor of IFNαR signalling for use of any of claims 6-10, wherein the vector is a viral vector,optionally wherein the viral vector is a lentiviral vector, such as an integrase-defective lentiviral vector, an adeno-associated viral vector, an adenoviral vector, a herpes viral vectors, a retroviral vector, a baculoviral vector and / or a virus-like particle vector,preferably wherein the vector is an enveloped viral vector selected from the group consisting of lentiviral vector, such as integrase-defective lentiviral vector, herpes viral vector, retroviral vector, baculoviral vector and / or enveloped virus-like particle vector,more preferably wherein the viral vector is a lentiviral vector.
12. The vector for use of any of claims 1-5 or 11, or the inhibitor of IFNαR signalling for use of any of claims 6-11, wherein the nucleic acid of interest is a gene of interest.
13. The vector for use of any of claims 1-5 or 11-12, or the inhibitor of IFNαR signalling for use of any of claims 6-12, wherein the HSPCs are circulating HSPCs.
14. The vector for use of any of claims 1-5 or 11-13, or the inhibitor of IFNαR signalling for use of any of claims 6-13, wherein the disease is selected from the group consisting of an immunodeficiency, a hemoglobinopathy, an osteochondrodysplasia, an inherited bone marrow failure syndrome, an inherited metabolic disorder, hematological cancers, and solid tumors, optionally wherein the disease is selected from the group consisting of adenosine deaminase-deficient severe combined immunodeficiency, autosomal recessive osteopetrosis, and Fanconi Anemia.
15. The vector for use of any of claims 1-5 or 11-14, or the inhibitor of IFNαR signalling for use of any of claims 6-14, wherein the vector is administered systemically, optionally wherein the administration of the vector is selected from the group consisting of intravenous administration, intraosseous administration, intra-arterial administration, subcutaneous administration, intramuscular administration, intrathecal administration or intraperitoneal administration, preferably wherein the administration of the vector is intravenous administration.
16. The vector for use of any of claims 1-5 or 11-15, or the inhibitor of IFNαR signalling for use of any of claims 6-15, wherein: (a) the subject is a newborn and is optionally administered a mobilisation regimen for HSPCs and / or an inhibitor of IFNαR signalling prior to administration of the vector; or (b) the subject is not a newborn and is administered a mobilisation regimen for HSPCs and / or an inhibitor of IFNαR signalling prior to administration of the vector.
17. The vector for use of any of claims 1-5 or 11-15, or the inhibitor of IFNαR signalling for use of any of claims 6-15, wherein: (a) the subject is a human subject 2 months of age or younger and is optionally administered a mobilisation regimen for HSPCs and / or an inhibitor of IFNαR signallingprior to administration of the vector; or (b) the subject is a human subject older than 2 months of age and is administered a mobilisation regimen for HSPCs and / or an inhibitor of IFNαR signalling prior to administration of the vector.
